

Netherlands The Journal of Medicine

MISSION STATEMENT

The mission of the journal is to serve the need of the internist to practise up-to-date medicine and to keep track with important issues in health care. With this purpose we publish editorials, original articles, reviews, controversies, consensus reports, papers on speciality training and medical education, book reviews and correspondence.

EDITORIAL INFORMATION

Editor in chief

Marcel Levi, Department of Medicine,
Academic Medical Centre, University
of Amsterdam, the Netherlands

Associate editors

Ineke J. ten Berge
Ulrich H. Beuers
Harry R. Büller
Eric Fliers
Martin Grobusch
Ton Hagenbeek
Joost B. Hoekstra
Jaap Homan van der Heide
John J. Kastelein
Joep Lange
Saskia Middeldorp
Rien H. van Oers
Tom van der Poll
Jan M. Prins
Kees Punt
Peter Reiss
Hans Romijn
Marcus J. Schultz
Erik Stroes

Junior associate editors

Ward van Beers
Godelieve de Bree
Goda Choi
Danny Cohn
Michiel Coppens

Onno Holleboom

Joppe W. Hovius
Lars Klieverik
Paul T. Krediet
Mirjam Langeveld
Wieneke Michels
Tatjana Niers
Max Nieuwdorp
Sander W. Tas
Rogier M. Thurlings
Alexander Vlaar
Liffert Vogt
Iris Wentholt
Joost Wiersinga

Editorial board

G. Agnelli, Perugia, Italy
J.T. van Dissel, Leiden, the Netherlands
R.O.B. Gans, Groningen,
the Netherlands
A.R.J. Girbes, Amsterdam,
the Netherlands
D.E. Grobbee, Utrecht, the Netherlands
E. de Jonge, Leiden, the Netherlands
D.L. Kastner, Bethesda, USA
M.H. Kramer, Amsterdam,
the Netherlands
E.J. Kuipers, Rotterdam,
the Netherlands
Ph. Mackowiak, Baltimore, USA
J.W.M. van der Meer, Nijmegen,
the Netherlands

B. Lipsky, Seattle, USA
B. Lowenberg, Rotterdam,
the Netherlands
G. Parati, Milan, Italy
A.J. Rabelink, Leiden, the Netherlands
D.J. Rader, Philadelphia, USA
J.L.C.M. van Saase, Rotterdam,
the Netherlands
M.M.E. Schneider, Utrecht,
the Netherlands
J. Smit, Nijmegen, the Netherlands
Y. Smulders, Amsterdam,
the Netherlands
C.D.A. Stehouwer, Maastricht,
the Netherlands
J.L. Vincent, Brussels, Belgium
R.G.J. Westendorp, Leiden,
the Netherlands

Editorial office

Academic Medical Centre,
Department of Medicine (E2-126)
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
Tel.: +31 (0)20-566 21 71
Fax: +31 (0)20-691 96 58
E-mail: m.m.levi@amc.uva.nl
[http://mc.manuscriptcentral.com/
nethjmed](http://mc.manuscriptcentral.com/nethjmed)

CITED IN

Biosis database; embase/excerpta medica; index medicus (medline) science citation index, science citation index expanded, isi alerting services, medical documentation services, current contents/clinical medicine, PubMed.

ISSN: 0300-2977

Copyright

© 2012 Van Zuiden Communications B.V. All rights reserved. Except as outlined below, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Permission may be sought directly from Van Zuiden Communications B.V.

Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

Derivative works

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is also required for all other derivative works, including compilations and translations.

Electronic storage

Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article.

Responsibility

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, independent verification of diagnoses and drug dosages is advised.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Subscriptions

General information

An annual subscription to The Netherlands Journal of Medicine consists of 11 issues. Issues within Europe are sent by standard mail and outside Europe by air delivery. Cancellations should be made, in writing, at least two months before the end of the year.

Subscription fee

The annual subscription fee within Europe is € 705, for the USA € 735 and for the rest of the world € 845. Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis.

Payment method

Please make your cheque payable to Van Zuiden Communications B.V., PO Box 2122, 2400 CC Alphen aan den Rijn, the Netherlands or you can transfer the fee to ING Bank, account number 67-89.1 0.872, Castellumstraat 1, Alphen aan den Rijn, the Netherlands, swift-code: ING BNL 2A. Do not forget to mention the complete address for delivery of the Journal.

Claims

Claims for missing issues should be made within two months of the date of dispatch. Missing issues will be mailed without charge. Issues claimed beyond the two-month limit must be prepaid at back copy rates.


Orders, preprints, advertising, changes in address, author or general enquiries

Please contact the publisher.



Van Zuiden Communications B.V.

PO Box 2122
2400 CC Alphen aan den Rijn
The Netherlands
Tel.: +31 (0)172-47 61 91
Fax: +31 (0)172-47 18 82
E-mail: kapteyn@vanzuidencommunications.nl
Internet: www.njm-online.nl



Contents

EDITORIAL

Hospital volume determines favourable outcome: probably also in internal medicine 157

M. Levi

REVIEWS

Myeloproliferative neoplasia: a review of clinical criteria and treatment 159

S.M. Koopmans, A.M.W. van Marion, H.C. Schouten

Walled-off pancreatic necrosis 168

J.M. Ramia, R. de la Plaza, J.E. Quiñones-Sampedro, C. Ramiro, P. Veguillas, J. García-Parreño

BK virus infection in transplant recipients: Clinical manifestations, treatment options and the immune response 172

M.C. van Aalderen, K.M. Heutinck, C. Huisman, I.J.M. ten Berge

ORIGINAL ARTICLE

Low complication rates in the use of port-a-caths in oncology patients 184

M.M.E.M. Bos, L. Smeets, J. Koning, I. Dumay, E. de Jonge

CASE REPORT

An unexpected cause of multiple intra-abdominal abscesses in an HIV-positive patient 190

A.H. van der Spek, J.L. Vosters, C.E. Visser, M. van der Valk, J.F.J.B. Nellen

PHOTO QUIZZES

A patient with haemorrhagic bullae 189

H. Westdorp, H.A.M. Sinnige

An unexpected cause of chest pain 192

D.J.L. van Twist, M.B.I. Lobbes, S. Vanwetswinkel, P.M. Stassen

An unusual cause of ascites 193

M.M. Smits, P.W.G. van der Linden

A man with painless scrotal swelling 194

D. Boumans, R.A.A. van Zanten, B.W. Schot

SPECIAL ARTICLE

Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis 199

A. van Tellingén, A.E. Voskuyl, M.G. Vervloet, M. Bijl, R.G.L. de Sévaux, S.P. Berger, R.H.W.M. Derksen, J.H.M. Berden

Hospital volume determines favourable outcome: probably also in internal medicine

M. Levi

Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands, e-mail: m.m.levi@amc.uva.nl

The very rapid development in molecular genetics and biotechnology, imaging technology, detailed insights into intricate mechanisms such as immunology, host defence, metabolism, tissue differentiation and cell regulation, and a host of new invasive and non-invasive techniques have resulted in revolutionary changes in medicine in the current era. Diagnostic management, therapeutic options, and preventive strategies are developing at a breath-holding pace while few physicians who practise day-to-day medicine seem to realise they are part of a highly exciting time in medicine, which is unparalleled by any other era in the preceding centuries. As these developments occur, in some situations medicine is getting increasingly complex, requiring highly specific and multifaceted infrastructure and demanding skills of medical and paramedical professionals. One of the responses of medical professionals is subspecialisation, which is not only widely present in internal medicine, but in virtually all medical specialisms.¹

As the complexity of medicine increases, some specialities have come to the realisation that the outcome of medical treatment may be dependent on the number of patients that are treated within a given time interval. This association was hypothesised as early as in 1979 by Luft.² In recent years a large number of studies have been published demonstrating a clear relationship between hospital volume and clinically relevant outcome parameters, including survival. Initially, these studies were mainly done in surgical patients undergoing complex procedures, such as oesophageal resection, pancreaticoduodenectomy, or coronary artery bypass surgery.^{3,4} However, similar associations have been demonstrated for complex urological procedures, such as cystectomy, and gynaecological oncology, including hysterectomy for uterine or cervical cancer.^{5,6} Most of these studies show a near linear relationship between hospital volume and outcome and virtually all studies demonstrate a threshold below which the rate of complications and an unfavourable outcome steeply increases. As the awareness of the

association between a minimal number of procedures and a favourable outcome of surgery increases, surgical societies have proposed a minimum of procedures as a quality indicator and in some situations regulatory bodies have adopted these minimum numbers. Interestingly, implementation of these minimum hospital volumes in the US or Canada has resulted in improving the outcome for major procedures.^{7,8} In the Netherlands a similar trend has been demonstrated for major gastrointestinal oncological procedures.⁹ For a long time it was assumed that the underlying mechanism that determines the relationship between hospital volume and patient outcome was the (surgical) skills of the doctor. However, it is becoming increasingly clear that other factors are at least as important and are doctor-independent. These factors include set up and organisation of preoperative and postoperative care and intensive care departments, experience of imaging and laboratory personnel, knowledge and skills of nurses and other paramedical disciplines, and familiarity of the entire institution with particularly complex patient groups, which for example determines the ability to quickly recognise complications at an early stage and act adequately in these situations.

However, if the relationship between hospital volume and patient outcome does not entirely depend on the skill of the operator, it may be hypothesised that a similar relationship may exist for complex non-surgical diagnoses. Indeed, some initial studies have shown such associations for the management of acute myocardial infarction, stroke, and even for common medical diagnoses including pulmonary embolism and peptic ulcer treatment.¹⁰⁻¹³ Obviously, it is questionable whether these associations are universally translatable to other medical settings, for example in countries with a high level of medical care such as in the Netherlands. On the other hand, it is quite surprising that for medical specialities there is hardly any discussion on hospital volume as a determinant of patient outcome or even minimum volumes to achieve an acceptable outcome. While in surgical specialities there is intense debate on

this issue, it is awkwardly silent in societies of medical specialities in Europe and other parts of the Western world. However, it may safely be assumed that for many serious and highly complex, low-volume conditions in internal medicine a minimum volume of patients per year is required to achieve optimal patient outcome. Can we go on to treat severe antiphospholipid syndrome, Graves ophthalmopathy, acute renal failure, advanced chronic lymphatic leukaemia, hypertensive crises, Wegener's granulomatosis, chest syndrome in sickle cell disease, or cryptococcal meningitis in virtually all hospitals, even if the medical and paramedical staff are very rarely or hardly ever confronted with these problems and do not really know how precisely to handle these conditions and their associated complications?¹⁴⁻¹⁸ Should we at least start some clinical studies to determine whether the care of patients with these conditions is up-to-date and achieves equal outcomes in (very) low-volume hospitals versus hospitals that see these patients on a more regular basis? It may be about time internal medicine and other medical specialities wake up and take the example of surgical colleagues and societies and start to think about adequate hospital volume as a determinant of patient outcome in low-volume complex medical disorders. Based on the results of these surveys it may well be that doctors need to suppress their (understandable) professional pride and face the reality that some patients may be better off in another clinical setting than under their care. And that has nothing to do with the individual knowledge and skills of doctors but merely depends on the clinical setting in which they work.

REFERENCES

- 1 Levi MM. Generalism of journals of internal medicine. *Neth J Med.* 2011;69:478-9.
- 2 Luft HS, Bunker JP, Enthoven AC. Should operations be regionalized? The empirical relation between surgical volume and mortality. *N Engl J Med.* 1979;301:1364-9.
- 3 Dikken JL, Dassen AE, Lemmens VE, et al. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. *Eur J Cancer.* 2012;67:212-3.
- 4 van Heek NT, Kuhlmann KF, Scholten RJ, et al. Hospital volume and mortality after pancreatic resection: a systematic review and an evaluation of intervention in the Netherlands. *Ann Surg.* 2005;242:781-8.
- 5 Kim SP, Boorjian SA, Shah ND, et al. Contemporary trends of in-hospital complications and mortality for radical cystectomy. *BJU Int.* 2012, Mar 22. [Epub ahead of print].
- 6 Wright JD, Lewin SN, Deutsch I, et al. The influence of surgical volume on morbidity and mortality of radical hysterectomy for cervical cancer. *Am J Obstet Gynecol.* 2011;205:225-7.
- 7 Gasper WJ, Clidden DV, Jin C, et al. Has recognition of the relationship between mortality rates and hospital volume for major cancer surgery in California made a difference? A follow-up analysis of another decade. *Ann Surg.* 2009;250:472-83.
- 8 Simunovic M, Rempel E, Theriault ME, et al. Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. *Can J Sur.* 2006;49:251-8.
- 9 Nienhuijs SW, Rutten HJ, Luiten EJ, et al. Reduction of in-hospital mortality following regionalisation of pancreatic surgery in the south-east of the Netherlands. *Eur J Surg. Oncol.* 2010;36:652-6.
- 10 Srinivas VS, Hailpern SM, Koss E, et al. Effect of physician volume on the relationship between hospital volume and mortality during primary angioplasty. *J Am Coll Cardiol.* 2009;53:574-9.
- 11 Aujesky D, Mor MK, Geng M, et al. Hospital volume and patient outcomes in pulmonary embolism. *CMAJ.* 2008;178:27-33.
- 12 Saposnik G, Baibergenova A, O'Donnell M, et al. Hospital volume and stroke outcome: does it matter? *Neurology.* 2007;69:1142-51.
- 13 Lou HY, Lin HC, Chen KY. Hospital case volume and clinical outcomes for peptic ulcer treatment. *J Gen Intern Med.* 2008;23:1693-7.
- 14 Habib SM, Betjes MG, Fieren MW, et al. Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment. *Neth J Med.* 2011;69:500-7.
- 15 Kater AP, Wittebol S, Chamuleau M, et al. Guidelines for diagnosis and treatment of chronic lymphocytic leukemia (CLL) 2011. *Neth J Med.* 2011;69:422-9.
- 16 Soeters MR, van Zeijl CJ, Boelen A, et al. Optimal management of Graves orbitopathy: a multidisciplinary approach. *Neth J Med.* 2011;69:302-8.
- 17 Teunisse CC, Kalsbeek AJ, de Vries ST, et al. Reversible cardiac valvular disease in catastrophic antiphospholipid syndrome. *Neth J Med.* 2010;68:215-20.
- 18 van den Born BJ, Beutler JJ, Gaillard CA, et al. Dutch guideline for the management of hypertensive crisis -- 2010 revision. *Neth J Med.* 2011;69:248-55.

Myeloproliferative neoplasia: a review of clinical criteria and treatment

S.M. Koopmans^{*1}, A.M.W. van Marion², H.C. Schouten³

¹Department of Pathology of the University Hospital Maastricht, Maastricht, the Netherlands, ²Department of Pathology of the VieCuri Medical Centre, Venlo, the Netherlands, ³Department of Internal Medicine, Division of Haematology of the University Hospital Maastricht, Maastricht, the Netherlands, *corresponding author: tel.: +31 (0)43 3874641, e-mail: s.koopmans@mumc.nl

ABSTRACT

Essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) belong to the group of Philadelphia chromosome-negative myeloproliferative neoplasia (Ph- MPN). MPNs are clonal bone marrow stem cell disorders characterised by a proliferation of one or more of the myeloid, erythroid or megakaryocytic cell lines. Due to the different affected cell lines, MPNs show typical clinical and histological features. In 2005, a mutation in the JAK2 gene was discovered which generated more insight into the pathogenetic working mechanism of MPNs. However, the treatment of MPN patients is still mainly only palliative, although progress in reducing the symptoms of MPN patients has been made. This review will give a general overview of MPN patients for internal medicine physicians.

KEYWORDS

MPN, myeloproliferative neoplasia, essential thrombocythemia, polycythemia vera, primary myelofibrosis, treatment myeloproliferative neoplasia

HAEMATOPOIESIS

Haematopoiesis is the development of the cellular components of the blood. The formation and development of blood cells is initiated by the haematopoietic stem cells (HSCs). HSCs are primitive cells capable of self-renewal and differentiation. Due to the self-renewal capability, at least one of the daughter cells possesses the same HSC characteristics as the mother cell after cell division. During the entire life of an individual, the stem cell pool is maintained due to the self-renewal capability of the HSCs and supplies cells for multilineage haematopoiesis.^{1,2}


Currently it is considered that long-term repopulating HSCs (LT-HSC) differentiate into a short-term repopulating HSC (ST-HSC) and, as schematically shown in *figure 1*, they will differentiate further into multipotent progenitor cells (MPP) only capable of differentiating into the myeloid lineage or the lymphoid lineage. The common myeloid progenitors (CMP) give rise to megakaryocyte-erythroid progenitors (MEP), which differentiate into megakaryocytes and erythrocytes, and granulocyte-monocyte progenitors (GMP), which differentiate into macrophages and neutrophil granulocytes. The eosinophilic and basophilic granulocytes differentiate directly from the CMP. The common lymphoid progenitors (CLP) differentiate into T- and B-lymphoid cells and natural killer cells (*figure 1*). The progeny that arises from HSCs progressively loses its self-renewal capacity and gradually becomes more restricted to one lineage.^{3,4}

HSCs require intrinsic and extrinsic factors for their activities provided by the stem cell niche. The interaction of HSCs with the stem cell niche determines whether the HSCs remain in a quiescent state or proliferate to progenitor cells and differentiate into mature blood cells.^{5,6}

MYELOPROLIFERATIVE NEOPLASIA

Myeloproliferative neoplasia (MPNs) are clonal bone marrow stem cell disorders involving a multipotent haematopoietic stem cell, characterised by proliferation of one or more lineages of the myeloid, erythroid and megakaryocytic cell lines. This proliferation results in increased numbers of granulocytes, erythrocytes or platelets in the peripheral blood respectively.⁷ William Dameshek was the first to introduce the term 'myeloproliferative disorders' in 1951 including essential

Figure 1. Development of haematopoietic stem cells, a schematic view



HSC = haematopoietic stem cells; LT-HSC = long-term repopulating HSC; ST-HSC = short-term repopulating HSC; MPP = multipotent progenitor; CMP = common myeloid progenitor; MEP = megakaryocyte-erythroid progenitor; GMP = granulocyte-macrophage progenitor; CLP = common lymphoid progenitor.

thrombocytopenia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), chronic myelogenous leukaemia (CML) and erythroleukaemia (Di Guglielmo syndrome). These disorders were grouped together based on their similarities in clinical phenotype and the belief that there was an underlying undiscovered stimulus responsible for the proliferative activity of bone marrow cells in these myeloproliferative disorders.⁸

According to the World Health Organization (WHO) 2008 criteria, MPNs are now divided in classical MPNs which carry the Philadelphia (Ph+) chromosome (chronic myeloid leukaemia) and classical MPNs which do not carry the Philadelphia (Ph-) chromosome, including ET, PV and PMF. The Philadelphia chromosome is a result of t(9:22) with the *BCR-ABL1* fusion gene.⁹ In this article the classical Ph- MPNs are highlighted.


Clinical and histological criteria of MPN

The typical features of ET are thrombotic and haemorrhagic complications, although most patients are asymptomatic. Transient ischaemic attacks, erythromelalgia and Budd-Chiari syndrome are complications which can occur in ET patients or can develop before the diagnosis of ET is apparent. Bleeding

complications are a result of an extremely high platelet count resulting in an acquired von Willebrand disease; von Willebrand factor will be proteolysed with increasing platelet counts.¹⁰ Histomorphological findings in the bone marrow of ET patients are loose clusters of predominant large to giant megakaryocytes. The megakaryocytes exhibit a normal maturation with hyperlobulated and staghorn-like nuclei (*figure 2*). No marked left-shifting of the erythroid or myeloid cell line is apparent. The presence of reticulin is extremely rare in ET patients at presentation and very few patients (<10%) develop myelofibrosis during their disease course, known as post-ET myelofibrosis. ET patients have a risk of approximately 2% to develop acute myeloid leukaemia (AML).^{11,12}

Polycythemia vera is characterised by a trilineage proliferation of the erythroid, myeloid and megakaryocytic cell line, usually resulting in mainly increased erythrocytes and often also leucocytes and blood platelets. Patients also display a persistently raised haemoglobin and haematocrit level. The clinical features of PV patients are vascular occlusive events, enlarged spleen, aquagenic pruritus (intense itching after a hot bath or shower) and haemorrhagic complications after injuries and surgery. In about 30% of the patients PV will develop to myelofibrosis, known as post-PV myelofibrosis, and leukaemic transformation will occur in about 10% of the PV patients.¹² The bone marrow of PV patients displays panmyelosis and therefore an increase in cellularity. The megakaryocytes reveal a range from small to giant megakaryocytes without maturation defects of nuclei and cytoplasm and are arranged in loose clusters (*figure 2*). There is always a proliferation and often a left-shifting of the myeloid cell lineage and especially of the erythroid precursor cells. Slightly increased reticulin fibrosis can be seen in the bone marrow.¹¹

Figure 2. Examples of morphological features in megakaryocytes



A. Dense clustering (HE, 630x) B. Loose clustering (HE, 1000x) C. Dysmorphic nucleus (HE, 1000x) D. Hyperlobulated nucleus (HE, 1000x) E. Staghorn nucleus (HE, 1000x) F. Cloud-like nucleus (HE, 1000x)

In primary myelofibrosis the patient's complaints and symptoms depend mainly on the degree of anaemia and splenomegaly. The typical early symptoms are fatigue, weight loss, night sweating and fever. These constitutional symptoms are believed to be mediated by the abnormal release of cytokines from clonal megakaryocytes as a result of emperipolesis. When the fibrosis is in an advanced stage, the complaints are, apart from the constitutional symptoms, paleness due to anaemia, hepatosplenomegaly, spleen infarct and osteosclerosis. Budd-Chiari syndrome can be a feature of early-phase disease and can be the presenting symptom.^{12,13} In the bone marrow of prefibrotic PMF an overall hypercellularity is evident including prominent growth of abnormally differentiated and giant megakaryocytes. The megakaryocytes reveal hypolobulated, cloud-like and hyperchromatic nuclei and demonstrate dense clustering (*figure 2*), often accompanied by left-shifted granulocyte proliferation. In the prefibrotic PMF reticulin fibrosis may be absent, but during the disease course reticulin fibrosis increases, finally resulting in collagen fibrosis with osteosclerosis. Leukaemic transformation occurs in about 10% of the PMF patients.¹⁴ However, the symptoms listed above are not strictly limited to ET or PV or PMF patients, in fact they can occur in all three classical Ph- MPN, such as bleeding complications (spontaneous or after surgery), thrombosis and fatigue. MPN patients may even be asymptomatic in the early phases of the disease and it may be a coincidence that an MPN disease is discovered by abnormal blood counts or by diseases which are features of early-phase MPN, such as Budd-Chiari syndrome, heart attack, cerebral vascular accident, pulmonary thrombus and deep venous thrombosis. An important factor in thromboembolic events is the $JAK2^{V617F}$ mutation. No differences in thromboembolic events were seen between heterozygous and homozygous $JAK2^{V617F}$ PV patients, in contrast to homozygous ET patients, who show increased risk of cardiovascular events compared with heterozygous and wild-type ET patients. It was also shown that ET and PV patients with a higher allele burden have a higher risk of thrombotic events.¹⁵ This indicates an important risk factor for the $JAK2^{V617F}$ mutation in the development of thrombosis. The $JAK2^{V617F}$ occurrence rate in patients with thrombosis of the deep veins (DVT) and pulmonary embolism (PE) is low, therefore a general $JAK2^{V617F}$ screening is not recommended among patients with spontaneous DVT and PE. This is in contrast to patients who present with splanchnic and intrahepatic vein thrombosis; these patients show a high prevalence of the $JAK2^{V617F}$ mutation and a diagnosis of ET or PV should be kept in mind.^{16,17}

The Polycythemia Vera Study Group (PVSG) made the first attempt to establish diagnostic criteria for the Ph-MPNs in


1967. The diagnostic criteria were updated several times during the following decades and are even now widely used by haematologists. However, the appropriate use of bone marrow biopsy (BMB) histology as a diagnostic tool was neglected. To stress the relevance of a BMB, the WHO added a set of histological diagnostic criteria in 2001. The recent discovery of the $JAK2^{V617F}$ mutation and the recognition of pre-fibrotic PMF resulted in the 2008 WHO classification of MPNs.¹⁸⁻²⁰ However, the early phases of ET, PV and PMF are difficult to distinguish on morphology alone as they share many morphological characteristics. It was shown by Wilkins *et al.* that some of the histological criteria as described in the WHO classification were difficult to reproduce.²¹ Nevertheless, it is very important to distinguish these three MPN subtypes reliably in the early phase, because of a different risk of thromboembolic complications of PV and the worse survival rate of PMF patients compared with ET patients, who have a normal life expectancy.^{21,22}

Although Ph- MPNs are divided into three clinically distinct entities, the use of three distinct diagnoses can also be questioned; ET, PV and PMF show a great abundance of overlap in their morphological characteristics, clinical signs and symptoms and can also share the same molecular mutation ($JAK2^{V617F}$). A proposed simplistic model for revision of the MPN classification is shown in *figure 3*. It might be more reasonable to divide the MPNs into $JAK2$ positive and negative diseases and subdivide them into patients with and without myelofibrosis.²³

THE $JAK2$ MUTATION AND MPN

In 2005, several groups identified a mutation in the tyrosine kinase domain of $JAK2$ in MPN patients, resulting in a substitution of valine for phenylalanine at position 617 of $JAK2$ ($JAK2^{V617F}$). The first genetic step is an acquired point mutation and results in a heterozygous

Figure 3. Proposed model for reconsidering the classification of MPNs



mutational status. The homozygous $JAK2^{V617F}$ mutation is the result of mitotic recombination between homologous chromosomes 9p and results in loss of heterogeneity of 9p (LOH) and is a second genetic step in the aetiology of the MPNs.²⁴⁻²⁸ The $JAK2^{V617F}$ mutation is present in granulocytes, erythroblasts and myeloblasts and in all erythropoietin (EPO)-independent erythroid colonies. The erythroid colonies with the $JAK2^{V617F}$ mutation are able to grow in the absence of EPO. Therefore, the $JAK2^{V617F}$ mutation also results in factor-independent growth of various haematopoietic cell lines.²⁹ Further, the receptors of bone marrow progenitor cells are hypersensitive to thrombopoietin (TPO, stimulates proliferation and differentiation of megakaryocytes), EPO (stimulates erythroblasts), stem cell factor (SCF, induces proliferation and self-renewal of multipotent haematopoietic progenitors) and granulocyte-stimulating factor (G-CSF, stimulates proliferation and differentiation of granulocytes). The hypersensitivity for these cytokines results in specific stimulation of the megakaryopoiesis, erythropoiesis and granulopoiesis.³⁰

The $JAK2^{V617F}$ mutation is present in >95% of the PV patients and in approximately 50% of the ET and PMF patients.^{15,31} The $JAK2^{V617F}$ mutation deregulates the JAK2 kinase activity. The mutation is located in the JH2 domain of the JAK2 gene, which negatively regulates the activity of the kinase domain, JH1. Valine 617 and cysteine 618 both maintain the kinase domain of JAK2 in an inactive state. Substitution of valine 617 for phenylalanine destabilises this inhibitory interaction, resulting in increased JAK2 kinase activity. Altogether, this suggests that there is a sustained JAK2 activation, while the feedback mechanism has been destroyed with a growth factor independent activation.²⁴ PV patients without the $JAK2^{V617F}$ mutation virtually all have a $JAK2^{V617F}$ exon 12 mutation. Also, more early genetic abnormalities are currently being defined and related with disease development.

TREATMENT OF MPN

The current treatment of MPN patients is mostly supportive, while standard therapy has not been defined firmly. The treatment of ET and PV patients should be done according to their risk stratification for the occurrence of thromboembolic processes (*table 1* and *table 2*) as evaluated in a large prospective study of the European Collaboration on Low-dose Aspirin in Polycythemia (ECLAP).³² Age greater than 60 years and a previous history of thrombosis were found to be risk factors for thrombosis in both ET and PV. If one of these two criteria present the ET and PV patient is at high risk, whereas if none of the criteria are present ET and PV patients are at low risk. ET and PV patients who have platelets >1000 x

Table 1. Risk stratification of patients with ET and PV for the occurrence of thrombosis

Risk category	Age >60 years or history of thrombosis	Generic cardiovascular risk factors
Low	No/No	No
Intermediate	Platelets >1000 x 10 ⁹ /l	Yes
High	Yes/No or No/Yes	Irrelevant

Table 2. Treatment of ET and PV according to their risk stratification

Risk category	ET	PV
Low	Low-dose aspirin* if microvascular disturbances are present	Phlebotomy + low dose aspirin*
Intermediate	Low-dose aspirin* if microvascular disturbances are present	Phlebotomy + low dose aspirin*
High	Low-dose aspirin* if microvascular disturbances are present + hydroxyurea [†]	Phlebotomy + low dose aspirin* + hydroxyurea [†]

*In the case of major bleeding or presence of von Willebrand syndrome, aspirin is a contraindication; hydroxyurea intolerance or resistance, use anagrelide or peg-INF- α .

10⁹/l are of intermediate risk to develop thrombosis or if they have any of the following risk factors: hypertension, hypercholesterolaemia, smoking and diabetes mellitus (*table 1*). These are generic cardiovascular risk factors, and their role is still controversial. Other possible risk factors, which have to be validated in prospective studies, might be leukocytosis and the presence of the $JAK2^{V617F}$ mutation, although the latter is controversial.

ET patients belonging to the low-risk or intermediate-risk category and without any symptoms do not need therapy; however, aspirin is recommended to prevent microvascular disturbances as erythromelalgia, although major bleeding or presence of von Willebrand syndrome are contraindications for the use of aspirin. High-risk ET is an indication for the use of hydroxyurea (HU), which inhibits thrombocyte, erythrocyte and leucocyte production, combined with low-dose aspirin if thrombosis or microvascular symptoms are present, of course in the absence of contraindications (*table 2*).^{23,32-35} In the MRC-PT-1 trial researchers compared HU plus aspirin with anagrelide plus aspirin in ET patients at high risk for thrombosis, observing that HU plus low-dose aspirin is superior to anagrelide plus low-dose of aspirin.³⁶ The administration of aspirin to PV patients has been widely investigated. In 1986, the PVSG concluded that aspirin was ineffective and dangerous, due to increased gastrointestinal bleeding and intracerebral haemorrhage, based on a randomised trial of 163 PV patients receiving either 900 mg/day aspirin plus dipyridamole or radioactive

phosphorus (^{32}P).³⁷ However, more studies on the administration of aspirin have been done, resulting in the conclusion of the safe use of a considerably lower dose of aspirin in PV patients. The Gruppo Italiano Studio Policitemia Vera demonstrated the safe use of low-dose aspirin (40 mg/day) in PV patients.³⁸ The study by Landolfi *et al.*³⁹ showed a significant reduction in the combined risk of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism or major venous thrombosis with 100 mg/day of aspirin. Therefore, low-dose aspirin plus phlebotomies are recommended in the low-risk and intermediate-risk category.²³

In 1953, the most effective treatment of PV included phlebotomies combined with radioactive phosphorus (^{32}P) resulting in prolonged survival; however ^{32}P was shown to be leukemogenic.⁴⁰ The PVSG study group conducted a randomised trial comparing phlebotomy alone with ^{32}P plus phlebotomy and with chlorambucil plus phlebotomy. Patients treated with phlebotomy alone showed a higher incidence of thrombosis in the first three years of treatment. After three to five years of study, a considerable number of patients treated with ^{32}P or chlorambucil developed acute leukaemia, lymphoma and carcinomas of the gastrointestinal tract and skin, compared with those treated with phlebotomy alone. Therefore, patients treated with phlebotomy alone had a better overall median survival of 13.9 years than patients treated with chlorambucil (8.9 years) or ^{32}P (11.8 years).³³ The PVSG also compared HU with phlebotomy; a slightly higher incidence of acute leukaemia, less myelofibrosis and fewer deaths among the patients treated with HU were apparent.⁴¹

Interferon- α is able to inhibit *in vitro* proliferation of haematopoietic progenitors and inhibition of the thrombopoietin-induced MPL receptor signalling resulting in megakaryopoiesis repression. The use of IFN- α in PV patients was shown to be effective and non-leukemogenic. However, the use of IFN- α has been limited due to its toxicity, parenteral administration and costs.^{42,43} The development of pegylated (peg) forms of IFN resulted in improved tolerance, efficacy and fewer side effects.^{44,45} Peg-IFN- α has been demonstrated to have clinical advantages, high rates of molecular response and lower toxicity in phase II trials in PV as well as ET patients.^{46,47} PV patients belonging to the low-risk or intermediate-risk category with high haematocrit level are treated with phlebotomies in order to obtain normal haematocrit levels (<0.45 l/l) plus low-dose aspirin, if no contraindications are present. If PV patients show poor compliance to phlebotomy or if they show progressive myeloproliferation, cytoreductive therapy should be given. The high-risk group should be treated with myelosuppression, with HU as the drug of choice (table 2). Anagrelide or peg-INF- α is used in PV and ET patients in case of intolerance or resistance to HU, to control platelet count or in those who develop

side effects to HU; however, long-term efficacy and safety features are still unknown.^{23,35,48}

The prognosis of PMF patients is worse than that of ET or PV patients (median survival six vs 20 years) and the disease course is not significantly modified by drug therapy, therefore treatment of PMF is mainly palliative. However, there is a wide heterogeneity in presentation and evolution among PMF patients. Therefore, the International Prognostic Scoring System (IPSS) uses five risk factors for estimating the survival of PMF patients at the time of diagnosis: age >65 years, constitutional symptoms (weight loss, fever, excessive sweating), haemoglobin level <10g/dl, leucocyte count >25 x 10⁹/l and circulating blasts >1%. Based on this system PMF patients can be categorised in the low-risk group (0 risk factors present), intermediate-1 (1 risk factor present), intermediate-2 (2 risk factors present) and high-risk group (≥ 3 risk factors present).⁴⁹ IPSS has been modified to Dynamic IPSS (DIPSS) with the same five risk factors to estimate survival during the disease course, while acquisition of additional risk factors modifies patients outcome.⁵⁰ Recently, the DIPSS was upgraded to DIPSS-plus by incorporating three independent prognostic factors, including the need for red cell transfusion, thrombocytopenia <100 x 10⁹/l and unfavourable karyotype (including +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3) or 11q23 rearrangement). Based on the DIPSS-plus PMF patients are categorised in the low (no risk factors), intermediate-1 (1 risk factor), intermediate-2 (2 or 3 risk factors) and high (≥ 4 risk factors) risk group. Unfavourable karyotype and thrombocytopenia both predict leukaemic transformation in PMF patients. If the patient needs red cell transfusion, the patient belongs to the intermediate-risk group, while the patient displays two risk factors: anaemia and red cell transfusion need.⁵¹

A wait-and-see approach is justified in PMF patients belonging to the low- or intermediate-1 risk group, while the median survival of these patients exceeds 15 and six years respectively.⁵¹ This relatively long median survival does not justify the risks of an allogeneic stem cell transplantation (alloSCT) or the start of investigational drug therapy. There is also no evidence to support the use of conventional drug therapy in low- or intermediate-1 risk group patients if the patients do not have complaints which can be treated (table 3).¹³ However, if PMF patients suffer from splenomegaly, the first drug of choice is HU and in the worst case splenectomy is indicated. Indications for splenectomy include symptomatic portal hypertension, drug-refractory splenomegaly with severe symptoms, transfusion-dependent anaemia, marked thrombocytopenia and uncontrollable haemolysis due to severe complications that can occur. Irradiation therapy of the spleen transiently reduces spleen size and reduces

Table 3. Treatment of PMF according to their risk stratification

Risk category	PMF
Low	Wait-and-see or conventional drug therapy
Intermediate-1	Wait-and-see or conventional drug therapy
Intermediate-2	Hydroxyurea* or experimental drugs or alloSCT
High	Hydroxyurea* or experimental drugs or alloSCT

*Hydroxyurea intolerance or resistance, use peg-INF- α .

the incidence of pancytopenia. Patients usually experience relief of constitutional symptoms when splenomegaly is treated. In the case of non-hepatosplenic extramedullary haematopoiesis (located mainly in the thoracic vertebral column or in lymph nodes, lung pleura, small bowel, peritoneum, urogenital tract and heart) low-dose irradiation therapy is indicated.^{52,53}

In patients belonging to the intermediate-1 risk group who suffer from the risk factor they display, conventional drug therapy should be given; anaemia can be treated with androgens, danazol, corticosteroids, thalidomide or lenalidomide. Thalidomide plus prednisone and lenalidomide plus prednisone show higher response rates with decreased toxicity. Thalidomide and lenalidomide are also effective in PMF patients with unfavourable karyotype. A recent study by Holle *et al.*⁵⁴ showed an improvement in haemoglobin and thrombocyte counts and a reduction in spleen size and bone marrow fibrosis in patients with PMF, post-ET and post-PV myelofibrosis treated with thalidomide. However, side effects are toxicity and mainly neurotoxicity. More promising might be lenalidomide, which shows fewer side effects with similar improvement in haematopoiesis.⁵³ The use of erythropoiesis-stimulating agents in myelofibrosis is not recommended due to the risk of splenomegaly exacerbation.^{52,55}

PMF patients in the intermediate-2 and high-risk group have an indication for therapy, as well as regular therapy as investigational drug therapy, due to the low survival rates in these patients (*table 3*). In the presence of thrombocytosis, leukocytosis, splenomegaly or bone pain, there is an indication for hydroxyurea. Anaemia can be treated as indicated for the intermediate-1 risk group and splenectomy is also indicated as stated above.^{23,53,56-60}

The only potentially curative treatment in PMF patients is allogeneic stem cell transplantation with an overall three-year survival ranging from 30 to 60%. AlloSCT can induce graft versus host disease (GvHD), which can be divided into acute GvHD and chronic GvHD, with an incidence of about 30 to 43% and 30 to 48%, respectively.⁶¹⁻⁶³ However, despite the high rate of death and the high risk of chronic morbidity due to GvHD, alloSCT is justified in PMF patients belonging

to the intermediate-2 or high-risk group, while the median survival of these patients is three years and one year⁶⁴ respectively (*table 3*). The three-year overall survival of PMF patients after alloSCT ranges from 37 to 58%.

Future treatment

New therapeutic strategies include JAK inhibitors and imatinib mesylate. Imatinib mesylate (tyrosine kinase inhibitor) is used in the treatment of chronic myelogenous leukaemia and has been shown to reduce spleen size and to reduce the proliferative activity in PV patients.⁶⁵ Several JAK inhibitors have been developed since the discovery of the JAK2^{V617F} mutation in 2005, among them ruxolitinib (INCBO18424), SAR302503 (TG101348), CYT387, lestaurtinib (CEP701) and SB1518.

Ruxolitinib is a JAK1 and JAK2 inhibitor which was tested in a phase I/II trial. Patients showed responses after one to two months including reduction of spleen size and improvement of constitutional symptoms including fatigue, weight loss, night sweats and pruritus. A more than 50% decrease in total symptom score after 24 weeks occurred in 46% of the patients compared with 5% for the placebo group. Haematological side effects were anaemia and thrombocytopenia (grade 3 or 4). Non-haematological toxic effects were low grade and infrequent. After 60 days the overall survival of the patients treated with ruxolitinib was higher compared with the placebo group (hazard ratio = 0.67). Allele burden was minimally decreased and ruxolitinib was shown to be effective in patients with the JAK2^{V617F} mutation, but also in patients without the JAK2 mutation.^{66,67} Ruxolitinib is now being tested in a phase III trial.

In a recent study by Tefferi *et al.* 51 patients were enrolled in the phase I/II COMFORT trial experiencing a very rapid relief of symptoms related to the presence of myelofibrosis and splenomegaly. However, the occurrence of serious anaemia and thrombocytopenia, loss or lack of response, disease progression, patient/physician choice often associated with lack of response, and death during the study prompted 47 patients to discontinue with ruxolitinib treatment. During treatment discontinuation, acute relapse of symptoms and splenomegaly were experienced by most patients, which sometimes required hospitalisation. This observation stresses the need for careful disclosure of the ruxolitinib withdrawal syndrome to myelofibrosis patients. Further, treatment discontinuation should be done under close supervision in a gradual tapering schedule, although the tapering schedule does not guarantee that the withdrawal symptoms will not occur.⁶⁸ However, these side effects and the occurrence of ruxolitinib withdrawal syndrome do not counteract the benefits MPN patients with myelofibrosis experience with ruxolitinib treatment. SAR302503 is a selective JAK2 inhibitor inducing rapid spleen size reduction and improvement of constitutional

symptoms. Further, the majority of patients with leukocytosis and thrombocytosis at baseline achieved normal blood counts. A significant decrease in the *JAK2^{V617F}* allele burden was observed. Grade 1 self-limiting side effects were nausea, diarrhoea and vomiting. Haematological side effects of grade 3 to 4 were anaemia, thrombocytopenia and less frequently neutropenia.⁶⁹ SAR302503 is being tested in a phase II trial at the moment.

CYT387 inhibits the *JAK1* and *JAK2* gene. First results are promising; improvement in spleen size, anaemia and constitutional symptoms. Side effects were headache and thrombocytopenia.⁷⁰ CYT387 is currently under investigation in a phase I/II trial.

Lestaurtinib inhibits *JAK2* and *JAK3* and improves spleen size, transfusion dependency and cytopenias. No effect was seen on the *JAK2^{V617F}* allele burden. Side effects were diarrhoea, anaemia and thrombocytopenia.⁷¹ Currently, lestaurtinib is under investigation in a phase II trial.

SB1518 is a highly selective *JAK2* inhibitor and was well tolerated in a phase I trial with a decrease in spleen size and improvement in clinical symptoms.⁷² SB1518 is currently being tested in a phase I/II trial.

Another promising drug might be pomalidomide, a second-generation immunomodulatory drug. Pomalidomide was shown to improve anaemia (in 25% of patients treated with 0.5 mg/day and in 36% of patients treated with 3.0 mg/day) and platelet count in patients with $\leq 100 \times 10^9/l$ (in 58% patients treated with 0.5 mg/day).^{73,74} Hypomethylating agents have also been investigated. The most promising is decitabine, which was tested in a phase II study in 21 MPN patients with myelofibrosis, showing a reduction of 61% in circulating *CD34⁺* cells. ITF2357, a histone deacetylase inhibitor, was shown to resolve pruritus in most patients, to reduce splenomegaly in 38% of the patients and showed a trend in reducing the *JAK2^{V617F}* allele burden.⁷⁵

Everolimus (RAD001) inhibits the mammalian target of rapamycin (mTOR) and was shown to reduce spleen size, to complete resolution of systemic symptoms and to reduce anaemia. Side effects were worsening of anaemia in 30% of the patients and grade two neutropenia or thrombocytopenia, although infrequent.⁷⁶

The *JAK* inhibitors are the most promising new drug strategies for MPN patients with improvement in quality of life and relatively minimal side effects. However, the long-term safety of these agents and whether they prolong survival should be determined. Therefore *JAK* inhibitors should only be started as a form of therapy in myelofibrosis patients belonging to the intermediate-2 or high-risk group.

REFERENCES

- Humphries RK, Eaves AC, Eaves CJ. Self-renewal of hemopoietic stem cells during mixed colony formation in vitro Proc Natl Acad Sci. USA, 1981;78(6):3629-33.
- Giebel B. Cell polarity and asymmetric cell division within human hematopoietic stem and progenitor cells. Cells Tissues Organs. 2008;188(1-2):116-26.
- Akashi, K, Traver, D, Miyamoto, T, Weissman, IL, A clonogenic common myeloid progenitor that gives rise to all myeloid lineages Nature. 2000;404(6774):193-7.
- Akashi, K, Traver, D, Kondo, M, Weissman, IL, Lymphoid development from hematopoietic stem cells Int J Hematol. 1999;69(4):217-26.
- Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell. 2007;1(6):685-97.
- Orkin, SH, Zon, LI, Hematopoiesis: an evolving paradigm for stem cell biology Cell, 2008 132(4):631-44
- Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-66.
- Dameshek, W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-5.
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
- Budde U, Scharf RE, Franke P, et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma Blood. 1993;82(6):1749-57.
- Thiele J, Kvasnicka HM, Fischer R. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders – aids to diagnosis and classification Ann Hematol. 1999;78(11):495-506.
- Murray J. Myeloproliferative disorders. Clin Med. 2005;5(4):328-32.
- Tefferi A. How I treat myelofibrosis. Blood. 117(13):3494-504.
- Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010;91(2):174-9.
- Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical correlates of *JAK2^{V617F}* presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299-307.
- Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating *JAK2* tyrosine kinase mutation *V617F* in the Budd-Chiari syndrome. Gastroenterology. 2006;130(7):2031-8.
- Regina S, Herault O, D'Alteroche L, et al. *JAK2 V617F* is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost. 2007;5(4):859-61.
- Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood. 2007;110(4):1092-7.
- Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms Leukemia. 2008;22(1):14-22.
- Turkington RC, Arnold EC, Percy MJ, et al. Comparison of diagnostic criteria for polycythemia vera. Hematology. 2007;12(2):123-30.
- Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60-70.
- Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-302.

- 23 Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. *CA Cancer J Clin.* 2009;59(3):171-91.
- 24 Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet.* 2005;365(9464):1054-61.
- 25 James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature.* 2005;434(7037):1144-8.
- 26 Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *N Engl J Med.* 2005;352(17):1779-90.
- 27 Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell.* 2005;7(4):387-97.
- 28 Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. *Blood.* 2005;106(6):2162-8.
- 29 Toyama K, Karasawa M, Yamane A, et al. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets. *Br J Haematol.* 2007;139(1):64-9.
- 30 Florensa L, Bellosillo B, Besses C, et al. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E, and CFU-GM) in essential thrombocythemia patients. *Leukemia.* 2006;20(10):1903-5.
- 31 Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. *Blood.* 2008;111(8):3931-40.
- 32 Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. *J Clin Oncol.* 2005;23(10):2224-32.
- 33 Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. *Semin Hematol.* 1986;23(2):132-43.
- 34 Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. *Blood Rev.* 2005;19(5):243-52.
- 35 Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. *Leukemia.* 2008;22(8):1494-502.
- 36 Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. *N Engl J Med.* 2005;353(1):33-45.
- 37 Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. *Semin Hematol.* 1986;23(3):172-6.
- 38 Gruppo Italiano Studio Policitemia (GISP). Low-dose aspirin in polycythaemia vera: a pilot study. *Br J Haematol.* 1997;97(2):453-6.
- 39 Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. *N Engl J Med.* 2004;350(2):114-24.
- 40 Scott RB. Treatment of polycythaemia rubra vera. *Br Med J.* 1953;1(4820):1128-31.
- 41 Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. *Semin Hematol.* 1997;34(1):17-23.
- 42 Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. *Lancet.* 1988;2(8607):403.
- 43 Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. *Cancer.* 2006;107(3):451-8.
- 44 Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL- negative myeloproliferative disorders: final result of a phase 2 study. *Cancer.* 2007;110(9):2012-8.
- 45 Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. *Cancer.* 2006;106(11):2397-405.
- 46 Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. *J Clin Oncol.* 2009;27(32):5418-24.
- 47 Kiladjan JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. *Blood.* 2008;112(8):3065-72.
- 48 Landolfi R, Nicolazzi MA, Porfida A, et al. Polycythemia vera. *Intern Emerg Med.* 2010;5(5):411-3.
- 49 Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood.* 2009;113(13):2895-901.
- 50 Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood.* 2010;115(9):1703-8.
- 51 Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol.* 2011;29(4):392-7.
- 52 Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol.* 2011;29(6):761-70.
- 53 Mishchenko E, Tefferi A. Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms: JAK2 inhibitors, radiotherapy, splenectomy and transjugular intrahepatic portosystemic shunt. *Eur J Haematol.* 2010;85(3):192-9.
- 54 Holle N, de Witte T, Mandigers C, et al. Thalidomide and lenalidomide in primary myelofibrosis. *Neth J Med.* 2010;68(11):293-8.
- 55 Tefferi A, Vainchenker W. Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies. *J Clin Oncol.* 2011;29(5):573-82.
- 56 Cervantes F. Modern management of myelofibrosis. *Br J Haematol.* 2005;128(5):583-92.
- 57 Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. *Br J Haematol.* 2005;129(6):771-5.
- 58 Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. *Br J Haematol.* 2004;127(4):399-403.
- 59 Cervantes F, Hernandez-Boluda JC, Alvarez A, et al. Danazol treatment of idiopathic myelofibrosis with severe anemia. *Haematologica.* 2000;85(6):595-9.
- 60 Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. *Cancer J.* 2007;13(6):377-83.
- 61 Stewart WA, Pearce R, Kirkland KE, et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. *Bone Marrow Transplant.* 2010;45(11):1587-93.
- 62 Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). *Br J Haematol.* 2011;152(3):331-9.
- 63 Lissandre S, Bay JO, Cahn JY, et al. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. *Bone Marrow Transplant.* 2011;46(4):557-61.
- 64 Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood.* 2009;114(26):5264-70.
- 65 Gaikwad A, Verstovsek S, Yoon D, et al. Imatinib effect on growth and signal transduction in polycythemia vera. *Exp Hematol.* 2007;35(6):931-8.

- 66 Verstovsek S, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. *N Engl J Med.* 2010;363(12):1117-27.
- 67 Verstovsek S, Kantarjian H, Mesa RA, et al. Results of COMFORT-1, a Randomized Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib (INCB18424) versus Placebo for Patients With Myelofibrosis Oral Communication. *EHA*, 2011.
- 68 Tefferi A, Pardanani A. Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis *Mayo Clin Proc.* 2011;86(12):1188-91.
- 69 Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. *J Clin Oncol.* 2011;29(7):789-96.
- 70 Pardanani A, George G, Lasho T, et al. A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms. *Blood.* 2010;117 Abstr 460.
- 71 Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. *Blood.* 2010;115(6):1131-6.
- 72 Verstovsek S, Odenike O, Scott B, et al. Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/Polycythemia Vera Myelofibrosis. *Blood.* 2009;114 Abstr 3905.
- 73 Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. *Leukemia.* 2010;25(2):301-4.
- 74 Mesa RA, Pardanani AD, Hussein K, et al. Phase 1/2 study of Pomalidomide in myelofibrosis. *Am J Hematol.* 2010;85(2):129-30.
- 75 Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. *Br J Haematol.* 2010;150(4):446-55.
- 76 Vannucchi AM, Guglielmelli P, Lupo L, et al. A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results. *Blood* 2010;116:314 (ASH Annual Meeting Abstracts).

VEKORTE PRODUCTINFORMATIE

Janumet 50 mg/850 mg filmomhulde tabletten (sitagliptine met metformine)
Janumet 50 mg/1000 mg filmomhulde tabletten (sitagliptine met metformine)

Samenstelling

Elke tablet bevat 50 mg sitagliptine (als fosfaatmonohydraat) en 850 mg resp. 1000 mg metforminehydrochloride.

Farmacotherapeutische categorie: combinaties van orale bloedglucoseverlagende middelen, ATC-code: A10BD07 (een DPP4-remmer en een biguanide).

Indicaties

Voor patiënten met type 2-diabetes mellitus: Janumet is geïndiceerd, als aanvulling op dieet en lichaamsbeweging, voor verbetering van de bloedglucoseregulatie bij patiënten die niet optimaal gereguleerd zijn met de maximale verdraagbare dosis van metformine alleen of patiënten die al behandeld worden met een combinatie van sitagliptine en metformine. Janumet is geïndiceerd in combinatie met een sulfonylureumderivaat (een drievoudige combinatiebehandeling), als aanvulling op dieet en lichaamsbeweging, bij patiënten die niet optimaal gereguleerd zijn met de maximale verdraagbare dosis van metformine en een sulfonylureumderivaat. Janumet is geïndiceerd als drievoudige combinatiebehandeling (met een peroxisome proliferator-activated receptor gamma (PPARγ)-agonist (een thiazolidinedion) als aanvulling op dieet en lichaamsbeweging) bij patiënten die niet optimaal gereguleerd zijn met de maximale verdraagbare dosis van metformine en een PPARγ-agonist. Janumet is ook geïndiceerd als toevoeging bij insuline (drievoudige combinatiebehandeling) als aanvulling op dieet en lichaamsbeweging voor verbetering van de bloedglucoseregulatie bij patiënten die niet optimaal gereguleerd zijn met stabiele doses insuline en metformine alleen.

Contra-indicaties

- overgevoeligheid voor de werkzame bestanddelen of voor één van de hulpstoffen;
- diabetische ketoacidose, diabetisch precoma;
- matig-ernstige of ernstige nierfunctiestoornis (creatinineklaring < 60 ml/min)
- acute aandoeningen waarbij een risico van verandering van de nierfunctie bestaat, zoals: dehydratie, ernstige infectie, shock, intravasculaire toediening van jodiumhoudende contrastmiddelen;
- acute of chronische aandoeningen die weefselhypoxie kunnen veroorzaken, zoals: hartfalen of respiratoire insufficiëntie, recent myocardinfarct, shock;
- leverfunctiestoornis;
- acute alcoholovergiftiging, alcoholisme;
- borstvoeding.

Bijzondere waarschuwingen en voorzorgen bij gebruik

Janumet mag niet worden gebruikt bij patiënten met type 1-diabetes en moet niet worden gebruikt voor de behandeling van diabetische ketoacidose.
Pancreatitis
Sinds het geneesmiddel op de markt is, zijn er spontane meldingen van bijwerkingen van acute pancreatitis. Patiënten moeten worden geïnformeerd over het kenmerkende symptoom van acute pancreatitis: aanhoudende, ernstige buikpijn. Na stopzetting van sitagliptine (met of zonder ondersteunende behandeling) is waargenomen dat de pancreatitis verdwenen, maar er zijn zeer zeldzame gevallen van necrotiserende of hemorrhagische pancreatitis en/of overlijden gemeld. Als pancreatitis vermoed wordt, moeten Janumet en andere mogelijk suspecte geneesmiddelen worden stopgezet.
Lactaatacidose
Lactaatacidose kan zich voordoen bij accumulatie van metformine. Gerapporteerde gevallen van lactaatacidose bij patiënten die met metformine werden behandeld, zijn primair vastgesteld bij diabetespatiënten met significant nierfalen.
Van metformine en sitagliptine is bekend dat zij voor een belangrijk deel door de nieren worden uitgescheiden. De kans op metforminegerelateerde lactaatacidose neemt toe met de mate van nierinsufficiëntie. Bij oudere patiënten komt een verminderde nierfunctie vaak voor en is deze asymptomatisch. Bijzondere voorzichtigheid is geboden in situaties waarin kans op een vermindering van de nierfunctie bestaat, bijvoorbeeld

aan het begin van een antihypertensieve behandeling, een behandeling met diuretica of bij aanvang van een behandeling met niet-steroidale ontstekingsremmers (NSAIDs).

Bij combinatie van Janumet met een sulfonylureumderivaat of met insuline is de kans op hypoglykemie verhoogd. Het kan daarom nodig zijn om de dosering van het sulfonylureumderivaat of de insuline te verlagen. Er zijn postmarketingmeldingen van ernstige overgevoeligheidsreacties. Deze reacties zijn onder andere angio-oedeem, angio-oedeem en exfoliatieve huidaandoeningen, waaronder Stevens-Johnson-syndroom. Deze reacties begonnen in de eerste 3 maanden na aanvang van de behandeling met sitagliptine, met enkele meldingen na de eerste dosis. Omdat Janumet metforminehydrochloride bevat, moet de behandeling 48 uur voor een electieve chirurgische ingreep onder algemene, onder spinale of epidurale anesthesie onderbroken worden. Intravasculaire toediening van jodiumhoudende contrastmiddelen voor radiologisch onderzoek kan leiden tot nierfalen dat in verband is gebracht met lactaatacidose bij patiënten die met metformine behandeld worden. Daarom moet de behandeling met Janumet voor of op het moment van het onderzoek onderbroken worden. Een patiënt met type 2-diabetes die eerder goed gereguleerd was met Janumet en die afwijkende laboratoriumwaarden of klinische ziekteverschijnselen krijgt (vooral vage, weinig gedefinieerde klachten) moet direct worden onderzocht op aanwijzingen voor ketoacidose of lactaatacidose. Bij elke vorm van acidose moet de behandeling met Janumet direct gestaakt worden en moet de patiënt gericht behandeld worden.

Bijwerkingen

Sitagliptine/metformine
Geneesmiddelgerelateerde bijwerkingen die vaker (> 0,2 % en verschil > 1 patiënt) voorkwamen dan bij placebo en die gemeld werden bij patiënten die in dubbelblind onderzoek sitagliptine in combinatie met metformine kregen, werden hieronder vermeld. De frequenties zijn gedefinieerd als: zeer vaak (> 1/10), vaak (> 1/100 tot < 1/10), soms (> 1/1000 tot < 1/100), zelden (> 1/10.000 tot < 1/1000) en zeer zelden (< 1/10.000).

Tabel 1. De frequentie van bijwerkingen, vastgesteld in placebogecontroleerd klinisch onderzoek

Bijwerking	Frequentie van bijwerkingen per behandeling			
	Sitagliptine met metformine ¹	Sitagliptine met metformine en een sulfonylureumderivaat ²	Sitagliptine met metformine en een PPARγ-preparaat (rosiglitazon) ³	Sitagliptine met metformine en insuline ⁴
Tijdstip	24 weken	24 weken	18 weken	24 weken
Voedings- en stofwisselingsstoornissen				
Hypoglykemie ⁵		Zeer vaak	Vaak	Zeer vaak
Zenuwstelselaandoeningen				
Hoofdpijn			Vaak	Soms
Slaperigheid	Soms			
Maag-darmstelselaandoeningen				
Diarree	Soms		Vaak	
Misselijkheid	Vaak			
Obstipatie		Vaak		
Pijn in de bovenbuik	Soms			
Braken			Vaak	
Droge mond				Soms
Algemene aandoeningen en toedieningsplaatsstoornissen				
Perifeer oedeem			Vaak ⁶	
Onderzoeken				
Verlaagd bloedglucose	Soms			

¹ Tijdens klinisch onderzoek met sitagliptine als monotherapie en sitagliptine als onderdeel van een combinatiebehandeling met metformine of metformine en een PPARγ-preparaat, was de frequentie van met sitagliptine gemelde hypoglykemie vergelijkbaar met die bij patiënten die placebo kregen.

² Waargenomen in de analyse na 54 weken.
³ Incidentie van bijwerkingen* bij patiënten die werden behandeld met sitagliptine/metformine versus behandeling met placebo/metformine 9,3 % respectievelijk 10,1 %.
⁴ Incidentie van bijwerkingen* bij met sitagliptine/metformine behandelde patiënten versus sulfonylureum/metformine was 14,5 % respectievelijk 30,3 %.

⁵ In gepoolde studies die tot 1 jaar duurden waarin sitagliptine/metformine met sulfonylureumderivaat/metformine werden vergeleken, bij patiënten die met sitagliptine 100 mg werden behandeld traden vaker (> 0,2 % en verschil > 1 patiënt) anorexie en gewichtsverlies op dan bij patiënten die het sulfonylureumderivaat kregen.

⁶ Incidentie van bijwerkingen* bij patiënten die met sitagliptine in combinatie met glibepride/metformine werden behandeld in vergelijking met behandeling met placebo in combinatie met glibepride/metformine was 18,1 % respectievelijk 7,1 %.

⁷ Incidentie van bijwerkingen* bij patiënten die werden behandeld met sitagliptine in combinatie met rosiglitazon/metformine versus patiënten die werden behandeld met de placebo combinatie was 15,3 % respectievelijk 10,9 %. Bijwerkingen in de analyse na 54 weken (frequentie vaak) bij patiënten die werden behandeld met de sitagliptine combinatie en die vaker (< 0,2 % en verschil > 1 patiënt) optreden dan bij patiënten die met de placebo combinatie werden behandeld, waren: hoofdpijn, hoest, braken, hypoglykemie, huitschimmelfunctie en bovenstelselgereguleerde.

⁸ Incidentie van bijwerkingen* bij patiënten die werden behandeld met sitagliptine in combinatie met insuline/metformine versus patiënten die werden behandeld met de placebo combinatie was 16,2 % respectievelijk 9,0 %.

⁹ die werden geacht met het geneesmiddel samen te hangen

Postmarketinggegevens

Sinds het op de markt komen van Janumet of sitagliptine, één van de werkzame bestanddelen van Janumet, zijn aanvullende bijwerkingen gemeld (frequentie onbekend). Deze bijwerkingen zijn gemeld bij gebruik van Janumet of sitagliptine alleen en/of in combinatie met andere antihyperglykemische middelen: overgevoeligheidsreacties, waaronder angio-oedeem, uitslag, urticaria, cutane vasculitis en exfoliatieve huidaandoeningen waaronder Stevens-Johnson-syndroom; acute pancreatitis, waaronder fatale en niet-fatale hemorrhagische en necrotiserende pancreatitis; verminderde nierfunctie, waaronder acuut nierfalen (waarvoor soms nierdialyse nodig is); braken.

Metformine

Gegevens uit klinisch onderzoek en postmarketinggegevens
Tabel 2 geeft de bijwerkingen weer naar systeem-organklasse en frequentie categorie. De frequentie categorieën zijn gebaseerd op gegevens uit de Samenvatting van Productkenmerken van metformine, beschikbaar in de EU.

Tabel 2. De frequentie van bijwerkingen van metformine, vastgesteld in klinisch onderzoek en uit postmarketinggegevens

Bijwerking	Frequentie
Voedings- en stofwisselingsstoornissen	
lactaatacidose	Zeer zelden
vitamine B12-deficiëntie ^a	Zeer zelden
Zenuwstelselaandoeningen	
metaal smaak	Vaak
Maag-darmstelselaandoeningen	
maag-darmklachten ^b	Zeer vaak
Lever- en galtaandoeningen	
leverfunctiestoornissen, hepatitis	Zeer zelden
Huid- en onderhuids-aandoeningen	
urticaria, erytheem, pruritus	Zeer zelden

^a Langtermijnbehandeling met metformine wordt in verband gebracht met een afname van de absorptie van vitamine B12 wat in zeer zeldzame gevallen kan leiden tot klinisch significante vitamine B12-deficiëntie (bv. megaloblastaire anemie).

^b Maag-darmklachten als misselijkheid, braken, diarree, buikpijn en verlies van eetlust komen het meest voor in het begin van de behandeling en verdwijnen in de meeste gevallen spontaan.

Afleverstatus

UR

Vergoeding
Janumet wordt uitsluitend vergoed voor een verzekerde met diabetes mellitus type 2 die niet behandeld kan worden met de combinatie van metformine en een sulfonylureumderivaat, geen insuline gebruikt en dit middel gebruikt als een tweevoudige of drievoudige behandeling in combinatie met metformine of een sulfonylureumderivaat.

Raadpleeg de volledige productinformatie (SPC) voordat u Janumet voorschrijft.

14 december 2010.

Merck Sharp & Dohme BV
Postbus 581
2003 PC HAARLEM
www.msdl.nl



Walled-off pancreatic necrosis

*J.M. Ramia, R. de la Plaza, J.E. Quiñones-Sampedro, C. Ramiro, P. Veguillas, J. García-Parreño

Hepato-Pancreato-Biliary Surgical Unit, Department of Surgery, Hospital of Guadalajara, Guadalajara, Spain, *corresponding author: tel.: +34 (0)616292056, e-mail: jose_ramia@hotmail.com

ABSTRACT

Acute severe pancreatitis may be complicated by the development of 'walled-off pancreatic necrosis' (WOPN), which is characterised by a mixture of solid components and fluids on imaging studies as a consequence of organised pancreatic tissue necrosis. We present here an overview of the definition, clinical features, and diagnostic and therapeutic management of this clinical condition, which is mostly based on consensus as adequate clinical trials are lacking.

KEYWORDS

Pancreatitis, walled-off, review

INTRODUCTION

The term 'walled-off pancreatic necrosis' (WOPN) was first used in 2005 to define a mixed fluid-solid collection [i.e. a picture that is composed of solid components and fluids], with a similar appearance to pancreatic pseudocyst, which occurs after severe acute pancreatitis.^{1,3} Previous designations for the condition are organised pancreatic necrosis, post-necrosis pseudocyst, pancreatic sequestration or necroma.³⁻⁶ In 2006, the term 'walled-off pancreatic necrosis' was officially accepted at the American Gastroenterological Association meeting.⁷ However, the new nomenclature had various interpretations and consensus about its radiological characteristics and therapeutic options was lacking. In a PubMed search (June 2011) of "walled-off pancreatic necrosis" we only found 18 entries, but some articles were not totally related to the item, so no more than ten articles about WOPN are currently available.^{1,3,6-11} We have performed a comprehensive review of this topic.

DEFINITION OF WOPN

In 1992, the Atlanta Classification added clear terms and definitions for the diagnosis of acute pancreatitis and its complications. This allowed the comparison of the results of different working groups in the medical community and simplified the common management of patients around the world.¹² In recent years, new concepts or terms, such as WOPN, have been postulated and this classification will probably have to be updated.¹³

In 1996, Baron *et al.* first used the term 'organised pancreatic necrosis' to describe a transitional collection between pancreatic necrosis and pancreatic pseudocyst that contained different amounts of fluid and necrotic tissue.⁴ This entity was caused by the necrosis and liquefaction of pancreatic and peripancreatic tissue, with or without pancreatic duct communication.^{3,5}

A temporary proposed classification of acute pancreatitis postulated the new term 'post-necrotic pancreatic and peri-pancreatic collections'.¹⁴ These collections consisted of different proportions of fluid and solid necrosis and can be identified three to six weeks after the episode of acute pancreatitis. When the collections are fully developed, the presence of a thin wall without epithelium may lead to a misdiagnosis of pancreatic pseudocyst. Once walled-off collections are present, WOPN can be diagnosed.^{6,14}

WOPN occurs in 1 to 9% of cases of acute necrotising pancreatitis.^{5,6,8} Acute biliary pancreatitis is the most common cause of WOPN (50 to 70%) and other aetiologies are alcohol abuse and idiopathic.⁸⁻¹⁰ Only a few cases of WOPN are caused by chronic pancreatitis (4-16%).^{1,2,6} No difference in the frequency of WOPN formation between men and women has been clearly demonstrated.⁷ The most frequent locations of WOPN are the pancreatic body and tail (80 to 92% of the cases), and extension to the paracolic gutters often occurs.^{1,6,8-10} The mean size of published WOPNs is between 11 and 17 cm.^{1,2,6,8-10}

CLINICAL FEATURES

WOPN typically occurs later in the course of pancreatitis, several weeks (>3-6 weeks) after the start of the attack.⁷ After the first episode of acute pancreatitis, WOPN patients might be asymptomatic (50%) or present with symptoms (50%) such as abdominal pain, malaise, relapsing or recurrent pancreatitis, feeding intolerance or weight loss.^{1,6} In severe cases, WOPN can obstruct the gastrointestinal tract, fistulise to adjacent anatomic strictures, and compress or erode into blood vessels or the bile duct.¹¹ WOPN can be infected or aseptic.^{1,6} A third of the patients have infected WOPN, sometimes after percutaneous drainage or endoscopy treatment, which could be the source of infection. There is no clear correlation between the symptoms and WOPN infection. If infection is present, gas can be observed on the computed tomography (CT) but only a positive test after percutaneous puncture and gram staining will confirm the infection. The most commonly isolated bacteria in WOPN are *E. coli*, *K. pneumoniae*, *E. faecalis* and *S. aureus*.^{6,7} Splenic vein thrombosis is seen in 40% of cases.⁶

DIAGNOSTIC METHODS

No specific clinical chemistry tests define WOPN.⁷ The degree of pancreatic enzyme elevation does not correlate with the degree of necrosis.⁷ WOPN can be identified with the use of initial and subsequent CT scans that show progression of the initial early necrosis to WOPN which occupies and expands the initial necrotic areas. On CT, WOPN appears as a mostly heterogeneous collection (mixture of fat, fluid and solids) usually without gas.^{3,11} Gas within a WOPN collection does not always mean infection. For the most part it is due to fistulisation to the stomach or more commonly the duodenum, in which case it may be sterile. When WOPN fistulises to the colon it is always infected. CT accuracy in the differential diagnosis between WOPN and pseudocyst is about 79 to 84%.³ A correct diagnosis is crucial because it influences the management of the pancreatic collection. Magnetic resonance imaging (MRI) and endoscopic ultrasound scans provide a better definition of the solid component inside necrotic collections.^{3,13,14}

MANAGEMENT OF WOPN

This new term (WOPN) creates a challenge for identifying the most appropriate management. WOPN rates have probably been underestimated in the past because of an unclear definition, multiple names and incorrect diagnosis.

The management of asymptomatic patients is unclear. Discussions centre on the need for, time and duration of management.^{2,6} In symptomatic patients, infection evidenced by fever, leukocytosis and/or sepsis syndrome is the most common indication for the treatment of WOPN.⁶ Other indications are: progressive increase in size, pain, gastric or duodenal outlet obstruction that interferes with feeding or causes persistent nausea or vomiting, biliary obstruction, portal thrombosis, fistulous connection between WOPN and adjacent strictures or clinical deterioration.^{1,10,11} The start of WOPN treatment has ranged from 42 to 72 days (range 20 to 300 days) after the onset of acute pancreatitis.^{1,2,6} However, there is no absolute time frame and intervention is based upon the severity of clinical symptoms and degree of organisation. There are several treatment options: percutaneous drainage, endoscopic drainage, laparoscopic drainage, surgical necrosectomy and mixtures of these techniques.^{1,2,11} WOPN was historically believed to be less amenable to endoscopic or percutaneous treatment because of non-viable solid components. More recently, there has been a paradigm shift in the management of WOPN toward less invasive approaches.⁸ The goal of these techniques is to provide minimal access necrosectomy equivalent to open necrosectomy.⁸ The therapeutic options are:

- Percutaneous drainage (PD) and combined endoscopy plus PD

The solid component of WOPN limits the management of patients with percutaneous drainage, so the resolution rate is low.^{2,9} Percutaneous therapy alone had a worse success rate and more prolonged length of stay, complications, need for surgery and deaths compared with combined therapy.¹¹ Percutaneous therapy is only effective if multiple large drains are used with frequent upsizing, removal of solid debris and aggressive irrigation. The main indications for PD are: PD combined with endoscopic procedures and puncture to rule out infection.^{2,10}

Gluck *et al.* proposed combined therapy (percutaneous drainage and endoscopy). They first inserted a percutaneous drainage tube. If effective, they waited for the clinical outcome; if not, they immediately performed endoscopic therapy plus ERCP in selected cases.¹¹

- Endoscopy

Baron described the endoscopic treatment of WOPN in 1996.^{4,8,9} The main advantage of endoscopic therapy is the avoidance of surgical necrosectomy, because this procedure is associated with high morbidity and mortality. In addition, endoscopic necrosectomy is associated with a lower risk of pancreatic-cutaneous fistula compared with percutaneous drainage or surgical procedures.^{10,11} A few articles about per-oral transgastric necrosectomy in infected pancreatic necrosis have been published, but we are going to focus on articles dedicated to WOPN.¹⁵⁻¹⁸

One problem of endoscopic treatment is that it is inconvenient for patients because it takes at least three sessions.^{6,8,9,11} The endoscopic procedure is also a major interventional procedure associated with major morbidity in 10 to 26% of cases (most commonly bleeding and perforation), mortality of 2 to 7% and need for laparotomy in 0 to 23%.^{1,2,6,8-10} Moreover, endoscopy is not feasible in

Figure 1. Abdominal CT: Mixed solid-liquid collection (WOPN) Star: solid component




Figure 2. Abdominal CT: Patient from figure 1: check-up one year after open surgical necrosectomy




Figure 3. Abdominal CT: Mixed solid-liquid collection (WOPN)




Table 1. Messages

WOPN is a new name for an old entity (necroma, organised pancreatic necrosis,...)
WOPN is a transitional collection after pancreatic necrosis that contained various amounts of fluid and necrotic tissue, occurring 6 weeks after an acute pancreatitis attack
CT and MRI are the best diagnostic methods; differential diagnosis with pseudocyst is crucial
Asymptomatic patients would probably not be treated
Transmural endoscopic debridement of WOPN should be the first therapeutic technique performed in symptomatic patients
Surgery should be done only in selected cases (WOPN over 15 cm or affecting both paracolic gutters) after the failure of endoscopic techniques

patients with WOPN located more than 1.5 cm from the gastrointestinal lumen or coagulopathy.¹¹ The transgastric route is the most frequent access used (73 to 85%), but the duodenal route is also employed.⁸⁻¹⁰ Endoscopic ultrasound guidance is often used, but not always.^{8,9}

Simple endoscopic drainage of WOPN has been found to be less effective than transmural endoscopic debridement (NED).^{8,10} NED is successful in approximately 90% vs 50% with standard endoscopic drainage.^{1,8-10} This outcome is probably due to the fact that standard endoscopy does not allow correct drainage of solid debris. The wider tract fistula and direct cleaning performed in NED improve the results of endoscopy.^{8,10}

Papachristou *et al.* described 53 WOPN patients initially managed by endoscopic drainage. Endoscopy alone solved the situation in half of the cases, endoscopy and percutaneous drainage in 25% and surgical management was required in 25%.¹ Two later studies compared only irrigation-based debridement with NED, demonstrating that NED achieves better outcomes (high successful resolution rate and low rates of surgical rescue, percutaneous drainage and recurrent collection).^{8,10} In 2011, Gardner *et al.* published a multicentre study of 104 patients with WOPN treated with NED. All the patients were symptomatic. Successful resolution of WOPN was achieved with NED in 95 of 104 patients (91%). Recurrent collection and recurrent pancreatitis were the main causes of failed NED. The mean time to resolution of WOPN was 4.1 months. BMI >32 was a risk factor for failed NED. In conclusion, Gardner *et al.* stated that NED is the most efficacious technique for treating WOPN with an acceptable safety profile.⁹

Varadarajulu *et al.* described a new EUS-based approach to WOPN management consisting of creating multiple transluminal gateways to facilitate effective drainage of the necrotic contents with fewer procedures than conventional endoscopy. The associated success rate was 91.7%.¹⁰

Fischer *et al.* described six patients treated with a novel endoscopic laparoscopic drainage technique. Only one

patient required surgery. An average of six endoscopic sessions was needed (range 4-11).²

• Surgery

The classical indications for surgical therapy of WOPN are infection, complications or failed non-surgical therapies.¹¹ Surgical minimally invasive necrosectomy is technically feasible and acceptable outcomes are achieved.¹⁸ The laparoscopic approaches to pancreatic necrosectomy can be classified by access route (transperitoneal, retroperitoneal, transgastric) and type of scope (endoscope, laparoscope or nephroscope).^{6,19} The main pitfall of the laparoscopic approach is incomplete or unsuccessful drainage.² Laparoscopic and hybrid techniques that utilise wide external drainage have high rates of pancreatic fistula formation.⁶ An open approach should be used when endoscopic or laparoscopic treatment fails.^{1,2} Operative management of WOPN involves open debridement, lavage of the cavity followed by closed packing and/or drainage.⁶ Open debridement for necrotising acute pancreatitis is associated with a high morbidity (55%) and mortality (14%); no data about surgical necrosectomy for WOPN are available but will probably be lower.¹¹ Several complications have been reported: pancreatocutaneous fistula (up to 53%), enteric fistulae (16%) and abdominal wall hernias.^{6,9} Necrosectomy in WOPN patients is not easy but is less technically demanding than necrosectomy performed in necrotising acute pancreatitis.⁹

Three prognostic factors for which WOPN requires a surgical approach have been proposed: preoperative diabetes mellitus, size bigger than 15 cm and WOPN on both sides of the abdomen.^{1,8}

Munene *et al.* treated ten patients with open transgastric debridement and internal drainage for symptomatic non-infected WOPN. No mortality was observed, morbidity was 20%, and no pancreatic fistula occurred. Symptoms resolved in 90% of patients.⁶ The limitations of this technique are: lack of opposition of the gastric wall to WOPN and extension via paracolic gutters. The main problem of internal WOPN drainage is that it could lead to continuous retroperitoneal contamination. The advantages of this surgical technique compared with the endoscopic approach are similar morbidity, no mortality, reduced length of hospital stay and fewer procedures.⁶

CONCLUSION

WOPN is a new term for an established pancreatic condition. There have been very few studies of WOPN. Indications and management guidelines remain unclear and no randomised clinical trial about WOPN has been conducted. Asymptomatic patients probably would not be treated. Transmural endoscopic debridement of WOPN is efficacious with an acceptable safety profile and probably should be the first therapeutic technique to

be performed in symptomatic patients. Surgery should only be performed in selected cases: WOPN over 15 cm or affecting both paracolic gutters after endoscopic techniques have failed.

REFERENCES

1. Papachristou GI, Takahashi N, Chahal P, Sarr MG, Baron TH. Peroral endoscopic drainage/debridement of walled-off pancreatic necrosis. *Ann Surg.* 2007;245:943-51.
2. Fischer A, Schrag HJ, Keck T, et al. Debridement and drainage of walled-off pancreatic necrosis by a novel laparoendoscopic rendezvous maneuver. Experience with 6 cases. *Gastrointest Endosc.* 2008;67:871-8.
3. Takahashi N, Papachristou GI, Schmit GD, et al. CT findings of walled off pancreatic necrosis: differentiation from pseudocyst and prediction of outcome after endoscopic therapy. *Eur Radiol.* 2008;18:2522-9.
4. Baron TH, Thaggard WG, Morgan DE, Stanley RJ. Endoscopic therapy for organized pancreatic necrosis. *Gastroenterology.* 1996;111:755-64.
5. Ramos-De la Medina AM, Reid-Lombardo KM, Sarr MG. Strategies for surgical treatment of pseudocysts after acute pancreatitis. Chapter 30. In: *The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery.* Edited by H. G. Beger, A. L. Warshaw, M. W. Büchler, et al. 2008 Blackwell Publishing Limited. 2nd Edition.
6. Munene G, Dixon E, Sutherland F. Open transgastric debridement and internal drainage of symptomatic non-infected walled-off pancreatic necrosis. *HPB.* 2011;13:234-9.
7. Stamatakis M, Stefanaki C, Kontzoglou K, et al. Walled off pancreatic necrosis. *World J Gastroenterol.* 2010;16:1701-12.
8. Gardner TB, Chahal P, Papachristou GI, et al. A comparison of direct endoscopic necrosectomy with transmural endoscopic drainage for the treatment of walled-off pancreatic necrosis. *Gastrointest Endosc.* 2009;69:1085-91.
9. Gardner TB, Coelho N, Gordon SR, et al. Direct endoscopic necrosectomy for the treatment of walled-off pancreatic necrosis: results from a multicentre US series. *Gastrointest Endosc.* 2011;EPub.
10. Varadarajulu S, Phadnis MA, Christein JD, Wilcox CM. Multiple transluminal gateway technique for EUS-guided drainage of symptomatic walled-off pancreatic necrosis. *Gastrointest Endosc.* 2011;EPub.
11. Gluck M, Ross A, Irani S, et al. Endoscopic and percutaneous drainage of symptomatic walled-off pancreatic necrosis reduces hospital stay and radiographic resources. *Clin Gastroenterol Hepatol.* 2010;8:1083-8.
12. Bradley EL. A clinically based classification system for acute pancreatitis. *Arch Surg.* 1993;128:586-9.
13. Bollen TL, Besselink MGH, Santvoort HC, et al. Toward an update of the Atlanta classification on acute pancreatitis. *Pancreas.* 2007;35:107-13.
14. Sarr MG. Proposed revision of the Atlanta Classification of acute pancreatitis. *Acute Pancreatitis Classification Working Group.* http://www.suizou.org/Atlanta_Classification.pdf.
15. Friedland S, Kaltenbach T, Sugimoto M, Soetikno R. Endoscopic necrosectomy of organized pancreatic necrosis: a currently practiced NOTES procedure. *J Hepatobiliary Pancreat Surg.* 2009;16:266-9.
16. Voermans RP, Veldkamp MC, Rauws EA, et al. Endoscopic transmural debridement of symptomatic organized pancreatic necrosis. *Gastrointest Endosc.* 2007;66:909-16.
17. Escorrou J, Shehab H, Buscail L, et al. Peroral transgastric/transduodenal necrosectomy. Success in treatment of infected pancreatic necrosis. *Ann Surg.* 2008;248:1074-80.
18. Babu BI, Siriwardena AK. Current status of minimally invasive necrosectomy for post-inflammatory pancreatic necrosis. *HPB.* 2009;11:96-102.
19. Windsor JA. Minimally invasive pancreatic necrosectomy. *Br J Surg.* 2007;94:132-3.

BK virus infection in transplant recipients: Clinical manifestations, treatment options and the immune response

M.C. van Aalderen^{1,3*}, K.M. Heutinck^{1,3}, C. Huisman², I.J.M. ten Berge¹

¹Renal Transplant Unit, Department of Nephrology, ²Haematopoietic Stem Cell Transplant Unit, Department of Clinical Haematology, Division of Internal Medicine, ³Department of Experimental Immunology, Academic Medical Centre, Amsterdam, the Netherlands, *corresponding author: tel. +31 (0)20 5667732, fax: +31 (0)20 5669756, e-mail: m.c.vanaalderen@amc.uva.nl

ABSTRACT

Polyomavirus BK (BKV) is ubiquitously present amongst the general population establishing a latent, seemingly asymptomatic infection in immunocompetent individuals. In transplant recipients, however, BKV reactivation is common and can lead to distinctive pathological entities in different patient groups: in renal transplant (RT) recipients, it is associated with nephropathy (BKVN) and ureteral stenosis, and in haematopoietic stem cell transplant (HSCT) recipients with haemorrhagic cystitis (HC). Furthermore, BKV employs several potentially oncogenic mechanisms to promote its replication in cells and has been inconsistently linked to the development of malignancies. BKVN is currently a major cause of allograft failure in RT recipients. HC causes prolonged hospital stay and increased mortality in HSCT recipients. Despite its discovery more than 40 years ago, few advances have been made with regard to therapeutic strategies. Current therapies aim to restore the impaired immune response, e.g. by lowering immunosuppressive agents in RT recipients. However, this is a double-edged sword since it also increases the chance of rejection. Therefore, more specific and effective treatment strategies are urgently needed. Here, we will review the current knowledge on the structure and lifecycle of BKV, characteristics of the BKV-specific immune response, its clinical manifestations and the strengths and limitations of available treatments methods.

KEYWORDS

Haemorrhagic cystitis, nephropathy, polyomavirus BK, viral immunity, ureteral stenosis

INTRODUCTION

In 1971, Gardner and co-workers were the first to isolate polyomavirus BK (BKV) from both urine and ureteral epithelial cells of a Sudanese renal transplant (RT) recipient who presented with renal failure and ureteral stenosis. They named the virus after the initials of this patient.¹ Since then, numerous publications on various aspects of this virus have been published.

BKV seems to be ubiquitously present amongst the general population and up to 100% of tested individuals may be seropositive, with peak seroprevalences reported to occur in children and young adults.^{2,3} Up to now, BKV has not definitively been associated with disease in immunocompetent individuals. However, in immunocompromised individuals, the virus frequently reactivates and currently poses a major challenge to transplantation medicine. In this review, several aspects of this virus such as structure and lifecycle, BKV-directed immunity, as well as clinical manifestations and therapeutic strategies are discussed.

STRUCTURE AND LIFECYCLE

BKV is a small, ~45 nm in diameter, non-enveloped DNA virus with a double-stranded circular genome that comprises ~5000 base pairs. BKV shows 70 to 75% sequence homology to other polyomaviruses such as JC virus (JCV), and Simian vacuolating virus 40 (SV40).^{4,7} The viral capsid is composed of the structural virion proteins (VP) 1, 2 and 3, and accommodates the viral minichromosome. Pentameres of VP1, arranged in an icosahedral lattice, form the outer capsid.⁸ On the inside, the VP1 pentameres have a central groove in which VP2

or VP3 is inserted.⁹ All three structural proteins contain DNA-binding motifs.¹⁰ A simplified visualisation of the virus is presented in *figure 1*.

The lifecycle of BKV, visualised in *figure 2*, is initiated by the binding of VP1 to certain sialic acid motifs on N-linked glycoproteins and/or to gangliosides GD1b and GT1b on the cell membrane.¹¹⁻¹³ After attachment, BKV traverses the cell membrane by caveolae-mediated endocytosis.¹⁴ Caveolae

arise from lipid rafts, plasma membrane regions enriched in cholesterol and the aforementioned gangliosides.¹⁵ Next, BKV is transported towards the endoplasmic reticulum via microtubules.^{16,17} Disassembly of the outer capsid is essential for the exposure of VP2 and VP3 which mediate entry into the nucleus via importins.¹⁸ The precise mechanism of capsid disassembly is not known but seems to involve an early acidification step and ultimately leads to cleavage of VP1 molecules and capsid rearrangement.¹⁷ The viral minichromosome consists of circular double-stranded DNA wound around histones.¹⁹ The BKV genome can roughly be divided into three regions as depicted schematically in *figure 3*: the non-coding control region (NCCR), which contains the origin of replication, a bidirectional promoter-enhancer region and binding sites for host transcription factors;^{20,21} the early region, containing genes coding for the tumour antigen (TA) proteins; and the late region, which contains genes coding for agnoprotein and VP1, 2 and 3.

Counter-clockwise transcription of the early region is the first step of replication and leads to the production of the TA proteins. Three T antigen proteins are produced: large TAg (LTA), truncated TAg (TruncTAg), and the small T antigen (stAg). Multiple LTA molecules form a dodecameric complex that binds to the viral origin of DNA replication. Here it acts like a helicase by opening up and unwinding the DNA to initiate clockwise transcription of the late regions.^{22,23} LTA was also demonstrated to bind

Figure 1. The BKV capsid and minichromosome




Figure 2. Lytic lifecycle of BKV





Figure 3. A schematic overview of the BKV genome



to heat shock proteins, members of the retinoblastoma protein family, and p53, as such driving the cell into the S phase and preventing cell cycle arrest.²⁴⁻²⁶ Knowledge on the function of BKV stAg is limited. In mice, stAg of murine polyomavirus (mPyv) complements LTA_g in driving cell cycle progression by several mechanisms, such as activation of the promoter of the proto-oncogene *c-myc*.^{27,28} TruncTA_g results from alternative splicing of the LTA_g transcript and its functions remain to be elucidated.²⁹ Transcription of the late region genes leads to the production of the structural VP₁, VP₂ and VP₃ proteins, as well as the non-structural agnoprotein. Little is known on the functions of agnoprotein but it seems to mediate assembly of BKV virions.³⁰ JCV agnoprotein was found to inhibit double-stranded DNA repair and may as such increase the production rate of more virulent mutant viruses.³¹ Intracellular accumulation of daughter virions ultimately results in rupture of cell membranes, thereby releasing virus progeny into the extracellular space.^{32,33}

IMMUNE RESPONSE

The precise route of transmission of BKV is still unclear but may involve salivary, faecal and possibly even transplacental transmission.³⁴⁻³⁶ Recently, it was demonstrated that certain defensins, small cationic molecules involved in neutralising a broad spectrum of pathogenic microbes, are able to inhibit BKV infection in an early stage of the virus lifecycle. The human α -defensin 5 (HD5), which is present in the small intestine and in the urogenital tract, reduces the binding of BKV to the cell surface, probably via electrostatic binding to the BKV capsid. Moreover, HD5 aggregates virions, thereby sequestering them away from cells.³⁷

Immune and non-immune cells express various receptors that recognise viral nuclear acids and/or viral proteins. Triggering of these sensors induces the production of pro-inflammatory, chemotactic, anti-viral and pro-apoptotic mediators that are crucial for the activation of innate and adaptive immune responses aimed at restricting viral replication.³⁸ The receptors that recognise proteins and/or nucleic acids of BKV have not been identified thus far, but a recent study showed that BKV infection enhanced expression of the double-stranded RNA sensor, Toll-like receptor 3, the cytokine IL-6 and the chemokine IL-8/CXCL8 in renal collecting duct cells.³⁹ We observed that expression of TLR3 and the cytosolic dsRNA sensors MDA5 and RIG-I in kidney transplant biopsies was enhanced during BKV infection [Heutinck *et al.* 2012, in press]. These findings raise the question to what extent dsRNA receptors mediate anti-viral immune responses against BKV.

Using microarrays, the global effects of BKV infection on gene expression have been addressed in human

proximal tubular epithelial cells and endothelial cells.^{40,41} In both studies, BKV infection was found to activate genes involved in cell division, DNA replication and apoptosis. Surprisingly, the virus did not promote transcription of pro-inflammatory cytokines, type I interferons or chemokines. In tubular epithelial cells only two inflammatory genes, PTX3 and MICB, were upregulated after infection with BKV.⁴⁰ In BKV-infected endothelial cells, immunological defence genes, amongst which IL-15, tended to be down-regulated or unaffected.⁴¹ One could therefore hypothesise that BKV employs immunosuppressive strategies by inhibiting the expression of genes involved in the anti-viral response. In line with this hypothesis, induction of IL-6 and IL-8 transcription occurred only within the first six hours after BKV infection in collecting duct cells, but was not maintained.³⁹

The adaptive immune response and in particular T cells play a crucial role in the clearance of most viral infections. Given the occurrence of BKV-associated disease in transplant recipients and to a lesser degree in HIV-infected patients, T cells are likely to be important. Indeed, BKV-specific T cells are detectable in the peripheral blood of both healthy individuals and transplant recipients.⁴²⁻⁴⁷ T cells are directed against epitopes from all viral proteins, except for agnoprotein which does not seem to be immunogenic.^{42,43,48} T cells specific for the structural proteins VP₁, VP₂ and VP₃ appear prior to T cells that recognise TA_g proteins. The latter seem to play a leading role in the control of BKV infection and correlated with a drop in viral load.⁴³ *In vitro* analysis of T-cell reactivity against overlapping peptide pools suggests that CD4⁺ T cells dominate over CD8⁺ T cells.^{42,49} However, this finding might have been biased by the use of peptide pools that favour presentation in major histocompatibility complex (MHC) class II molecules. BKV-specific T cells can be polyfunctional with regard to production of IFN γ , IL-2, and TNF α .^{42,50} Interestingly, polyfunctional T cells directed against LTA_g were less frequently detectable in patients with high viral loads and/or BKV nephropathy (BKVN), compared with patients with a rapid viral clearance or no reactivation.^{42,51} *In vitro* expanded BKV-specific CD4⁺ and CD8⁺ T cells appeared to express cytotoxic mediators and could eliminate peptide-loaded targets.⁵²⁻⁵⁴ Direct *ex vivo* analysis of the cytotoxic potential of BKV-specific T cells is hampered by their low frequency in peripheral blood. Nevertheless, the availability of BKV-peptide-HLA multimers will enable examination of the phenotype of BKV-specific T cells in the future. Notably, several studies revealed a significant cross-reactivity between BKV and JCV multimers.⁴⁴⁻⁴⁷

Development of both cellular and humoral immunological memory is important in the immune response against BKV. As mentioned previously, BKV-specific antibodies

are ubiquitously present amongst the population. However, their presence alone does not protect against BKV reactivation, BKVN or HC.^{55,56} Nevertheless, negative or low antibody titres prior to transplantation have been proposed as risk factors for BKV viraemia and BKVN.⁵⁷⁻⁵⁹ Also, the report on BKVN in a patient with hyper-IgM syndrome suggests that immunoglobulin class-switching and affinity maturation may be important in the control of BKV infection.⁶⁰ BKV reactivation is associated with significantly increased levels of BKV-specific IgG and IgM. Antibodies were neither quantitatively nor qualitatively related to viral load or to recovery from BKVN,^{43,57} indicating the importance of other, and probably cellular immune responses.

BKV persists latently in healthy individuals, thus having developed ways to evade the immune system. As of yet, little is known regarding this subject. One study of particular interest showed that BKV and JCV produce a microRNA (miRNA) that suppresses the expression of ULBP3, a protein recognised by the activating receptor NKG2D present on natural killer cells and CD8+ T cells. Expression of this miRNA reduced the effector function of NK cells *in vitro*.⁶¹ In the case of SV40, this virus encodes another viral miRNA that accumulates during infection and paradoxically reduces the expression of TAG proteins, apparently without affecting viral replication. This downregulation of TAG proteins was proposed to reduce immunogenicity.⁶² Lastly, BKV replication leads to the emergence of 'quasispecies'; virions with mutated NCCRs and/or structural proteins of which several may be found in a given individual. Selective pressure might lead to the rise of mutants that are capable of evading immunological surveillance.^{63,64}

CLINICAL MANIFESTATIONS AND THERAPEUTIC STRATEGIES

The cellular reservoir of latent BKV infection in immunocompetent individuals seems to comprise numerous cell types, including cervical squamous epithelial cells, peripheral blood leucocytes, salivary gland cells, prostate glandular epithelial cells, and urothelial cells.^{34,65-68} BKV was also found in the urine in 7% of healthy individuals, but never in plasma.⁶⁹ In immunocompromised patients, BKV has been associated with several clinical manifestations amongst which most prominently BKVN, ureteral stenosis and late-onset HC. Also, the association of human polyomaviruses with malignancies remains a topic of ongoing discussion. Other less apparent associations include encephalitis, retinitis, respiratory tract infections and vasculopathy.⁷⁰⁻⁷³ In the next paragraphs, we will discuss the main clinical manifestations of BKV infection and its possible role in malignancies in more detail. *Table 1* gives an overview of therapeutic strategies available for BKVN and HC.

NEPHROPATHY

BKVN occurs in about 5% of RT recipients, mostly within one year after transplantation.^{55,74,75} Patients generally do not present with any symptoms other than a decrease in renal function. BKVN is also observed in native kidneys of HSCT recipients, lung and heart transplant recipients, as well as in immunocompromised HIV-infected patients. Even though BKVN is not specifically monitored in these patients, its prevalence seems to be lower.^{76,79}

Table 1. *Therapeutic interventions targeting BKV*

Intervention	Applicability		Proposed mechanism of action	Reported adverse events	Effectiveness	References
	BKVN	HC				
Tapering of immune suppression	Yes	No	Reconstitution of immune responses directed against BKV	Rejection of the allograft kidney	Effective	[74;92;94; 104;106; 108-110]
Cidofovir	Yes	Yes	Inhibitor of viral replication, mechanism unknown	Severe anterior uveitis, potentially nephrotoxic	Doubtful	[118-121]
Leflunomide	Yes	Yes	Pyrimidine depletion, tyrosine kinase inhibition	Thrombocytopenia, (haemolytic) anaemia and thrombotic microangiopathy	Doubtful	[125-129]
IVIg	Yes	Yes	Antibody-mediated neutralisation	Paradoxical increase in viral load	Doubtful	[122-124]
Fluorochinolones	Yes	Yes	Inhibition of large T antigen helicase activity	None	Doubtful	[130-132]
Statins	Yes	Yes	Prevention of caveolae-mediated endocytosis	None	Very doubtful	[133]

Development of BKVN has been associated to specific immunosuppressive agents such as the calcineurin inhibitor tacrolimus (TAC), the ionosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (MMF), therapy with polyclonal anti-T cell antibodies, and number of corticosteroid pulses given for the treatment of rejection.^{55,80-83} Other studies suggest that the cumulative intensity of the immunosuppressive regimen rather than one specific agent increases the risk for BKVN.^{84,85} Altogether, it remains unclear whether development of BKVN is attributable to qualitative and/or quantitative differences in immune suppression.

Given the strong association with renal allografts, kidney damage may be involved in the development of BKVN. Indeed, mPyv was found to reactivate and replicate to a significantly higher degree in damaged mouse kidneys.⁸⁶ However, transplantation factors leading to graft damage, such as cold ischaemia duration and donor origin (living or non-living), have been inconsistently associated with BKVN in humans.^{87,88} The immune system is pivotal in keeping BKV at bay but may also contribute to the pathogenesis of BKVN. In one study, detectable circulating BKV-specific CD8+ T cells were observed in two out of 15 RT recipients with particularly high plasma BKV viral loads. Interestingly, those two patients were the only ones who lost their grafts.⁸⁹ Other immunological factors involved in the development of BKVN might be allo-HLA-reactivity and heterologous immunity, the latter concerning T cells that cross-react to both BKV- and allo-antigens. Furthermore, one could reason that allo-HLA molecules presenting BKV peptides are not recognised by host BKV-specific effector-memory T cells, thereby at least temporarily allowing BKV to escape immunological surveillance. In this regard, murine renal allografts were indeed found to be more susceptible to mPyv infection than isografts.⁹⁰ Murine Pyv infection also led to an increase in allo-reactive T cells that, however, lacked cross-reactivity to the virus. The authors propose that virus-induced allograft inflammation and a subsequent increase in donor antigen presentation might explain this finding.⁹⁰ Nevertheless, CD4+ T cells with cross-reactivity against BKV VP1 and allo-HLA antigens have been observed in humans.⁸⁹ The number of HLA mismatches and rejection episodes are also reported inconsistently as risk factors for the development of BKVN in human RT recipients.^{55,80-82,87,88,91-99}

Lastly, viral factors have been proposed as the cause of BKVN. NCCR and/or capsid mutants may enhance BKV virulence.^{64,100,101} Indeed, in RT recipients with overt viral activity, i.e. viraemia and BKVN, more mutants were detected.^{64,102} However, extensive virus replication would logically lead to the emergence of more mutants, thereby confounding associations with clinical disease severity. Of specific interest is the report on more cytopathology in kidneys infected with multiple NCCR mutants.¹⁰²

The renal disease spectrum seems to begin with viruria and ends with extensive irreversible kidney damage and graft failure. It is therefore of paramount importance to intervene in an early phase to prevent graft loss. Screening for active BKV replication may involve the detection of viral DNA by quantitative PCR in urine and in blood. Monitoring of the urine may also comprise the detection of BKV-infected 'decoy cells' or aggregates of BKV virions, the so-called 'haufen'. Solitary point prevalence measurements of urinary BKV viral load, positive in 20 to 57% of RT recipients,^{88,103} and/or decoy cells, positive in 13 to 42% of renal RT recipients,^{75,104} were found to have low positive predictive value for the development of BKVN.^{55,75} However, sustained viruria as well as the presence of haufen were found to have a higher predictive value.^{94,104,105} Viraemia only occurs in immunocompromised patients, with 7 to 29% of RT recipients showing BKV viraemia at least once after transplantation.^{83,88,94} Moreover, viruria always precedes viraemia.⁹⁴ As such, viraemia seems to reflect a state of more elaborate infection. Indeed, high plasma viral loads and sustained viraemia were found to be even better predictors for the development of BKVN than the presence of viruria.^{75,94,106}

Ultimately, BKVN is a histopathological diagnosis. Histopathological grades of severity have been defined ranging from stage A: viral cytopathic changes of near-normal renal parenchyma and no or minimal tubular atrophy, interstitial fibrosis or inflammation, to stage C: diffusely scarred renal tissue with extensive tubular atrophy, interstitial fibrosis and inflammation.¹⁰⁷ Since BKV affects the kidney in a random, multifocal manner, false-negative biopsy results may occur, especially in an early stage of disease.

Currently, reducing immunosuppression is the only established mode of therapy and aims to restore the anti-viral immune response. Graft loss due to BKVN is significantly higher in RT recipients with BKVN than in control RT recipients, and may be especially high when tapering of immunosuppression is not applied.^{92,108} The combination of regular screening for BKV replication and subsequent pre-emptive adjustment of immunosuppressive therapy seems to be particularly effective.^{74,94,104,106,109,110} Given the lack of an evident link between one specific immunosuppressive agent and the development of BKVN, there is no standard strategy for adjusting immunosuppressive therapy. *Ex vivo* and *in vitro* analyses with different immunosuppressive agents revealed that BKV-specific T cells were particularly inhibited by TAC and not so much by MMF or prednisone,¹¹¹ indicating TAC as a first target of modification. Upon *in vitro* infection, BKV activates the intracellular PI3K/Akt/mTOR pathway. Subsequent titration with sirolimus reduced LTag expression in a dose-dependent manner.¹¹² Another option may, therefore, involve the use of the mTOR-inhibitors sirolimus or

everolimus, which also did not inhibit interferon- γ (IFN γ) production by BKV-specific T cells *in vitro*.¹¹¹ However, so far few and conflicting reports on the clinical efficacy of mTOR inhibitors in treating BKVN have been published.¹¹³⁻¹¹⁶

Beyond tapering and/or altering immunosuppression, other anti-viral agents have been proposed. Cidofovir, known to be nephrotoxic, showed *in vitro* inhibitory activity against polyomaviruses.¹¹⁷ Since polyomaviruses do not express the known target of cidofovir, viral DNA polymerase, its mechanism of action is unknown. Several studies proposed to administrate cidofovir simultaneously to reducing immunosuppressive agents,^{118,119} or when the latter alone proved ineffective.^{120,121} Unfortunately, randomised controlled trials are lacking and several confounders including, most importantly, the concomitant tapering of immunosuppression, complicate the interpretation of the effectiveness of cidofovir. Although long-lasting nephrotoxic effects have not been reported, severe anterior uveitis occurred in up to 7% of patients, sometimes leading to permanent visual impairment.¹¹⁹ Treatment with intravenous immunoglobulins (IVIg) might help to neutralise BKV particles.^{122,123} Surprisingly, IVIg was recently associated with a paradoxical increase in BKV viral load rather than a decrease.¹²⁴ The pyrimidine synthesis inhibitor leflunomide may be effective by inhibiting tyrosine kinase activity and by inducing pyrimidine depletion.¹¹² Apart from a doubtful clinical effect, leflunomide also has a high rate of side effects such as (haemolytic) anaemia, thrombocytopenia and possibly also thrombotic microangiopathy.¹²⁵⁻¹²⁹ Fluorochinolones have been described to inhibit LTA γ helicase activity. Nevertheless, also here the reports on clinical efficacy are contradicting.¹³⁰⁻¹³² Lastly, one study reported that statins inhibit the formation of caveolae and as such may block virus cell entry.¹³³

URETERAL STENOSIS

The original patient B.K. presented with a stenosis of his graft ureter. On further examination, a segment of the ureter appeared to be ischaemic and fibrotic, and large numbers of virions were observed in epithelial cells lining the ureter lumen.¹ Other publications on supposedly BKV-related ureteral stenosis in RT recipients followed, reporting a prevalence of 2 to 6%.^{83,134-136}

There has been discussion on the association of BKV with ureteral stenosis. However, its prevalence was found to be significantly higher in RT recipients who developed viraemia than in patients who did not.⁸³ Apart from a proposed role for BKV in a reversible form of ureteral stenosis in HSCT recipients with haemorrhagic cystitis,¹³⁷ to our knowledge BKV as the cause of irreversible ureteral

stenosis has not been reported in non-renal transplant patients. Treatment generally consists of (temporary) percutaneous nephrostomy and the concomitant lowering of immunosuppressive agents.

HAEMORRHAGIC CYSTITIS

BKV reactivation is common in HSCT recipients, viruria and viraemia, occurring at least once during follow-up in 47 to 94% and in 23 to 53% of recipients, respectively.¹³⁸⁻¹⁴⁰ HC occurs mainly in HSCT recipients and can be caused by conditioning, e.g. with cyclophosphamide and total body irradiation, but also by several viruses amongst which CMV, adenovirus and indeed BKV. The virally induced form of HC usually occurs after engraftment and is therefore referred to as late-onset HC, which occurs in 6 to 29% of HSCT patients, generally within the first two months after transplantation.^{140,141}

Patients present with haematuria, painful voiding, bladder cramps, and/or flank pain. Four degrees of disease severity are currently recognised: grade I: microscopic haematuria; grade II: macroscopic haematuria; grade III: haematuria and clots; and grade IV: haematuria with clots, clot retention and renal failure due to obstructive nephropathy. More often, late-onset HC is of a higher severity grade than early-onset HC.^{140,142} Bleeding may be so severe that patients require red blood cell and/or platelet transfusion, ultimately even necessitating cystectomy in some severe and refractory cases.^{143,144} Not only was HC reported to prolong hospital stay,¹⁴⁵ it also seems to have a significant negative effect on overall patient survival.^{146,147}

Also here, the connection of BKV to late-onset HC remains a topic of discussion. Various groups found an association with solely BKV reactivation, defined as detectable virus in urine and/or blood,^{146,148-150} whereas others could only relate HC to very high urinary BKV viral loads.^{140-142,151} Of specific interest is one study reporting on a correlation between the degrees of viruria and haematuria.¹³⁹ Lastly, with 81 to 100% of late-onset HC patients having viruria and 75% viraemia,^{138,140,142,146} BKV viral replication seems to occur more frequently in these patients than in HSCT patients in general. Together these studies suggest that BKV reactivation contributes to the pathogenesis of late-onset HC.

The pathogenesis of HC has been proposed to involve two steps: I) Severe immune suppression together with urothelial damage due to conditioning and irradiation, creating an environment favourable for viral replication, as well as leading to an increase in immunological danger signals and antigen presentation. II) Attack of virus-infected host urothelial cells by donor T cells.¹⁵² In support of this theory, BKV-associated HC patients

showed more signs of immune hyperactivity such as graft versus host disease (GVHD) than patients with adenovirus-associated HC.^{140,150,152,153} Other inconsistently reported risk factors include donor origin, i.e. cord blood or haploidentical graft, NCCR mutants, treatment with antithymocyte globulins, full conditioning instead of reduced intensity conditioning, and conditioning with busulphan.^{140,145,148,149,152,154} Taken together, the pathogenesis of HC is complex but may very well involve immune reconstitution rather than immune suppression.

Due to the risk of GVHD and to the possibility that HC is caused by immune reconstitution, tapering of immunosuppressive therapy is an unattractive treatment option in this clinical context. In many patients, symptoms can be relieved by (intravenous) hydration. Cidofovir has been proposed in the treatment of HC, especially since it may also be given locally by bladder instillation, thereby reducing (cumulative) nephrotoxicity of cidofovir alone or in addition to the several other nephrotoxic agents often used in treating HSCT recipients.¹⁵⁵ Interestingly, both patients treated with cidofovir and patients treated only with supportive care achieved remission.¹⁴⁰ The self-limiting nature of late-onset HC, apparently occurring in a significant number of patients, has been confirmed by other studies.^{138,156,157} Remission of symptoms varied from two to seven weeks after haematuria, and did not differ significantly in duration between cidofovir or supportively treated patients.¹⁴⁰ With regard to other virus-targeting strategies, prophylactic treatment with ciprofloxacin led to a significant reduction in the occurrence of HC in one retrospective analysis,¹⁵⁸ but not in another.¹⁵⁹ To our knowledge, no publications have addressed the use of leflunomide or IVIg in the treatment of BKV-associated HC. Taken together, it seems that treatment of BKV-associated HC should mainly be supportive. Supportive treatment strategies, not directly targeting the virus, are beyond the scope of this review and have been reviewed in detail by Harkensee and co-workers.¹⁶⁰

BKV AND MALIGNANCY

BKV has been associated with several human neoplasms, amongst which bladder and prostate carcinoma, brain tumours, tumours of pancreatic islets, Kaposi sarcoma, Ewing sarcoma and osteogenic sarcoma.¹⁶¹⁻¹⁶⁸ Of specific interest are the cases of a simultaneous pancreas and kidney transplant recipient with BKVN and a metastasised bladder carcinoma, and a kidney transplant recipient without BKVN who developed a renal cell carcinoma.^{169,170} In each of them, the primary tumours as well as the metastases contained BKV DNA and expressed high amounts of LTag. Nevertheless, numerous other studies did not find BKV to be related to malignancy.¹⁷¹⁻¹⁷⁹

In rodent cells, BKV drives malignant transformation *in vitro*, giving rise to full-blown tumours after subsequent inoculation back into the animals.^{180,181} Furthermore, the majority of transgenic mice expressing a single copy of the BKV early region developed renal and lymphoid malignancies.¹⁸² Human embryo fibroblast and foreskin cells, however, were not inclined to such transformation,^{183,184} possibly owing to the presence of specific human tumour suppressor genes.¹⁸⁵

The previously mentioned actions of LTag and agnoprotein would render an infected cell less capable of arresting the cell cycle for DNA repair and may drive a cell towards a continuously dividing state. Not only does BKV benefit from the ensuing increase in host-derived transcription factors, it can thereby also contribute to malignant transformation. In permissive cells, BKV infection results in either cell lysis, leading to release of viral particles, or latency, which is characterised by low expression of viral genes and immune evasion. Infection of non-permissive cells may lead to an aberrant form of replication with continuous expression of only the early region of the BKV genome. In these cells, TAg proteins accumulate, which may ultimately result in malignant transformation. Interestingly, BKV species with mutated NCCRs were found to possess altered replicative and/or transforming capabilities.^{167,186-189}

In conclusion, BKV possesses oncogenic potency and is theoretically able to at the least contribute to malignant transformation of cells. A definitive association with specific human malignancies remains to be proven. For a more in-depth review on this topic, we refer to the publication by Abend and co-workers.¹⁹⁰

CONCLUSION

BKV is ubiquitously present amongst the general population. When immunological surveillance is hampered, BKV reactivates and causes BKVN and/or ureteral stenosis in RT recipients, and late-onset HC in HSCT recipients. Treatment options targeting viral replication are still limited. The most effective therapy in RT patients is improvement of the host immunological defence by lowering immunosuppressive drugs. In refractory cases of BKV-associated disease, antiviral agents such as cidofovir, leflunomide, IVIg and fluorochinolones may be applied. The effectiveness of these agents is, however, doubtful and some of them can cause severe side effects. BKV has also been implied to be involved in human malignancies, yet its precise role remains to be elucidated. All compartments of the immune system seem to be involved in keeping BKV at bay, virus-specific T cells being of particular importance. In order to develop novel effective treatment strategies and vaccines, more research

towards the characteristics of the BKV-specific immune response is necessary.

ACKNOWLEDGEMENTS

We would like to thank Professor René A.W. van Lier for critically reading the manuscript.

REFERENCE LIST

- 1 Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. *Lancet*. 1971 Jun 19;1(7712):1253-7.
- 2 Shah KV, Daniel RW, Warszawski RM. High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. *J Infect Dis*. 1973 Dec;128(6):784-7.
- 3 Portolani M, Marzocchi A, Barbanti-Brodano G, La Placa M. Prevalence in Italy of antibodies to a new human papovavirus (BK virus). *J Med Microbiol*. 1974 Nov;7(4):543-6.
- 4 Yang RC, Wu R. BK virus DNA: complete nucleotide sequence of a human tumor virus. *Science*. 1979 Oct 26;206(4417):456-62.
- 5 Seif I, Khoury G, Dhar R. The genome of human papovavirus BKV. *Cell*. 1979 Dec;18(4):963-77.
- 6 Dhar R, Lai CJ, Khoury G. Nucleotide sequence of the DNA replication origin for human papovavirus BKV: sequence and structural homology with SV40. *Cell*. 1978 Feb;13(2):345-58.
- 7 Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. *J Virol*. 1984 Aug;51(2):458-69.
- 8 Seehafer J, Salmi A, Scraba DG, Colter JS. A comparative study of BK and polyoma viruses. *Virology*. 1975 Jul;66(1):192-205.
- 9 Chen XS, Stehle T, Harrison SC. Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry. *EMBO J*. 1998 Jun 15;17(12):3233-40.
- 10 Clever J, Dean DA, Kasamatsu H. Identification of a DNA binding domain in simian virus 40 capsid proteins Vp2 and Vp3. *J Biol Chem*. 1993 Oct 5;268(28):20877-83.
- 11 Dugan AS, Gasparovic ML, Tsomaia N, et al. Identification of amino acid residues in BK virus VP1 that are critical for viability and growth. *J Virol*. 2007 Nov;81(21):11798-808.
- 12 Dugan AS, Eash S, Atwood WJ. An N-linked glycoprotein with alpha(2,3)-linked sialic acid is a receptor for BK virus. *J Virol*. 2005 Nov;79(22):14442-5.
- 13 Low JA, Magnuson B, Tsai B, Imperiale MJ. Identification of gangliosides GD1b and GT1b as receptors for BK virus. *J Virol*. 2006 Feb;80(3):1361-6.
- 14 Eash S, Querbes W, Atwood WJ. Infection of vero cells by BK virus is dependent on caveolae. *J Virol*. 2004 Nov;78(21):11583-90.
- 15 Singh RD, Marks DL, Holicky EL, et al. Gangliosides and beta1-integrin are required for caveolae and membrane domains. *Traffic*. 2010 Mar;11(3):348-60.
- 16 Moriyama T, Sorokin A. Intracellular trafficking pathway of BK Virus in human renal proximal tubular epithelial cells. *Virology*. 2008 Feb. 20;371(2):336-49.
- 17 Jiang M, Abend JR, Tsai B, Imperiale MJ. Early events during BK virus entry and disassembly. *J Virol*. 2009 Feb;83(3):1350-8.
- 18 Nakanishi A, Itoh N, Li PP, Handa H, Liddington RC, Kasamatsu H. Minor capsid proteins of simian virus 40 are dispensable for nucleocapsid assembly and cell entry but are required for nuclear entry of the viral genome. *J Virol*. 2007 Apr;81(8):3778-85.
- 19 Fang CY, Chen HY, Wang M, et al. Global analysis of modifications of the human BK virus structural proteins by LC-MS/MS. *Virology*. 2010 Jun 20;402(1):164-76.
- 20 Deyerle KL, Subramani S. Linker scan analysis of the early regulatory region of human papovavirus BK. *J Virol*. 1988 Sep;62(9):3378-87.
- 21 Gorrill TS, Khalili K. Cooperative interaction of p65 and C/EBPbeta modulates transcription of BKV early promoter. *Virology*. 2005 Apr 25;335(1):1-9.
- 22 Mastrangelo IA, Hough PV, Wall JS, Dodson M, Dean FB, Hurwitz J. ATP-dependent assembly of double hexamers of SV40 T antigen at the viral origin of DNA replication. *Nature*. 1989 Apr 20;338(6217):658-62.
- 23 Wang W, Simmons DT. Simian virus 40 large T antigen can specifically unwind the central palindrome at the origin of DNA replication. *J Virol*. 2009 Apr;83(7):3312-22.
- 24 Kelley WL, Georgopoulos C. The T/t common exon of simian virus 40, JC, and BK polyomavirus T antigens can functionally replace the J-domain of the Escherichia coli DnaJ molecular chaperone. *Proc Natl Acad Sci U S A*. 1997 Apr 15;94(8):3679-84.
- 25 Dyson N, Bernards R, Friend SH, et al. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. *J Virol*. 1990 Mar;64(3):1353-6.
- 26 Bollag B, Chuke WF, Frisque RJ. Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: identification of sequences important for efficient transformation. *J Virol*. 1989 Feb;63(2):863-72.
- 27 Berger H, Wintersberger E. Polyomavirus small T antigen enhances replication of viral genomes in 3T6 mouse fibroblasts. *J Virol*. 1986 Nov;60(2):768-70.
- 28 Klucky B, Wintersberger E. Polyomavirus small T antigen transactivates genes by its ability to provoke the synthesis and the stabilization of MYC. *Oncogene*. 2007 Sep 20;26(43):6356-60.
- 29 Abend JR, Joseph AE, Das D, Campbell-Cecen DB, Imperiale MJ. A truncated T antigen expressed from an alternatively spliced BK virus early mRNA. *J Gen Virol*. 2009 May;90(Pt 5):1238-45.
- 30 Myhre MR, Olsen GH, Gosert R, Hirsch HH, Rinaldo CH. Clinical polyomavirus BK variants with agnogene deletion are non-functional but rescued by trans-complementation. *Virology*. 2010 Mar 1;398(1):12-20.
- 31 Darbinyan A, Siddiqui KM, Slonina D, et al. Role of JC virus agnoprotein in DNA repair. *J Virol*. 2004 Aug;78(16):8593-600.
- 32 Drachenberg CB, Papadimitriou JC, Wali R, Cubitt CL, Ramos E. BK polyoma virus allograft nephropathy: ultrastructural features from viral cell entry to lysis. *Am J Transplant*. 2003 Nov;3(11):1383-92.
- 33 Low J, Humes HD, Szczypka M, Imperiale M. BKV and SV40 infection of human kidney tubular epithelial cells in vitro. *Virology*. 2004 Jun 1;323(2):182-8.
- 34 Jeffers LK, Madden V, Webster-Cyriaque J. BK virus has tropism for human salivary gland cells in vitro: implications for transmission. *Virology*. 2009 Nov 25;394(2):183-93.
- 35 Vanchiere JA, Abudayyeh S, Copeland CM, Lu LB, Graham DY, Butel JS. Polyomavirus shedding in the stool of healthy adults. *J Clin Microbiol*. 2009 Aug;47(8):2388-91.
- 36 Boldorini R, Allegrini S, Miglio U, et al. BK virus sequences in specimens from aborted fetuses. *J Med Virol*. 2010 Dec;82(12):2127-32.
- 37 Dugan AS, Maginnis MS, Jordan JA, et al. Human alpha-defensins inhibit BK virus infection by aggregating virions and blocking binding to host cells. *J Biol Chem*. 2008 Nov 7;283(45):31125-32.
- 38 Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. *Nat Rev Immunol*. 2008 Dec;8(12):911-22.
- 39 Ribeiro A, Wornle M, Motamedi N, et al. Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy. *Kidney Int*. 2011 Sep 14.
- 40 Abend JR, Low JA, Imperiale MJ. Global effects of BKV infection on gene expression in human primary kidney epithelial cells. *Virology*. 2010 Feb 5;397(1):73-9.
- 41 Grinde B, Gayorfar M, Rinaldo CH. Impact of a polyomavirus (BKV) infection on mRNA expression in human endothelial cells. *Virus Res*. 2007 Jan;123(1):86-94.

- 42 Mueller K, Schachtner T, Sattler A, et al. BK-VP3 as a new target of cellular immunity in BK virus infection. *Transplantation*. 2011 Jan 15;91(1):100-7.
- 43 Schachtner T, Muller K, Stein M, et al. BKV-Specific Immunity Kinetics: A Predictor of Recovery From Polyomavirus BK-Associated Nephropathy. *Am J Transplant*. 2011 Aug 10.
- 44 Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. *J Virol*. 2006 Apr;80(7):3495-505.
- 45 Sharma MC, Zhou W, Martinez J, et al. Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals. *Virology*. 2006 Jun 20;350(1):128-36.
- 46 Krymskaya L, Sharma MC, Martinez J, et al. Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. *J Virol*. 2005 Sep;79(17):11170-8.
- 47 Li J, Melenhorst J, Hensel N, Rezvani K, et al. T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. *J Gen Virol*. 2006 Oct;87(Pt 10):2951-60.
- 48 Leuenberger D, Andresen PA, Gosert R, et al. Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. *Clin Vaccine Immunol*. 2007 Aug;14(8):959-68.
- 49 Binggeli S, Egli A, Schaub S, et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. *Am J Transplant*. 2007 May;7(5):1131-9.
- 50 Blyth E, Clancy L, Simms R, et al. BK Virus-Specific T Cells for Use in Cellular Therapy Show Specificity to Multiple Antigens and Polyfunctional Cytokine Responses. *Transplantation*. 2011 Nov 27;92(10):1077-84.
- 51 Trydzenskaya H, Sattler A, Muller K, et al. Novel approach for improved assessment of phenotypic and functional characteristics of BKV-specific T-cell immunity. *Transplantation*. 2011 Dec 15;92(11):1269-77.
- 52 Zhou W, Sharma M, Martinez J, et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. *Viral Immunol*. 2007 Sep;20(3):379-88.
- 53 Ramaswami B, Popescu I, Macedo C, et al. The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response. *Clin Vaccine Immunol*. 2011 May;18(5):815-24.
- 54 Provenzano M, Bracci L, Wyler S, et al. Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. *J Transl Med*. 2006;4:47.
- 55 Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. *N Engl J Med*. 2002 Aug 15;347(7):488-96.
- 56 Bogdanovic G, Priftakis P, Taemmeraes B, et al. Primary BK virus (BKV) infection due to possible BKV transmission during bone marrow transplantation is not the major cause of hemorrhagic cystitis in transplanted children. *Pediatr Transplant*. 1998 Nov;2(4):288-93.
- 57 Bohl DL, Brennan DC, Ryschewitsch C, Gaudreault-Keener M, Major EO, Storch GA. BK virus antibody titers and intensity of infections after renal transplantation. *J Clin Virol*. 2008 Oct;43(2):184-9.
- 58 Ginevri F, De SR, Comoli P, et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. *Transplantation*. 2003 Apr 27;75(8):1266-70.
- 59 Smith JM, McDonald RA, Finn LS, Healey PJ, Davis CL, Limaye AP. Polyomavirus nephropathy in pediatric kidney transplant recipients. *Am J Transplant*. 2004 Dec;4(12):2109-17.
- 60 Rosen S, Harmon W, Krensky AM, et al. Tubulo-interstitial nephritis associated with polyomavirus (BK type) infection. *N Engl J Med*. 1983 May 19;308(20):1192-6.
- 61 Bauman Y, Nachmani D, Vitenshtein A, et al. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. *Cell Host Microbe*. 2011 Feb 17;9(2):93-102.
- 62 Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. *Nature*. 2005 Jun 23;435(7042):682-6.
- 63 Randhawa PS, Khaleel-Ur-Rehman K, Swalsky PA, et al. DNA sequencing of viral capsid protein VP-1 region in patients with BK virus interstitial nephritis. *Transplantation*. 2002 Apr 15;73(7):1090-4.
- 64 Luo C, Hirsch HH, Kant J, Randhawa P. VP-1 quasispecies in human infection with polyomavirus BK. *J Med Virol*. 2012 Jan;84(1):152-61.
- 65 Comar M, Bonifacio D, Zanconati F, et al. High prevalence of BK polyomavirus sequences in human papillomavirus-16-positive precancerous cervical lesions. *J Med Virol*. 2011 Oct;83(10):1770-6.
- 66 Dorries K, Vogel E, Gunther S, Czub S. Infection of human polyomaviruses JC and BK in peripheral blood leukocytes from immunocompetent individuals. *Virology*. 1994 Jan;198(1):59-70.
- 67 Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. *Prostate*. 2002 Dec 15;53(4):263-76.
- 68 Saitoh K, Sugae N, Koike N, Akiyama Y, Iwamura Y, Kimura H. Diagnosis of childhood BK virus cystitis by electron microscopy and PCR. *J Clin Pathol*. 1993 Aug;46(8):773-5.
- 69 Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. *J Infect Dis*. 2009 Mar 15;199(6):837-46.
- 70 Lesprit P, Chaline-Lehmann D, Authier FJ, Ponnelle T, Gray F, Levy Y. BK virus encephalitis in a patient with AIDS and lymphoma. *AIDS*. 2001 Jun 15;15(9):1196-9.
- 71 Hedquist BG, Bratt G, Hammarin AL, et al. Identification of BK virus in a patient with acquired immune deficiency syndrome and bilateral atypical retinitis. *Ophthalmology*. 1999 Jan;106(1):129-32.
- 72 Vallbracht A, Lohler J, Gossmann J, et al. Disseminated BK type polyomavirus infection in an AIDS patient associated with central nervous system disease. *Am J Pathol*. 1993 Jul;143(1):29-39.
- 73 Petrogiannis-Haliotis T, Sakoulas G, Kirby J, et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. *N Engl J Med*. 2001 Oct 25;345(17):1250-5.
- 74 Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. *Am J Transplant*. 2010 Dec;10(12):2615-23.
- 75 Viscount HB, Eid AJ, Espy MJ, et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. *Transplantation*. 2007 Aug 15;84(3):340-5.
- 76 Verghese PS, Finn LS, Englund JA, Sanders JE, Hingorani SR. BK nephropathy in pediatric hematopoietic stem cell transplant recipients. *Pediatr Transplant*. 2009 Nov;13(7):913-8.
- 77 Egli A, Helmersen DS, Taub K, Hirsch HH, Johnson A. Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. *Am J Transplant*. 2010 Oct;10(10):2324-30.
- 78 Menahem SA, McDougall KM, Thomson NM, Dowling JP. Native kidney BK nephropathy post cardiac transplantation. *Transplantation*. 2005 Jan 27;79(2):259-60.
- 79 Bratt G, Hammarin AL, Grandien M, et al. BK virus as the cause of meningoencephalitis, retinitis and nephritis in a patient with AIDS. *AIDS*. 1999 Jun 18;13(9):1071-5.
- 80 Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. *Clin J Am Soc Nephrol*. 2007 Sep;2(5):1037-42.
- 81 Namba Y, Moriyama T, Kyo M, et al. Prevalence, characteristics, and outcome of BK virus nephropathy in Japanese renal transplant patients: analysis in protocol and episode biopsies. *Clin Transplant*. 2005 Feb;19(1):97-101.
- 82 Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. *Nephrol Dial Transplant*. 2003 Jun;18(6):1190-6.
- 83 Geddes CC, Gunson R, Mazonakis E, et al. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen. *Transpl Infect Dis*. 2011 Apr;13(2):109-16.

- 84 Barri YM, Ahmad I, Ketel BL, et al. Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy. *Clin Transplant*. 2001 Aug;15(4):240-6.
- 85 Binet I, Nিকেলেইт V, Hirsch HH, et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. *Transplantation*. 1999 Mar 27;67(6):918-22.
- 86 Atencio IA, Shadan FF, Zhou XJ, Vaziri ND, Villarreal LP. Adult mouse kidneys become permissive to acute polyomavirus infection and reactivate persistent infections in response to cellular damage and regeneration. *J Virol*. 1993 Mar;67(3):1424-32.
- 87 Priftakis P, Bogdanovic G, Tyden G, Dalianis T. Polyomaviruria in renal transplant patients is not correlated to the cold ischemia period or to rejection episodes. *J Clin Microbiol*. 2000 Jan;38(1):406-7.
- 88 Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. *Am J Transplant*. 2005 Aug;5(8):1926-33.
- 89 Hammer MH, Brestrich G, Andree H, et al. HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. *Am J Transplant*. 2006 Mar;6(3):625-31.
- 90 Han Lee ED, Kembal CC, Wang J, et al. A mouse model for polyomavirus-associated nephropathy of kidney transplants. *Am J Transplant*. 2006 May;6(5 Pt 1):913-22.
- 91 Bressollette-Bodin C, Coste-Burel M, Hourmant M, Sebille V, Andre-Garnier E, Imbert-Marcille BM. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. *Am J Transplant*. 2005 Aug;5(8):1926-33.
- 92 Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. *J Am Soc Nephrol*. 2002 Aug;13(8):2145-51.
- 93 Awadalla Y, Randhawa P, Ruppert K, Zeevi A, Duquesnoy RJ. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. *Am J Transplant*. 2004 Oct;4(10):1691-6.
- 94 Babel N, Fendt J, Karaivanov S, et al. Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples. *Transplantation*. 2009 Jul 15;88(1):89-95.
- 95 Mindlova M, Boucek P, Saudek F, et al. Prevalence and risk factors of polyomavirus BK replication in simultaneous pancreas/kidney transplant recipients from a single transplant center. *Clin Transplant*. 2012;26:267-74.
- 96 Girmanova E, Brabcova I, Bandur S, Hribova P, Skibova J, Viklicky O. A prospective longitudinal study of BK virus infection in 120 Czech renal transplant recipients. *J Med Virol*. 2011 Aug;83(8):1395-400.
- 97 Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. *Kidney Int*. 2005 Oct;68(4):1834-9.
- 98 Alexander RT, Langlois V, Tellier R, Robinson L, Hebert D. The prevalence of BK viremia and urinary viral shedding in a pediatric renal transplant population: a single-center retrospective analysis. *Pediatr Transplant*. 2006 Aug;10(5):586-92.
- 99 Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. *Am J Transplant*. 2005 Sep;5(9):2213-21.
- 100 Nukuzuma S, Takasaka T, Zheng HY, et al. Subtype I BK polyomavirus strains grow more efficiently in human renal epithelial cells than subtype IV strains. *J Gen Virol*. 2006 Jul;87(Pt 7):1893-901.
- 101 Olsen GH, Hirsch HH, Rinaldo CH. Functional analysis of polyomavirus BK non-coding control region quasispecies from kidney transplant recipients. *J Med Virol*. 2009 Nov;81(11):1959-67.
- 102 Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. *J Exp Med*. 2008 Apr 14;205(4):841-52.
- 103 Herman J, Van RM, Snoeck R, Beuselinc K, Lerut E, Van Damme-Lombaerts R. Polyomavirus infection in pediatric renal transplant recipients: evaluation using a quantitative real-time PCR technique. *Pediatr Transplant*. 2004 Oct;8(5):485-92.
- 104 Huang G, Chen LZ, Qiu J, et al. Prospective study of polyomavirus BK replication and nephropathy in renal transplant recipients in China: a single-center analysis of incidence, reduction in immunosuppression and clinical course. *Clin Transplant*. 2010 Sep;24(5):599-609.
- 105 Singh HK, Andreoni KA, Madden V, et al. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. *J Am Soc Nephrol*. 2009 Feb;20(2):416-27.
- 106 Almeras C, Foulongne V, Garrigue V, et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. *Transplantation*. 2008 Apr 27;85(8):1099-104.
- 107 Drachenberg CB, Hirsch HH, Ramos E, Papadimitriou JC. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. *Hum Pathol*. 2005 Dec;36(12):1245-55.
- 108 Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. *Transplantation*. 1999 Jan 15;67(1):103-9.
- 109 Almeras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G. Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. *Transpl Infect Dis*. 2011 Apr;13(2):101-8.
- 110 Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. *Am J Transplant*. 2005 Mar;5(3):582-94.
- 111 Egli A, Kohli S, Dickenmann M, Hirsch HH. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. *Transplantation*. 2009 Nov 27;88(10):1161-8.
- 112 Liacini A, Seamone ME, Muruve DA, Tibbles LA. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. *Transplantation*. 2010 Dec 27;90(12):1450-7.
- 113 Tedesco SH, Jr., Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. *Am J Transplant*. 2010 Jun;10(6):1401-13.
- 114 Gralla J, Wiseman AC. Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. *Transplantation*. 2009 Jun 15;87(11):1712-9.
- 115 Wali RK, Drachenberg C, Hirsch HH, et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. *Transplantation*. 2004 Oct 15;78(7):1069-73.
- 116 Benavides CA, Pollard VB, Mauyyedi S, Podder H, Knight R, Kahan BD. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. *Transplantation*. 2007 Jul 15;84(1):83-8.
- 117 Andrei G, Snoeck R, Vandeputte M, et al. Activities of various compounds against murine and primate polyomaviruses. *Antimicrob Agents Chemother*. 1997 Mar;41(3):587-93.
- 118 Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. *Am J Transplant*. 2005 Aug;5(8):1997-2004.
- 119 Kuypers DR, Bammens B, Claes K, Evenepoel P, Lerut E, Vanrenterghem Y. A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. *J Antimicrob Chemother*. 2009 Feb;63(2):417-9.
- 120 Araya CE, Lew JF, Fennell RS, III, Neiberger RE, Dharnidharka VR. Intermediate-dose cidofovir without probenecid in the treatment of BK virus allograft nephropathy. *Pediatr Transplant*. 2006 Feb;10(1):32-7.
- 121 Araya CE, Lew JF, Fennell RS, Neiberger RE, Dharnidharka VR. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. *Pediatr Transplant*. 2008 Nov;12(7):790-5.
- 122 Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. *Transplantation*. 2006 Jan 15;81(1):117-20.
- 123 Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. *Transplantation*. 2010 Jun 27;89(12):1462-5.

- 124 Maggiore U, Medici MC, Vaglio A, Buzio C. Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy. *Transpl Infect Dis.* 2010 Oct;12(5):470-2.
- 125 Williams JW, Javadi B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. *N Engl J Med.* 2005 Mar 17;352(11):1157-8.
- 126 Josephson MA, Gillen D, Javadi B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. *Transplantation.* 2006 Mar 15;81(5):704-10.
- 127 Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. *Transpl Int.* 2007 Nov;20(11):962-9.
- 128 Leca N, Muczynski KA, Jefferson JA, et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. *Clin J Am Soc Nephrol.* 2008 May;3(3):829-35.
- 129 Bernhoff E, Tylden GD, Kjerpeseth LJ, Gutteberg TJ, Hirsch HH, Rinaldo CH. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. *J Virol.* 2010 Feb;84(4):2150-6.
- 130 Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. *Clin J Am Soc Nephrol.* 2010 Jul;5(7):1298-304.
- 131 Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. *Antiviral Res.* 2011 Oct;92(1):115-23.
- 132 Koukoulaki M, Apostolou T, Hadjiconstantinou V, Drakopoulos S. Impact of prophylactic administration of ciprofloxacin on BK polyoma virus replication. *Transpl Infect Dis.* 2008 Dec;10(6):449-51.
- 133 Moriyama T, Sorokin A. Repression of BK virus infection of human renal proximal tubular epithelial cells by pravastatin. *Transplantation.* 2008 May 15;85(9):1311-7.
- 134 Coleman DV, Mackenzie EF, Gardner SD, Poulding JM, Amer B, Russell WJ. Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. *J Clin Pathol.* 1978 Apr;31(4):338-47.
- 135 Mackenzie EF, Poulding JM, Harrison PR, Amer B. Human polyoma virus (HPV)--a significant pathogen in renal transplantation. *Proc Eur Dial Transplant Assoc.* 1978;15:352-60.
- 136 Gardner SD, MacKenzie EF, Smith C, Porter AA. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. *J Clin Pathol.* 1984 May;37(5):578-86.
- 137 Khan H, Oberoi S, Mahvash A, et al. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. *Biol Blood Marrow Transplant.* 2011 Oct;17(10):1551-5.
- 138 Gorczynska E, Turkiewicz D, Rybka K, et al. Incidence, clinical outcome, and management of virus-induced hemorrhagic cystitis in children and adolescents after allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2005 Oct;11(10):797-804.
- 139 O'Donnell PH, Swanson K, Josephson MA, et al. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoietic stem cell transplants. *Biol Blood Marrow Transplant.* 2009 Sep;15(9):1038-48.
- 140 Gaziev J, Paba P, Miano R, et al. Late-onset hemorrhagic cystitis in children after hematopoietic stem cell transplantation for thalassemia and sickle cell anemia: a prospective evaluation of polyoma (BK) virus infection and treatment with cidofovir. *Biol Blood Marrow Transplant.* 2010 May;16(5):662-71.
- 141 Wong AS, Chan KH, Cheng VC, Yuen KY, Kwong YL, Leung AY. Relationship of pretransplantation polyoma BK virus serologic findings and BK viral reactivation after hematopoietic stem cell transplantation. *Clin Infect Dis.* 2007 Mar 15;44(6):830-7.
- 142 Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viremia in hemorrhagic cystitis complicating bone marrow transplantation. *Blood.* 2001 Sep 15;98(6):1971-8.
- 143 Koc S, Hagglund H, Ireton RC, Perez-Simon JA, Collins SJ, Appelbaum FR. Successful treatment of severe hemorrhagic cystitis with cystectomy following matched donor allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant.* 2000 Oct;26(8):899-901.
- 144 Garderet L, Bittencourt H, Sebe P, et al. Cystectomy for severe hemorrhagic cystitis in allogeneic stem cell transplant recipients. *Transplantation.* 2000 Dec 27;70(12):1807-11.
- 145 Silva LP, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. *Haematologica.* 2010 Jul;95(7):1183-90.
- 146 Cesaro S, Facchin C, Tridello G, et al. A prospective study of BK-virus-associated haemorrhagic cystitis in paediatric patients undergoing allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2008 Feb;41(4):363-70.
- 147 Haines HL, Laskin BL, Goebel J, et al. Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2011 Oct;17(10):1512-9.
- 148 Giraud G, Priftakis P, Bogdanovic G, et al. BK-viremia and hemorrhagic cystitis are more frequent in allogeneic hematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. *Bone Marrow Transplant.* 2008 Apr;41(8):737-42.
- 149 Giraud G, Bogdanovic G, Priftakis P, et al. The incidence of hemorrhagic cystitis and BK-viremia in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. *Haematologica.* 2006 Mar;91(3):401-4.
- 150 Bogdanovic G, Priftakis P, Giraud G, et al. Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation. *J Clin Microbiol.* 2004 Nov;42(11):3394-6.
- 151 Tanaka K, Hori T, Hatakeyama N, et al. Quantification of BK polyoma viremia in Japanese children and adults with hemorrhagic cystitis complicating stem cell transplantation. *J Med Virol.* 2008 Dec;80(12):2108-12.
- 152 Leung AY, Mak R, Lie AK, et al. Clinicopathological features and risk factors of clinically overt hemorrhagic cystitis complicating bone marrow transplantation. *Bone Marrow Transplant.* 2002 Mar;29(6):509-13.
- 153 Mori Y, Miyamoto T, Kato K, et al. Different Risk Factors Related to Adenovirus- or BK Virus-Associated Hemorrhagic Cystitis following Allogeneic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2012 Mar;18(3):458-65.
- 154 Priftakis P, Bogdanovic G, Kalantari M, Dalianis T. Overrepresentation of point mutations in the Sp1 site of the non-coding control region of BK virus in bone marrow transplanted patients with hemorrhagic cystitis. *J Clin Virol.* 2001 Apr;21(1):1-7.
- 155 Bridges B, Donegan S, Badros A. Cidofovir bladder instillation for the treatment of BK hemorrhagic cystitis after allogeneic stem cell transplantation. *Am J Hematol.* 2006 Jul;81(7):535-7.
- 156 Peinemann F, de Villiers EM, Dorries K, Adams O, Vogeli TA, Burdach S. Clinical course and treatment of hemorrhagic cystitis associated with BK type of human polyomavirus in nine paediatric recipients of allogeneic bone marrow transplants. *Eur J Pediatr.* 2000 Mar;159(3):182-8.
- 157 Cesaro S, Brugiolo A, Faraci M, et al. Incidence and treatment of hemorrhagic cystitis in children given hematopoietic stem cell transplantation: a survey from the Italian association of pediatric hematology oncology-bone marrow transplantation group. *Bone Marrow Transplant.* 2003 Nov;32(9):925-31.
- 158 Miller AN, Glode A, Hogan KR, et al. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. *Biol Blood Marrow Transplant.* 2011 Aug;17(8):1176-81.
- 159 Leung AY, Chan MT, Yuen KY, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis.* 2005 Feb 15;40(4):528-37.
- 160 Harkensee C, Vasdev N, Gennery AR, Willetts IE, Taylor C. Prevention and management of BK-virus associated hemorrhagic cystitis in children following hematopoietic stem cell transplantation--a systematic review and evidence-based guidance for clinical management. *Br J Haematol.* 2008 Sep;142(5):717-31.
- 161 Corallini A, Pagnani M, Viadana P, et al. Association of BK virus with human brain tumors and tumors of pancreatic islets. *Int J Cancer.* 1987 Jan 15;39(1):60-7.

- 162 Fiori M, di MG. Occurrence of BK virus DNA in DNA obtained from certain human tumors. *Proc Natl Acad Sci U S A*. 1976 Dec;73(12):4662-6.
- 163 Dorries K, Loeber G, Meixensberger J. Association of polyomaviruses JC, SV40, and BK with human brain tumors. *Virology*. 1987 Sep;160(1):268-70.
- 164 Das D, Wojno K, Imperiale MJ. BK virus as a cofactor in the etiology of prostate cancer in its early stages. *J Virol*. 2008 Mar;82(6):2705-14.
- 165 Weinreb DB, Desman GT, Amolat-Apiado MJ, Burstein DE, Godbold JH, Jr., Johnson EM. Polyoma virus infection is a prominent risk factor for bladder carcinoma in immunocompetent individuals. *Diagn Cytopathol*. 2006 Mar;34(3):201-3.
- 166 Monini P, Rotola A, Di Luca D, et al. Latent BK virus infection and Kaposi's sarcoma pathogenesis. *Int J Cancer*. 1996 Jun 11;66(6):717-22.
- 167 Negrini M, Rimessi P, Mantovani C, et al. Characterization of BK virus variants rescued from human tumours and tumour cell lines. *J Gen Virol*. 1990 Nov;71 (Pt 11):2731-6.
- 168 De Mattei M, Martini F, Corallini A, et al. High incidence of BK virus large-T-antigen-coding sequences in normal human tissues and tumors of different histotypes. *Int J Cancer*. 1995 Jun 9;61(6):756-60.
- 169 Narayanan M, Szymanski J, Slavcheva E, et al. BK virus associated renal cell carcinoma: case presentation with optimized PCR and other diagnostic tests. *Am J Transplant*. 2007 Jun;7(6):1666-71.
- 170 Geetha D, Tong BC, Racusen L, Markowitz JS, Westra WH. Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. *Transplantation*. 2002 Jun 27;73(12):1933-6.
- 171 Rollison DE, Sexton WJ, Rodriguez AR, Kang LC, Daniel R, Shah KV. Lack of BK virus DNA sequences in most transitional-cell carcinomas of the bladder. *Int J Cancer*. 2007 Mar 15;120(6):1248-51.
- 172 Grossi MP, Meneguzzi G, Chenciner N, et al. Lack of association between BK virus and ependymomas, malignant tumors of pancreatic islets, osteosarcomas and other human tumors. *Intervirology*. 1981;15(1):10-7.
- 173 Greenlee JE, Becker LE, Narayan O, Johnson RT. Failure to demonstrate papovavirus tumor antigen in human cerebral neoplasms. *Ann Neurol*. 1978 Jun;3(6):479-81.
- 174 Becker LE, Narayan O, Johnson RT. Studies of human papovavirus tumor antigen in experimental and human cerebral neoplasms. *Can J Neurol Sci*. 1976 May;3(2):105-9.
- 175 Wold WS, Mackey JK, Brackmann KH, Takemori N, Rigden P, Green M. Analysis of human tumors and human malignant cell lines for BK virus-specific DNA sequences. *Proc Natl Acad Sci U S A*. 1978 Jan;75(1):454-8.
- 176 Israel MA, Martin MA, Takemoto KK, et al. Evaluation of normal and neoplastic human tissue for BK virus. *Virology*. 1978 Oct 15;90(2):187-96.
- 177 Ibelgaufts H, Jones KW. Papovavirus-related RNA sequences in human neurogenic tumours. *Acta Neuropathol*. 1982;56(2):118-22.
- 178 Arthur RR, Grossman SA, Ronnett BM, Bigner SH, Vogelstein B, Shah KV. Lack of association of human polyomaviruses with human brain tumors. *J Neurooncol*. 1994;20(1):55-8.
- 179 Volter C, Hausen H, Alber D, de Villiers EM. Screening human tumor samples with a broad-spectrum polymerase chain reaction method for the detection of polyomaviruses. *Virology*. 1997 Oct 27;237(2):389-96.
- 180 Major EO, di Mayorca G. Malignant transformation of BHK21 clone 13 cells by BK virus--a human papovavirus. *Proc Natl Acad Sci U S A*. 1973 Nov;70(11):3210-2.
- 181 Takemoto KK, Martin MA. Transformation of hamster kidney cells by BK papovavirus DNA. *J Virol*. 1975 Jan;17(1):247-53.
- 182 Dalrymple SA, Beemon KL. BK virus T antigens induce kidney carcinomas and thymoproliferative disorders in transgenic mice. *J Virol*. 1990 Mar;64(3):1182-91.
- 183 Portolani M, Borgatti M. Stable transformation of mouse, rabbit and monkey cells and abortive transformation of human cells by BK virus, a human papovavirus. *J Gen Virol*. 1978 Feb;38(2):369-74.
- 184 Shah KV, Hudson C, Valis J, Strandberg JD. Experimental infection of human foreskin cultures with BK virus, a human papovavirus. *Proc Soc Exp Biol Med*. 1976 Oct;153(1):180-6.
- 185 Sabbioni S, Negrini M, Possati L, et al. Multiple loci on human chromosome 11 control tumorigenicity of BK virus transformed cells. *Int J Cancer*. 1994 Apr 15;57(2):185-91.
- 186 Monini P, Rotola A, Di Luca D, et al. DNA rearrangements impairing BK virus productive infection in urinary tract tumors. *Virology*. 1995 Dec 1;214(1):273-9.
- 187 Watanabe S, Yoshiike K, Nozawa A, Yuasa Y, Uchida S. Viable deletion mutant of human papovavirus BK that induces insulinomas in hamsters. *J Virol*. 1979 Dec;32(3):934-42.
- 188 Watanabe S, Yogo Y, Yoshiike K. Expression of viral early functions in rat 3Y1 cells infected with human papovavirus BK. *J Virol*. 1984 Jan;49(1):78-85.
- 189 Johnsen JI, Seternes OM, Johansen T, Moens U, Mantyjarvi R, Traavik T. Subpopulations of non-coding control region variants within a cell culture-passaged stock of BK virus: sequence comparisons and biological characteristics. *J Gen Virol*. 1995 Jul;76 (Pt 7):1571-81.
- 190 Abend JR, Jiang M, Imperiale MJ. BK virus and human cancer: innocent until proven guilty. *Semin Cancer Biol*. 2009 Aug;19(4):252-60.

Low complication rates in the use of port-a-caths in oncology patients

M.M.E.M. Bos^{1*}, L. Smeets², J. Koning³, I. Dumay¹, E. de Jonge⁴

Departments of ¹Internal Medicine, ²Microbiology, ³Surgery, Reinier de Graaf Hospital, Delft, the Netherlands, ⁴Department of Intensive Care, Leiden University Medical Centre, Leiden, the Netherlands, *corresponding author: tel. +31(0)15-2603165, e-mail: bos@rdgg.nl

ABSTRACT

Background: Port-a-caths (PACs) represent an important component of the care of cancer patients, in particular for administration of chemotherapy. We sought to analyse the longevity and complications of PACs in cancer patients in a large community hospital.

Methods: We retrospectively analysed the indications, duration of use, complications and reasons for removal of PACs in cancer patients treated in our centre from January 2005 to December 2010, and compared these with findings in patients who received a PAC in the same period for reasons not related to cancer.

Results: During the study period 152 cancer patients received a total of 170 PACs; in the same period, 21 patients received a total of 35 PACs for reasons unrelated to cancer. The total analysis comprised 70,919 days of PAC use. Most cancer patients had a solid tumour (97%). PACs were removed because of a complication in 25 cases in cancer patients (14.7%) vs 15 cases in non-cancer patients (42.9%, $p < 0.01$). Culture-proven infection was the reason for PAC removal in 16 cases in cancer patients (23.5%) vs eight cases in non-cancer patients (42.1%; $p = \text{NS}$). The total number of PAC-associated infections was 20 in cancer patients (0.35 infections per 1000 PAC days) vs 19 in non-cancer patients (1.43 infections per 1000 PAC days; $p < 0.01$). No PAC-associated thrombosis was found.

Conclusion: In clinical practice the use of PACs in cancer patients is safe with lower complication rates when compared with PAC use in patients without malignancy.

KEYWORDS

Cancer, chemotherapy, infection, oncology, Port-A-Cath

INTRODUCTION

Venous access is problematic for oncology patients receiving repeated courses of cytotoxic therapy. Totally implantable ports connected to a central venous catheter were first introduced in 1982 and soon replaced subcutaneously tunnelled catheters such as Hickman, Groshong and Broviac lines.^{1,2} These totally implantable venous access ports (TIVAPs), among which port-a-caths (PACs), now represent an important component of the regular care of cancer patients by providing a simple way of accessing the venous system for administration of chemotherapy, antibiotics, analgesics, blood products and fluids, and for the collection of blood. Although in general these devices are safe, their use can be associated with significant complications, most notably infection and thrombosis.

Previous studies have examined complication rates of PAC use in cancer patients.³⁻¹¹ Such knowledge is significant considering the importance of PACs for the clinical care of cancer patients and for guiding preventive measures. This in particular holds true for the main complications described in the literature: infection and thrombosis. In the current study we retrospectively analysed the indications, duration of use, complications and reasons for removal of PACs in patients with malignancies treated in our centre (a large community hospital in the Netherlands) from January 2005 to December 2010. In addition, we analysed the microbial causes of PAC-associated infections in these patients and their impact on PAC use and removal. In order to obtain insight into complications that may relate to cancer specifically, we compared findings in cancer patients with those in patients who received a PAC in the same period for reasons not related to cancer.

MATERIALS AND METHODS

Patients

We performed a retrospective analysis of 173 adult patients (>18 years of age) who received a total of 205 PACs in the Reinier de Graaf Hospital in Delft, the Netherlands between January 2005 and December 2010. The analysis was approved by the institutional medical ethics committee.

Study design

PAC removals within two days after implantation were excluded since these were considered to be related to the surgical procedure. A single type of PAC was used (Deltec™, Smiths Medical). The PACs were inserted by surgeons from the Department of Vascular Surgery in the operation room under general or local anaesthesia using a standardised surgical technique. The access route was chosen according to the patient's anatomy, preferably the right subclavian or external jugular vein. Prophylactic antibiotics were not routinely administered. The PACs were accessed and cared for by trained nursing staff. Lock with heparin solution was done after every PAC access and every four weeks if the PAC was not in use. Patients did not receive routine anticoagulant therapy. PAC-associated infection was defined as 1) a positive culture of blood obtained from either a peripheral vein or from the port and 2) clinical suspicion of PAC infection as reflected by local symptoms or absence of another infectious source.¹² For the analysis of PAC-associated infections, multiple positive blood cultures with a single pathogen in one

clinical episode were counted as one PAC-associated infection with this pathogen.¹² The occurrence of a PAC-associated infection was defined as a complication; other non-infection-related complications were analysed by studying reasons for PAC removal making use of patient hospital records. Diagnostic procedures were done as ordered by the physician; systematic venographies were not performed. Minor complications such as local pain, skin irritation and/or transient inability to draw blood from the PAC were not analysed.

Statistical analysis

Data are expressed as means, medians, interquartile range and ranges as indicated. Differences between cancer patients and non-cancer patients were analysed by the Mann-Whitney U test, Chi square test and log-rank test. A p value below 0.05 was considered to be statistically significant.

RESULTS

Patients

From January 2005 to December 2010, 152 patients with a malignancy received a total of 170 PACs; in the same period, 21 patients received a total of 35 PACs for reasons unrelated to cancer (*table 1*). In both groups, more women than men received a PAC (73.7% amongst cancer patients and 61.9% amongst non-cancer patients). The vast majority of patients with a malignancy suffered from a solid tumour, with breast and colorectal cancer as the

Table 1. Patient characteristics and indications for port-a-cath placement

	Total	Cancer patients	Non-cancer patients
Number of PACs (%)	205	170 (82.9%)	35 (17.1%)
Number of patients (%)	173	152 (87.9%)	21 (12.1%)
Female (%)	125 (72.3%)	112 (73.7%)	13 (61.9%)
Male (%)	48 (27.7%)	40 (26.3%)	8 (38.1%)
Mean age (range) at time of PAC placement	51.8 (18-80)	51.7 (26-77)	53.5 (18-80)
Diagnosis (%)		Breast cancer 72 (47.4%) Colorectal cancer 50 (32.9%) Upper GI cancer 9 (5.9%) Ovarian cancer 11 (7.3%) Lymphoma 4 (2.6%) Other 6 (3.9%)	Neuromuscular disease ¹ 12 (57.1%) Congestive heart failure 8 (38.1%) CIVD ² 1 (4.8%)
Indication		152 (100%)	-
• Chemotherapy		14 (9.2%)	10 (47.6%)
• Immunotherapy ³		-	2 (9.5%)
• Analgesics		-	8 (38.1%)
• Dopamine		-	1 (4.8%)
• Bisphosphonate (APD)		-	-
Mean (range) number of days in situ			
• Total	70.919	57.642	13.277
• Per PAC	346 (9-2064)	339 (9-2064)	379 (13-1839)

¹Dystrophia (n=4), chronic inflammatory demyelinating polyneuropathy (n=6) and multiple sclerosis (n=2); ²Common variable immunodeficiency; ³Refers to monoclonal antibodies: in cancer patients trastuzumab (Herceptin®, antibody directed against epidermal growth factor receptor-2) or bevacizumab (Avastin®, antibody binding to the vascular endothelial growth factor preventing binding to the receptor), in non-cancer patients gammaglobulin (Gammagard®).

predominant diagnoses (47.4% and 32.9%, respectively). In non-cancer patients neuromuscular disease was the most frequent diagnosis (57.1%). The total analysis comprised 70,919 days of PAC use, of which 57,642 days in cancer patients and 13,277 days in non-cancer patients. In cancer patients all PACs were used for administration of chemotherapy. In 14 cases (9.2%) it was also used for immunotherapy. In non-cancer patients ten PACs (47.6%) were inserted for immunotherapy and eight PACs (38.1%) for chronic treatment with dopamine for heart failure (table 1).

Longevity of PACs

Table 2 shows the longevity and reasons for removal of the inserted PACs. In cancer patients, 20% of PACs were in use at the end of follow-up, compared with 31.4% in non-cancer patients (p=NS). Figure 1 is a Kaplan-Meier plot showing that the average survival of the PACs was similar in cancer and non-cancer patients (mean time to removal 927 days vs 899 days, p=0.9 by log-rank test). The percentage of PACs removed during the follow-up period was 40% in cancer patients and 51.5% in non-cancer patients (p=NS). The mean number of days a PAC was *in situ* at the time of removal was 309 days and 500 days in cancer and non-cancer patients respectively, p=NS). In

Table 2. Numbers and reasons for port-a-cath removal

PACs	Total (n=205)	In cancer patients (n=170)	In non-cancer patients (n=35)
Number of PACs in situ at closure of data collection (%)	45 (22.0)	34 (20.0)	11 (31.4)
Number of PACs removed (%)	86 (41.9)	68 (40.0)	18 (51.5)
Number of days in situ ¹			
• Mean	353	312	500
• Median	224	215	247
• Range	6-2064	6-2064	24-1809
Number of patients with PAC removed	77	64	13
• Female	60	51	9
• Male	17	13	4
Reason for removal (% of total removed)			
• Treatment completed	46 (53.5)	43 (63.2)	3 (15.8)
• PAC infection ²	24 (27.9)	16 (23.5)	8 (42.1)
• Occlusion ³	4 (4.7)	2 (3.0)	2 (10.5)
• Malfunction ⁴	9 (10.5)	4 (5.9)	5 (26.3)
• Other ⁵	3 (3.5)	3 (4.5)	0

¹p=NS for difference between patients with cancer and non-cancer patients; ²PAC infection is defined as positive culture from blood obtained from the port or a peripheral vein and clinical suspicion of PAC as defined by symptoms or ruling out other foci; ³Defined as inability to infuse fluids into the PAC system, confirmed by administration of radiological contrast fluid into the port; ⁴For example nicking of the line, port moved away into deeper (breast) tissue, port turned away; ⁵Due to progressive disease in the chest wall covering the port, necessity to insert a Levine shunt, fat necrosis around the PAC.

cancer patients, most PACs were removed because therapy was completed (63.2 vs 15.8% in non-cancer patients, p<0.01). Twenty-five (14.7%) and 15 (42.9%) of PACs were removed for complications (infectious or non-infectious) in cancer and non-cancer patients respectively (p<0.01).

PAC-associated infections


PAC-associated bloodstream infection occurred in 25 of 173 patients (14.4%) (table 3). Amongst cancer patients, 18 (11.8%) were diagnosed with PAC-associated infection during the study period, vs seven (33.3%) non-cancer patients (p=0.02). The total number of PAC-associated

Table 3. Port-a-caths in patients with blood stream infections (BSI) and causative organisms

	All PACs	Cancer	Non-cancer	P-value
Number of PACs inserted	205	170	35	
Number of patients with PAC and BSI	25 (14.4%)	18 (11.8%)	7 (33.3%)	0.02
Number PACs with BSI (% of total)	30 (14.6)	18 (10.6)	12 (34.3)	<0.01
Number of episodes of positive blood cultures ¹	39	21	18	<0.01
Number of different organism in these cultures	43	21	22	
Number of days PAC in situ prior to positive blood culture				0.01
Median	167	100	414	
IQR	55-553	36-234	125-902	
Causative organisms				
Gram-positive	29	14	15	NS
• <i>Staphylococcus aureus</i>	10	5	5	
• Coagulase negative staphylococci	16	7	9	
• <i>Enterococcus</i>	1	-	1	
• <i>Streptococcus pneumoniae</i>	1	1	-	
• Other streptococci	1	1	-	
Gram-negative	13	6	7	NS
• <i>Escherichia coli</i>	2	1	1	
• <i>Pseudomonas aeruginosa</i>	2	-	2	
• <i>Klebsiella oxytoca</i>	1	-	1	
• <i>Klebsiella pneumoniae</i>	1	1	-	
• <i>Serratia marcescens</i>	1	1	-	
• <i>Rhizobacteria</i>	1	-	1	
• <i>Stenotrophomonas maltophilia</i>	1	-	1	
• <i>Enterobacter</i>	2	1	1	
• <i>Acinetobacter</i>	1	1	-	
• <i>Aeromonas hydrophilia</i>	1	1	-	
Yeasts	1	1	-	-
• <i>Candida glabratum</i>	1	1	-	


¹One blood culture per episode (i.e. if four blood cultures were positive for a particular pathogen during the same infection, only one culture was counted).

Figure 1. Cumulative proportion of port-a-caths (PACs) removed for any reason



Cases were censored at death or end of follow-up. P=NS by log rank test for difference between PACs in patients with cancer and PACs in other patients

Figure 2. Proportion of port-a-caths (PACs) removed for infectious complications



P=0.03 by log-rank test for difference between PACs in patients with cancer and PACs in other patients

infections was 21 in cancer patients (0.36 infections per 1000 PAC days) vs 18 in non-cancer patients (1.4 infections per 1000 PAC days; $p < 0.01$ vs cancer patients); Of interest, the median time that a PAC was *in situ* before a bloodstream infection occurred was shorter in cancer patients than in non-cancer patients (100 vs 414 days respectively, $p = 0.01$). The cumulative proportion of PACs removed for an infectious complication is shown in figure 2. Causative organisms did not differ between cancer and non-cancer patients (table 3). In both groups, gram-positive pathogens, in particular *Staphylococcus aureus* and coagulase-negative staphylococci, were most prevalent (more than two-thirds of all bloodstream infections).

DISCUSSION

In the last decades, much attention has been given to the achievement of an adequate means of venous access in cancer patients that is suitable for long-term use, in particular for repeated administration of chemotherapy and blood drawing for testing. Totally implantable venous access ports, such as PACs, are preferred to other approaches for many different reasons, including a reduced risk for infection and thrombosis, less visibility and fewer restrictions on daily activity.¹³ We here report on our experience with PACs in a large community hospital in the Netherlands during a six-year period (January 2005 to December 2010), comparing indications, duration of use, complications and reasons for removal in 170 cancer patients and 35 patients without malignancy, comprising more than 70,000 days (which is almost 200 patient-years) of PAC use.

The complication rate of PACs in cancer patients in part depends on the type of malignant disease (solid tumour or haematological malignancy) and neutrophil counts in peripheral blood.¹³ In the current analysis the vast majority of oncology patients had solid tumours, in particular breast and colorectal cancer (table 1), and only three patients had leucocytopenia at the time of PAC-associated infection (data not shown). Hence, our results predominantly apply to patients with solid tumours and normal leucocyte counts. The current study excluded early complications of PAC placements, such as pneumothorax, primary malposition and arterial perforation, since these are related to the surgical procedure. The overall rate of removal of PACs for infectious or non-infectious complications was lower in cancer patients compared with non-cancer patients. Furthermore, the risk that a PAC will be removed for infectious reasons is lower in cancer patients than in non-cancer patients. Although a definitive explanation for this difference is lacking, it may be related to a higher experience amongst oncology nurses in the management of PACs and/or differences in underlying diseases. For example, insufficient hygienic precautions, inadequate flushing of the system after the introduction of fluids or too long an interval between use of the port make the system at risk for irreversible complications. Insufficient dosing of positive pressure leading to narrowing of the lumen of the catheter due to deposits of fibrin or other substances will eventually obstruct the PAC.⁶ Different infection rates in cancer and non-cancer patients could have been caused by differences in susceptibility for infection due to the underlying disease. However, although the most important indication for PAC use in non-cancer patients was immunotherapy in the form of infusion of gammaglobulin, this therapy was provided for neuromuscular disease in all

but one patient (who had a common variable immunodeficiency). As such, infection rates in non-cancer patients are not biased due to a large number of patients with primary immunodeficiency.

Although PACs are associated with much fewer infectious complications than other approaches to obtain prolonged access to the venous circulation, infection remains an issue of concern.^{7,13} In clinical practice, the diagnosis of PAC-associated infection can be made with or without bacteriological confirmation.^{14,15} In the present analysis we only included culture-proven infection: PAC-associated infection was defined as a positive culture of blood obtained from either a peripheral vein or the port and clinical suspicion of PAC infection as reflected by local symptoms or absence of another infectious source.¹² The incidence of PAC-associated infection amongst cancer patients found here (11.8%) is within the same range as that reported in previous studies: positive blood cultures associated with PACs have been reported to occur in 2.4 to 16.0% of patients,^{3,4,11} representing a major cause of hospital-acquired bacteraemia and the most frequent reason for catheter removal.^{4,16} The vast majority of PAC-associated infections were caused by coagulase-negative staphylococci and *Staphylococcus aureus*, which is in accordance with earlier investigations.^{11,13}

There are no standard criteria for catheter removal in PACs.^{12,13} In the presence of uncomplicated infection due to coagulase-negative staphylococci, the PAC may be retained if there is no evidence of persisting or relapsing bacteraemia. For PAC-associated infection caused by pathogens other than coagulase-negative staphylococci, some physicians would retain the port, partially depending on the patient's clinical status. In our analysis, most PAC-associated infections resulted in PAC removal in cancer patients (80% of cases), but not in patients without cancer (42%). This difference was not related to a clear difference in causative pathogens. It is conceivable that medical oncologists are reluctant to continue chemotherapy through a PAC that has been infected and that as a consequence PAC-associated infection more often leads to PAC removal in cancer patients.

The reported incidence of venous thrombosis as a PAC-associated complication varies between zero and 10%.¹³ In our centre, thrombosis was never the cause of PAC removal during the six-year study period. Notably, since most cases of catheter-related thrombosis are asymptomatic,¹³ this does not exclude that thrombosis did occur in our population. Data on prophylactic anticoagulant therapy are not available for the studied population, but this is not a routine policy in our hospital.

Several earlier investigations have examined the complication rate of PACs in a single-centre setting. No device-related deaths were observed and complications

as infection and thrombosis were rare for all types of patients.^{5,9,11} In a Dutch retrospective analysis encompassing a period of 7.5 years (1992 to 1999) involving 38 PACs, the most prevalent complications were infection (two cases or 5.3%) and thrombosis (three cases or 7.9%).⁵ Although the number of PACs studied was relatively low, these data suggest that the incidence of PAC-associated thrombosis may have decreased in more recent years, probably at least in part as a result of better preventive care by the nursing staff.

Our study has several limitations. Firstly, the study has a low sample size relative to the low incidence of PAC-related problems, which in particular is true for thrombosis. Secondly, the study groups were not comparable with respect to baseline and prognostic variables, which may hamper appropriate comparisons.

The use of PACs is widely implemented in the clinical care of patients with cancer. These devices have a high acceptance among patients, nurses and doctors. The current analysis illustrates the low rate of complications associated with the use of PACs in the setting of a large community hospital in the Netherlands.

REFERENCES

1. Niederhuber JE, Ensminger W, Gyves JW, et al. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. *Surgery*. 1982 Oct;92(4):706-12.
2. Nanninga AG, de Vries EG, Willemse PH, et al. Continuous infusion of chemotherapy on an outpatient basis via a totally implanted venous access port. *Eur J Cancer*. 1991;27(2):147-9.
3. Biffi R, de Braud F, Orsi F, et al. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. *Ann Oncol*. 1998 Jul;9(7):767-73.
4. Silver DF, Hempling RE, Recio FO, et al. Complications related to indwelling caval catheters on a gynecologic oncology service. *Gynecol Oncol*. 1998 Sep;70(3):329-33.
5. Koolen DA, van Laarhoven HW, Wobbes T, Punt CJ. Single-centre experience with tunnelled central venous catheters in 150 cancer patients. *Neth J Med*. 2002 Nov;60(10):397-401.
6. Yeste Sanchez L, Galbis Caravajal JM, Fuster Diana CA, Moledo Eiras E. Protocol for the implantation of a venous access device (Port-A-Cath System). The complications and solutions found in 560 cases. *Clin Transl Oncol*. 2006 Oct;8(10):735-41.
7. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. *Mayo Clin Proc*. 2006 Sep;81(9):1159-71.
8. Liaw CC, Chen JS, Chang HK, et al. Symptoms and signs of port-related infections in oncology patients related to the offending pathogens. *Int J Clin Pract*. 2008 Aug;62(8):1193-8.
9. Samaras P, Dold S, Braun J, et al. Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients. *Oncology*. 2008;74(3-4):237-44.
10. Nishinari K, Wolosker N, Bernardi CV, Yazbek G. Totally implantable ports connected to valved catheters for chemotherapy: experience from 350 Groshong devices. *J Vasc Access*. 2010 Jan-Mar;11(1):17-22.

11. Heibl C, Trommet V, Burgstaller S, et al. Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis. *Eur J Cancer Care (Engl)*. 2010 Sep;19(5):676-81.
12. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009 Jul 1;49(1):1-45.
13. Kurul S, Saip P, Aydin T. Totally implantable venous-access ports: local problems and extravasation injury. *Lancet Oncol*. 2002 Nov;3(11):684-92.
14. Wickham R, Purl S, Welker D. Long-term central venous catheters: issues for care. *Semin Oncol Nurs*. 1992 May;8(2):133-47.
15. Greene JN. Catheter-related complications of cancer therapy. *Infect Dis Clin North Am*. 1996 Jun;10(2):255-95.
16. Freytes CO. Indications and complications of intravenous devices for chemotherapy. *Curr Opin Oncol*. 2000 Jul;12(4):303-7.

PHOTO QUIZ

A patient with haemorrhagic bullae

H. Westdorp*, H.A.M. Sinnige

Department of Internal Medicine, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, the Netherlands, *corresponding author: tel.: +31 (0)73 553 3791, fax: +31 (0)73 553 3236, e-mail: h.westdorp@jbz.nl

CASE REPORT

A 92-year-old man presented to our outpatient clinic with complaints of fatigue, muscle weakness and upper abdominal discomfort. There was no history of haematemesis, melaena, haematuria or epistaxis. In 2010, he was diagnosed with immune thrombocytopenic purpura (ITP) and was treated with prednisolone 1 mg/kg/day (80 mg/day) with good response. The dose was tapered down slowly without disease relapse. Three weeks prior to presentation, the patient had discontinued the prednisone.

Physical examination revealed purpura and petechiae, especially localised on the extremities. There was no lymphadenopathy or hepatosplenomegaly present. Laboratory findings showed a platelet count of less than $3 \times 10^9/l$. No other abnormal findings were noted. A bone marrow aspirate smear showed increased production of megakaryocytes without signs of dysplasia in all cell lines. The relapse of ITP was again treated with oral prednisolone 1 mg/kg/day, however, without effect. Also addition of intravenous immunoglobulin did not increase the platelet count. Because of the refractory character of the ITP we decided to give rituximab off-label. Five days after

Figure 1. Haemorrhagic bullae in the left groin region



administration of the first dose of rituximab the patient developed haemorrhagic bullous lesions on the left hip (figure 1).

WHAT IS YOUR DIAGNOSIS?

See page 195 for the answer to the photo quiz.

An unexpected cause of multiple intra-abdominal abscesses in an HIV-positive patient

A.H. van der Spek¹, J.L. Vosters¹, C.E. Visser², M. van der Valk¹, J.F.J.B. Nellen^{1,*}

Departments of ¹Internal Medicine, Division of Infectious Diseases, ²Medical Microbiology Academic Medical Centre, Amsterdam, the Netherlands, *corresponding author: tel.: +31 (0)20 5666093; fax: +31 (0)20 6972286; e-mail: f.j.nellen@amc.uva.nl

ABSTRACT

This case report describes a female HIV-positive patient diagnosed with pelvic actinomycosis using 16S rRNA gene sequence analysis. Actinomycosis is notoriously difficult to diagnose by microbiological culture. 16S rRNA gene sequence analysis allows rapid definitive diagnosis of actinomycosis and is potentially of great value in a clinical setting. This is the first report of pelvic actinomycosis in an HIV-1 infected patient.

KEYWORDS

16S rRNA gene sequence analysis, actinomycosis, HIV-1 infection


INTRODUCTION

Actinomycosis is notoriously difficult to diagnose due to both its variety in clinical presentation and its challenging growth in microbiological culture. As microbiological culture leads to confirmation of the diagnosis in less than 50% of clinically suspected cases, the final diagnosis is often based solely on the distinctive Gram stain of *Actinomyces*.^{1,3} Sequence analysis of the 16S ribosomal (r)RNA gene is another available method for the detection of *Actinomyces* species. This molecular technique allows earlier and improved diagnosis of actinomycosis without the difficulties encountered using traditional phenotypic methods.^{4,5} We present the case of a female human immunodeficiency virus 1 (HIV-1) infected patient with pelvic actinomycosis, diagnosed using 16S rRNA gene sequence analysis. We are the first to report pelvic actinomycosis in an HIV-1 infected patient.

CASE REPORT

A woman in her early thirties, previously healthy, was admitted to our hospital with a three-month history of fatigue, intermittent fever, poor appetite with marked weight loss and a productive cough with white sputum. The patient's vital functions were normal. Physical examination revealed no abnormalities besides evident cachexia (body mass index 14.0) and mild lower abdominal pain with no palpable mass. Laboratory tests indicated leucocytosis ($18.4 \times 10^9/l$), normochromic normocytic anaemia (Hb 3.5 mmol/l), hypoalbuminaemia (19 g/l), elevated C-reactive protein (139 mg/l) and impaired renal function (estimated creatinine clearance 64.0 ml/min). The chest radiograph showed no abnormalities. Urine analysis indicated leucocyturia. The HIV-antibody test was positive and the CD4 count was $170 \times 10^6/l$. Treatment with intravenous (iv) ceftriaxone was initiated for a presumed urinary tract infection and due to the possibility of a *Pneumocystis pneumonia* iv co-trimoxazole was added at a therapeutic dose. Both blood and urine cultures showed growth of an *E. coli* after which the antibiotics were switched to oral ciprofloxacin. Computed tomography (CT) of the chest showed no intrapulmonary abnormalities after which the co-trimoxazole was stopped. An abdominal ultrasound revealed an abscess-like lesion between the liver and right kidney and hydronephrosis of the left kidney. The CT abdomen revealed a left-sided tubo-ovarian abscess with compression of the left ureter and subsequent hydronephrosis, a large abscess of the abdominal wall and multiple smaller abscesses throughout the pelvis and abdomen (figure 1). Percutaneous nephrostomy was performed to relieve the left kidney and the patient's intra-uterine device (IUD) was removed. The two largest abscesses were drained and their contents cultured. The Gram-stain revealed branched Gram-positive

Figure 1. Computed tomography of the abdomen shows (A) a left-sided tubo-ovarian abscess (white arrow) measuring 5x5x7 cm with compression of the left ureter and subsequent hydronephrosis and (B) a right-sided abscess of the abdominal wall (white arrow) measuring 3x6x9 cm



rods, suspicious of *Actinomyces*. Anaerobic culture showed growth of colonies compatible with *Actinomyces* spp. Definitive identification was achieved using 16S rRNA gene sequence analysis after which treatment with iv penicillin G (2 million U, four times a day) was initiated. The patient's condition improved markedly. She was discharged after 15 days with an intravenous penicillin pump (12 million U/24 hours) for six weeks, followed by oral amoxicillin (500 mg, four times a day). On re-evaluation the CD4 count had increased to $380 \times 10^6/l$ and initiation of antiretroviral therapy was postponed.

DISCUSSION

In this case, the patient presented with surprisingly mild and unspecific symptoms given the extent of her pelvic actinomycosis. This illustrates the variable clinical picture that actinomycosis can present and the delay in diagnosis this can cause.^{6,7} Rapid reliable diagnostic testing such as 16S rRNA gene sequence analysis is an important tool in overcoming these difficulties.

Actinomycosis

Actinomycosis is a chronic granulomatous infection caused by anaerobic Gram-positive bacteria from the *Actinomyces* genus. These commensal inhabitants of the oral cavity and gastrointestinal tract cause infection after preceding mucosal disruption, resulting in the formation of multiple connecting abscesses.^{2,8} *A. israelii* is the most common pathogen in humans.^{2,8}

Due to the disease's variety in clinical presentation and invasive spread which is often mistaken for malignancy, the diagnosis is frequently missed making the overall incidence difficult to determine.^{3,6} Estimates range from

1/40,000 to 1/119,000 cases per year.⁸ Known risk factors include surgery, trauma and IUD use.

Actinomycosis usually involves the cervicofacial (50%), abdominal (20%) and thoracic (15%) regions.^{3,8} Clinical symptoms depend on the site of infection and are frequently unspecific including (mild) pain, fatigue and intermittent fever.

Anaerobic culture is the preferred diagnostic test; however, this can be time-consuming and yields results in only 50% of clinically suspected cases.¹³ The distinctive Gram stain is often the only indication of the diagnosis.⁸ Typically, affected tissues produce pus with sulphur granules of 1 to 2 mm containing branched, Gram-positive filaments. Although these sulphur granules are commonly considered pathognomonic for the disease, they are only present in 50% of cases.^{2,3} *Actinomycosis* therefore still poses a great diagnostic challenge when using traditional phenotypic methods.

Molecular genetic methods, such as 16S rRNA gene sequence analysis, bypass many of the problems encountered using traditional methods.⁹ The 16S rRNA gene is the part of the genetic code most commonly used for the taxonomy of bacteria.⁴ It contains both highly conserved genomic sequences and variable sequences which allow species differentiation. Sequence analysis of the 16S rRNA gene is an effective method for precise identification of bacteria which are otherwise rarely isolated.⁴ 16S rRNA gene sequence analysis allows rapid definitive diagnosis of actinomycosis and identification of specific *Actinomyces* strains and can be of great value in the clinical setting.^{5,10,11}

Actinomycosis requires long-term antibiotic therapy. The treatment of choice is high-dose iv penicillin G (10-20 million U/day) for four to six weeks followed by six to 12 months of oral penicillin or amoxicillin.⁸

Actinomycosis and HIV

Despite the impaired cellular and humoral immunity associated with HIV infection there is no increase in the incidence of actinomycosis in the HIV-positive population.¹² The sporadic examples available in the literature of HIV-positive patients with actinomycosis do indicate an increased prevalence of the atypical acute, invasive, ulcerative form of the disease.¹² Despite this observation, HIV infection does not appear to predispose an individual to actinomycosis.^{12,13}

CONCLUSION

Actinomycosis remains notoriously difficult to diagnose due to its variety in clinical presentation and challenging growth in microbiological culture. Molecular genetic methods such as 16S rRNA gene sequence analysis allow

more rapid and accurate diagnosis of actinomycosis than traditional phenotypic methods and are potentially of great value in the clinical setting. Actinomycosis is rare in the HIV-positive population. There are no other reported cases of pelvic actinomycosis in an HIV-1 infected patient.

REFERENCES

1. Bennhoff DF. Actinomycosis: diagnostic and therapeutic considerations and a review of 32 cases. *Laryngoscope*. 1984;94(9):1198-217.
2. Burden P. Actinomycosis. *J Infect*. 1989;19(2):95-9.
3. Garner JP, Macdonald M, Kumar PK. Abdominal actinomycosis. *Int J Surg*. 2007; 5(6):441-8.
4. Clarridge JE, III. Impact of 16S rRNA gene sequence analysis for identification of bacteria on clinical microbiology and infectious diseases. *Clin Microbiol Rev*. 2004; 17(4):840-62, table.
5. Jauh-Hsun C, Vinh T, Davies JK, Figdor D. Molecular approaches to the differentiation of Actinomyces species. *Oral Microbiol Immunol*. 1999; 14(4):250-6.
6. Acevedo F, Baudrand R, Letelier LM, Gaete P. Actinomycosis: a great pretender. Case reports of unusual presentations and a review of the literature. *Int J Infect Dis*. 2008;12(4):358-62.
7. Heidt J, Jansen CL, Leyten EM. An abdominal mass: not a 'clear cut' case! Actinomycosis. *Neth J Med*. 2010;68(10):319-21.
8. Cintron JR, Del Pino A, Duarte B, Wood D. Abdominal actinomycosis. *Dis Colon Rectum*. 1996;39(1):105-8.
9. Nagy E, Urban E, Soki J, Terhes G, Nagy K. The place of molecular genetic methods in the diagnostics of human pathogenic anaerobic bacteria. A minireview. *Acta Microbiol Immunol Hung*. 2006;53(2):183-94.
10. Stackebrandt E, Charfreitag O. Partial 16S rRNA primary structure of five Actinomyces species: phylogenetic implications and development of an Actinomyces israelii-specific oligonucleotide probe. *J Gen Microbiol*. 1990;136(1):37-43.
11. Hall V, Talbot PR, Stubbs SL, Duerden BI. Identification of clinical isolates of actinomyces species by amplified 16S ribosomal DNA restriction analysis. *J Clin Microbiol*. 2001;39(10):3555-62.
12. Chaudhry SI, Greenspan JS. Actinomycosis in HIV infection: a review of a rare complication. *Int J STD AIDS*. 2000;11(6):349-55.
13. Murchan EM, Redelman-Sidi G, et al. Esophageal actinomycosis in a fifty-three-year-old man with HIV: case report and review of the literature. *AIDS Patient Care STDS*. 2010;24(2):73-8.

PHOTO QUIZ

An unexpected cause of chest pain

D.J.L. van Twist^{1*}, M.B.I. Lobbes², S. Vanwetswinkel², P.M. Stassen¹

Departments of ¹Internal Medicine and ²Radiology, Maastricht University Medical Centre, Maastricht, the Netherlands, *corresponding author: tel.: +31 (0)43 3877005, fax: +31(0)43 3875006e, e-mail: daan.van.twist@mumc.nl

CASE REPORT

A 66-year-old man with a history of COPD and nicotine abuse visited our emergency department because of severe chest pain radiating to the left shoulder blade. The pain was continuous and started suddenly, approximately four hours before presentation. One week earlier, the patient underwent a gastroscopy and abdominal ultrasound because of upper abdominal pain, both without any abnormalities. At physical examination, blood pressure was 190/110 mmHg in both arms and the pulse was 77 beats/min. The patient had a respiratory rate of 20 breaths/min, normal oxygen saturation and temperature, and auscultation of heart, lungs, abdominal, and femoral arteries was normal. The pain could not be provoked

by palpation. Chest X-ray and routine laboratory tests (including cardiac enzymes) were normal, except for a slight elevation of the inflammatory parameters (leucocyte count $12.4 \times 10^9/l$, and C-reactive protein 19 mg/l). ECG showed slight left ventricular hypertrophy. A contrast-enhanced chest-computed tomography (CT), performed to rule out pulmonary embolisms, showed an abnormal aortic wall (see figure page 196).

WHAT IS YOUR DIAGNOSIS?

See page 196 for the answer to this photo quiz.

An unusual cause of ascites

M.M. Smits^{1,2*}, P.W.G. van der Linden¹

¹Department of Internal Medicine, Division of Oncology, Kennemer Gasthuis, Haarlem, the Netherlands, ²Department of Internal Medicine, VU Medical Centre, Amsterdam, the Netherlands, *corresponding author: e-mail: marksmits@live.nl

CASE REPORT

A 72-year-old woman with an extensive medical history, including cervical carcinoma, rheumatoid arthritis, hypertension and COPD, was seen at the internal medicine outpatient clinic because of ascites. The day of the scheduled ascites puncture, she presented herself to the Emergency Room with nausea, vomiting and diarrhoea. Ascitic fluid was obtained in which malignant cells were found. Histologically these were consistent with ovarian carcinoma. However, a tumour of the gastrointestinal system could not be excluded. We performed a computed tomography (CT) scan of the abdomen (*figure 1*) and thorax, which showed no signs of a gynaecological tumour or primary tumour of the gastrointestinal system. A vast amount of ascites and an omental cake were reported by the radiologist. We consulted a gynaecologist, who could not find a gynaecological tumour using transvaginal ultrasound.

We then tried to obtain histological material from the omental cake. Unfortunately the ultrasound-guided

Figure 1. Abdominal CT-slides showing an abdominal cake and ascites





Figure 2. Histologic material of the appendiceal mass



puncture failed because the lesion could not be recognised. In consultation with the gynaecologist it was decided to perform a laparoscopic exploration of the abdominal cavity. During the laparoscopy, no tumours of uterus or adnexes were observed. However, multiple miliary omental lesions and an appendiceal mass were reported. Biopsies were taken (*figure 2* shows the histology of the appendiceal mass).

WHAT IS YOUR DIAGNOSIS?

See page 197 for the answer to this photo quiz.

A man with painless scrotal swelling

D. Boumans*, R.A.A. van Zanten, B.W. Schot

Department of Internal Medicine, Ziekenhuisgroep Twente, Almelo, the Netherlands,
*corresponding author: tel.: +31 (0)546 693 693, fax: +31 (0)546 693 418, e-mail: de.boumans@zgt.nl

CASE REPORT

A 65-year-old man with a medical history of obstructive sleep apnoea syndrome presented with complaints of diarrhoea, abdominal pain, nausea, vomiting and fever for one week. Also, he showed signs of biliary obstruction. Further investigation revealed the presence of *Campylobacter jejuni* gastroenteritis and choledocholithiasis with minimal jaundice. A day later the patient developed cholangitis for which an endoscopic retrograde cholangiography (ERCP) with precut papillotomy was performed. Midazolam was used for procedural sedation. However, the procedure was

complicated by agitation despite higher doses of midazolam. Several attempts to cannulate the common bile duct were undertaken, but nevertheless unsuccessful. The next day, the patient experienced considerable painless scrotal swelling (*figure 1*). An abdominal X-ray was also performed (*figure 2*).

WHAT IS YOUR DIAGNOSIS?

See page 198 for the answer to this photo quiz.

Figure 1. Extensive scrotal swelling



Figure 2. Abdominal X-ray showing air within the retroperitoneum, as well as subcutaneous and scrotal emphysema



ANSWER TO PHOTO QUIZ (PAGE 189)
A PATIENT WITH HAEMORRHAGIC BULLAE

DIAGNOSIS

The affected dermatomal pattern on one side of the body, in conjunction with the immunosuppressive treatment, made us think of an opportunistic infection with varicella zoster virus (VZV). The haemorrhagic aspect was suggested to be caused by the underlying thrombocytopenia, which initially persisted despite therapy with rituximab. A polymerase chain reaction on the bullous fluid was positive for VZV DNA, indicating an active VZV infection.

ITP treatment with corticosteroids results in a complete response in 20% of adult patients. Most of the patients, however, will require a second-line treatment. For the clinical management of ITP we refer to a recent paper in this journal.¹ Rituximab, a chimeric anti-CD20 monoclonal antibody, depletes CD20+ B-cells which results in low or even undetectable levels for two to six months,

returning to pre-treatment levels within a year. Rituximab also induces complement-mediated cytotoxicity and dysfunction of CD4 T cells leading to abnormal cytotoxic T-cell-mediated responses.² The above predisposes the patient to opportunistic infections. Data from 356 patients receiving rituximab monotherapy showed a 30% incidence rate of infectious events; 19% of patients had a bacterial infection, 10% viral infections, 1% fungal infections and 6% infections of unknown aetiology.³ One randomised controlled trial showed opportunistic viral infections which included three dermatomal herpes zoster infections and four localised herpes simplex infections. Isolated cases of other viral infections have been associated with rituximab, such as cytomegalovirus, West Nile virus, JC virus, BK virus and parvovirus.⁴

Our patient was treated with valaciclovir 1000 mg twice a day. He responded very well to drug therapy and there was a major reduction of the bullae and herpes zoster rash. Additionally, after the third rituximab infusion, a significant increase in the platelet count to 70×10^9 cells/l was seen.

Figure 1. Haemorrhagic bullae in the left groin region



REFERENCES

1. Schipperus M, Fijnheer R. New therapeutic options for immune thrombocytopenia. *Neth J Med.* 2011;69:480-5.
2. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? *Int J Infect Dis.* 2011;15:e2-16.
3. Kimby E. Tolerability and safety of Rituximab (MabThera). *Cancer Treat Rev.* 2005;31:456-73.
4. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. *Leuk Lymphoma.* 2007;48:1307-12.

ANSWER TO PHOTO QUIZ (PAGE 192)
AN UNEXPECTED CAUSE OF CHEST PAIN


DIAGNOSIS

The chest CT shows a deep atheromatous ulcer in the descending aorta. A small intramural haematoma was also observed throughout the complete thoracic aorta (thickened aortic wall with slightly increased Hounsfield units). No evidence was found for aortic dissection or pulmonary embolism. Thus, the diagnosis was penetrating aortic ulcer (PAU), which is an ulceration of an atherosclerotic lesion leading to a disruption of the internal elastic lamina of the aortic wall and, subsequently, the development of an intramural haematoma.¹ Diagnosing PAU may be challenging as chest pain has a wide range of differential diagnoses. Sudden onset of severe chest pain in the elderly hypertensive patient is the classical presentation, although symptoms vary greatly.² PAU is often overlooked due to its low incidence and the fact that an aortic dissection is considered unlikely if the blood pressure is equal in both arms and vascular murmurs are absent. Unfortunately, other acute aortic syndromes besides aortic dissection, such as PAU or intramural haematoma, are often forgotten. The diagnosis is made by imaging studies, mostly by contrast-enhanced chest-CT.³ Since PAU has a high risk for progression into a fatal rupture of the aorta, emergent treatment is required. Both invasive (surgical or endovascular) and conservative treatments are considered appropriate.⁴ Our patient was treated conservatively (as a 'hypertensive emergency') with labetalol intravenously. His blood pressure decreased quickly and the pain dissolved. Six months later, the blood pressure was normal (using four antihypertensive drugs) and the patient no longer complained of pain. Control CT scans after 24 hours, seven days and six months showed no further progression of the aortic ulcer.

REFERENCES

1. Stanson AW, Kazmier FJ, Hollier LH, et al. Penetrating atherosclerotic ulcers of the thoracic aorta: natural history and clinicopathologic correlations. *Ann Vasc Surg.* 1986;1:15-23.
2. Troxler M, Mavor AI, Homer-Vanniasinkam S. Penetrating atherosclerotic ulcers of the aorta. *Br J Surg.* 2001;88:1169-77.
3. Salvolini L, Renda P, Fiore D, Scaglione M, Piccoli G, Giovagnoni A. Acute aortic syndromes: Role of multi-detector row CT. *Eur J Radiol.* 2008;65:350-8.
4. Sundt TM. Intramural hematoma and penetrating atherosclerotic ulcer of the aorta. *Ann Thorac Surg.* 2007;83:5835-41; discussion S46-50.

Figure 1. Contrast-enhanced CT of the thorax in the transverse imaging plane (A) and reconstructed coronal imaging plane (B) shows a thickened aortic wall with slightly elevated Hounsfield units, suggestive of intramural haematoma (black asterisk). The contrast-filled lumen expands within the aortic wall, which is visible in multiple reconstructed imaging planes with vascular calcifications on the luminal side of the aorta (therefore not compatible with thrombus), suggestive of the presence of a penetrating aortic ulcer (arrow). No dissection flap of the aorta was observed



DIAGNOSIS

Histology shows a mucoid adenocarcinoma with signet cell differentiation. In combination with the clinical findings we made the diagnosis of metastasised mucoid adenocarcinoma of the appendix. Interestingly, the CT scan showed an omental cake (*figure 1A*), but nothing of interest in the appendiceal area (*figure 1B*). This could be due to the fact that the carcinoma has a signet ring differentiation.

Multiple histological types of appendiceal carcinomas are known, of which signet ring differentiation is the smallest group.^{1,2} In signet cells the cell is filled with mucus, leading to an outward position of the nucleus. This type of cancer is exceedingly rare. Dutch numbers are lacking, but extrapolating from US data,³ a case of appendiceal adenocarcinoma with signet ring differentiation is only seen once every five years in the Netherlands.

The condition is usually an unexpected finding during surgery for another indication. However, 80% of cases present with abdominal pain or acute appendicitis.² Other symptoms are a bloated feeling or an abdominal mass. If a physician suspects an appendiceal carcinoma based on the patient's symptoms, regular imaging techniques can be used.

The treatment of choice is a right hemicolectomy.⁴ If the condition of the patient does not allow an operation, or

when (inoperable) metastases are present, the physician should consider chemotherapy. The prognosis of primary carcinoma of the appendix is dependent on the stage of the disease.³ Carcinoma with signet ring differentiation tends to have a poorer prognosis because of very early dissemination to the peritoneum,³ which is probably the reason why it did not show up on the CT scan. Physicians should always keep this type of tumour in mind when malignant cells are found in ascitic fluid without obvious lesions on imaging techniques.

REFERENCES

1. Kim HC, Yang DM, Jin W, Kim GY, Choi SI. Metastasis to the appendix from a hepatocellular carcinoma manifesting as acute appendicitis: CT findings. *Br J Radiol.* 2008 Jul;81(967):e194-e196.
2. Ko YH, Park SH, Jung CK, et al. Clinical characteristics and prognostic factors for primary appendiceal carcinoma. *Asia Pac J Clin Oncol.* 2010 Mar;6(1):19-27.
3. McCusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. *Cancer.* 2002 Jun 15;94(12):3307-12.
4. McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. *Dis Colon Rectum.* 2005 Dec;48(12):2264-71.

DIAGNOSIS

Because the first ERCP was unsuccessful, the procedure was repeated a day later, but this time in the operation room with adequate anaesthesia. Surprisingly, cholangiography revealed a *fausse route* with a duodenal perforation. The abdominal X-ray showed air within the retroperitoneum and subcutaneous, as well as inguinal and scrotal emphysema (*figure 2*). Abdominal computed tomography scan confirmed the diagnosis of scrotal emphysema (pneumoscotum) related to retroperitoneal perforation due to a *fausse route* during ERCP. The retroperitoneal perforation as well as the pneumoscotum resolved with conservative measures, including nasogastric decompression, antibiotics and intravenous fluids.

ERCP is a commonly used and well-tolerated procedure with low overall complication risk (1 to 5%) and mortality rate (0.2 to 0.5%).¹ Possible complications are, among others, pancreatitis, bleeding, infection, cardiopulmonary events and perforation. In our case the patient remained restless despite sedation, potentially increasing the complication risk. So, adequate sedation is essential during procedures such as ERCP. The risk of perforation is minimal (<0.05%) occurring in 0.2 to 0.6% of ERCP cases and originating from several anatomic sites such as the retroperitoneum.¹ Retroperitoneal perforations can cause subcutaneous emphysema, pneumomediastinum, pneumothorax and to lesser extent pneumoscotum.² Pneumoscotum develops in cases if air dissects down from the retroperitoneum through the anatomic connections between the retroperitoneum, fascial planes of the abdominopelvic cavity, inguinal canal and finally into the scrotal sac.² In case of retroperitoneal perforation

conservative management with broad-spectrum antibiotics, serial re-evaluations, decompression of the biliary tract, stomach and duodenum, is successful in most patients and approved for the initial treatment.^{1,3,4} Surgery should be considered with the co-existence of peritoneal signs (guarding, rebound tenderness), significant duodenal perforation, sepsis or failed conservative treatment.^{1,3,4} In our case, conservative management was successful and the patient recovered without life-threatening complications. However, because of their variable course of disease, these perforations are treacherous and can cause morbidity and mortality as well.⁵

When a patient develops a pneumoscotum after ERCP or another endoscopic intervention, a procedure-related perforation should be considered.

REFERENCES

1. Silveira ML, Seamon MJ, Porshinsky B, et al. Complications related to endoscopic retrograde cholangiopancreatography: a comprehensive clinical review. *J Gastrointest Liver Dis.* 2009;18(1):73-82.
2. Firman R, Heiselman D, Lloyd T, Mardesich P. Pneumoscotum. *Ann Emerg Med.* 1993;22(8):1353-6.
3. Avgerinos DV, Llaguna OH, Lo AY, Voli J, Leitman IM. Management of endoscopic retrograde cholangiopancreatography: related duodenal perforations. *Surg Endosc.* 2009;23(4):833-8.
4. Lai CH, Lau WY. Management of endoscopic retrograde cholangiopancreatography-related perforation. *Surgeon.* 2008;6(1):45-8.
5. Kobborg M, Helligsø P, Altmann P, Berner Hansen M. Unusual duodenal perforation following endoscopic retrograde cholangiopancreatography. *Gastroenterology Insights.* 2011;volume 3(e1).

Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis

A. van Tellingen^{1*}, A.E. Voskuyl², M.G. Vervloet¹, M. Bijl³, R.G.L. de Sévaux⁴, S.P. Berger⁵, R.H.W.M. Derksen⁶, J.H.M. Berden⁴, on behalf of the Dutch Working Party on Systemic Lupus Erythematosus

Departments of ¹Nephrology, ²Rheumatology, VU University Medical Centre, Amsterdam, the Netherlands, ³Department of Rheumatology and Clinical Immunology, University Medical Centre Groningen, Groningen, the Netherlands, ⁴Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands, ⁵Department of Internal Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, the Netherlands, ⁶Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, the Netherlands, *corresponding author: tel.: +31 (0)75-650 29 11, fax: +31 (0)75-6502379, e-mail: Tellinge.A@zaansmc.nl

ABSTRACT

Proliferative lupus nephritis is a strong predictor of morbidity and mortality in patients with systemic lupus erythematosus. Despite improvements in the management of lupus nephritis, a significant number of the patients do not respond to immunosuppressive therapy and progress to end-stage renal failure. In order to optimise the diagnostic strategy and treatment of patients with proliferative lupus nephritis, guidelines are needed.

In this review, the Dutch Working Party on Systemic Lupus Erythematosus provides recommendations regarding four important areas in patients with proliferative lupus nephritis: I) indications for a first renal biopsy, II) definitions of treatment response, III) selection of treatment options, and IV) indications for a repeat biopsy.

KEYWORDS

Azathioprine, cyclophosphamide, mycophenolate mofetil, proliferative lupus nephritis

INTRODUCTION

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterised by the production of auto-antibodies most prominent against nuclear antigens. Antibodies against nucleosomes and double-stranded DNA have a central role in the pathogenesis of the disease.¹ The systemic character of SLE is illustrated by the fact that

all kinds of tissues and/or organs may be involved in this disease.²

In Europe, the incidence of SLE is estimated at 3.3 to 5.0 per 100,000 persons and the prevalence at 25.4 to 91.0 per 100,000 persons.³ Most patients are women of childbearing potential. Lupus nephritis (LN) occurs in up to 50 to 75% of SLE patients during the course of the disease.^{4,5} The incidence of kidney involvement differs with ethnicity: a higher incidence of LN has been reported among Black, Hispanic and Asian patients compared with Caucasian patients.^{3,6} Although the clinical presentation may vary among patients, proliferative LN is a major cause of morbidity and mortality.^{7,8} Progression into end-stage renal disease (ESRD) despite aggressive immunosuppressive therapy does occur.⁹⁻¹¹

To date, no guidelines on how to manage patients with proliferative LN (ISN/RPS class III and IV) are available in the Netherlands although European guidelines have been published¹², and international (KDIGO) and US (American College of Rheumatology) guidelines are currently being developed. The Dutch Working Party on SLE has addressed this issue and developed recommendations based on opinions from expert panel meetings with nephrologists, rheumatologists and clinical immunologists, and a critical review of the present literature. A systemic search of the PubMed database was performed (1975 to January 2012), and all English language publications were considered. The following search terms were used: SLE, (refractory) LN, azathioprine, cyclophosphamide,

prednisone, mycophenolate mofetil (MMF), rituximab, hydroxychloroquine, renal biopsy, repeat biopsy, antiphospholipid syndrome nephropathy, induction treatment, maintenance treatment, and response.

The strength of evidence was graded using the following classification: Level A evidence represents data derived from multiple randomised controlled trials (RCT) or a meta-analysis; Level B from a single RCT or a non-randomised study; Level C from expert opinion.

In this article, we present recommendations regarding four important areas in the care of patients with proliferative LN: I) indications for a first renal biopsy, II) definitions of treatment response, III) selection of treatment options, and IV) indications for a repeat biopsy.

INDICATIONS FOR A FIRST RENAL BIOPSY IN PATIENTS WITH SLE

The occurrence of LN should be considered in any SLE patient with a recent onset of impaired kidney function, proteinuria and/or microscopic haematuria (≥ 5 red cells per high-power field). However, as these clinical features do not permit a reliable prediction of the class of LN (figure 1), the diagnosis must be confirmed by kidney biopsy, since this can have clinical consequences on treatment decisions.² Six classes of LN are distinguished in the current classification of the International Society of Nephrology and the Renal Pathology Society (ISN/RPS) (table 1).¹³ These histological findings provide the basis for treatment recommendations. Based on panel discussions, the Dutch Working Party formulated guidelines (as stated

Table 1. Abbreviated International Society of Nephrology/ Renal Pathology Society (ISN/RPS) classification of lupus nephritis 2003¹³


Class I	Minimal mesangial lupus nephritis
Class II	Mesangial proliferative lupus nephritis
Class III	Focal proliferative lupus nephritis (involving <50% of all glomeruli)
Class IV	Diffuse proliferative lupus nephritis ^{a,b} (involving $\geq 50\%$ of all glomeruli) Segmental lesions: IV-S (involving <50% of the glomerular tuft) Global lesions: IV-G (involving $\geq 50\%$ of the glomerular tuft)
Class V	Membranous lupus nephritis ^c
Class VI	Advanced sclerosing lupus nephritis without active lesions

^aIndicates the presence of active (A), active and chronic (A/C) and chronic (C) lesions; ^bIndicates the proportion of glomeruli with fibrinoid necrosis and cellular crescents; ^cClass V may occur in combination with class III or IV, in which case both will be diagnosed.

in figure 2) on when to perform a first renal biopsy in patients with SLE.


Although clinically silent proliferative LN occurs in a substantial proportion of patients, it is generally accepted to decide not to perform a renal biopsy in SLE patients who have a normal renal function, no haematuria and <0.5 g/24 hours of proteinuria (Level C).¹⁴ In such patients renal parameters should be monitored carefully. In SLE patients presenting with >0.5 g/24 hours of proteinuria, after exclusion of other causes a renal biopsy is indicated, independent of the presence of microscopic haematuria

Figure 1. Incidence of clinical symptoms in various forms of lupus nephritis⁹



Lupus nephritis, based on the 1995 classification published under the auspices of the World Health Organization.⁸⁰

Figure 2. Indications to perform a first renal biopsy in patients with systemic lupus erythematosus



*Systemic lupus erythematosus: at least 4 ACR criteria positive; **Consider a renal biopsy when either i) a persistent elevation of serum creatinine >30%, ii) other causes of renal impairment are excluded, iii) positive anti-phospholipid antibodies, iv) extra-renal involvement/presence of anti-dsDNA antibodies/hypocomplementaemia.

and/or an increase in serum creatinine (Level C). These patients may have focal or diffuse proliferative glomerulonephritis, or membranous lupus.

In SLE patients with microscopic haematuria in the absence of an increase in serum creatinine or proteinuria it is not clear whether a renal biopsy should be performed. Although prompt diagnosis after the onset of LN and subsequent initiation of appropriate therapy are associated with improved outcomes, persistent isolated microscopic haematuria has not been associated with a negative outcome so far and warrants close monitoring of other renal parameters (Level C).^{15,16}

An increase in serum creatinine may implicate a proliferative LN. However, is it possible that these patients present without microscopic haematuria or proteinuria? Since clinical features do not permit a reliable prediction of the class of LN, the Dutch Working Party came to an opinion-based agreement that in this setting a biopsy should be considered when the observed increase in serum creatinine is persistent over several weeks and is >30%, together with the presence of either I) extra-renal lupus manifestations and/or serological activity and/or II) the presence of anti-phospholipid antibodies.¹⁷⁻²⁰ Moreover, in the absence of an obvious extra-renal explanation for deteriorating renal function a kidney biopsy may be warranted to exclude renal pathology other than LN, including a tubulo-interstitial nephritis, vascular disease (e.g. thrombotic microangiopathy or vasculitis), diabetes or drug-induced nephrotoxicity (Level C).

DEFINITIONS OF TREATMENT RESPONSE IN LN

Standard definitions of treatment response have been assessed in proliferative LN.²¹⁻²³ However, no single initial renal parameter has been validated as a marker for determining response.^{12,23} Nonetheless, changes in renal function have been associated with renal outcome in several studies. In the National Institutes of Health (NIH) trials comparing prednisone, azathioprine and cyclophosphamide, doubling of serum creatinine was associated with the development of renal insufficiency.^{24,25} Moreover, in the Euro-Lupus Nephritis Trial a decrease of an initially elevated serum creatinine and/or decrease in proteinuria to <1 g/24 hours at six months were powerful predictors for improved long-term renal outcome.²⁶ A recent trial conducted by the Collaborative Study Group demonstrated that even patients with a partial response (a ≤25% increase in baseline creatinine and ≥50% reduction in baseline proteinuria to ≤1.5 g/24 hours [but >0.33 g/24 hours] within five years of entering the study) had a significantly better renal survival than patients who did not retain a response, but not as good as in patients

with complete response (serum creatinine of ≤1.4 mg/dl [98 mmol/l] and proteinuria ≤0.33 g/24 hours within five years of entering the study).²⁷ Moreover, the choice of time-point used to address response differs in clinical studies. In the above-mentioned study, the time for attaining a complete response was significantly longer than that required to attain a partial response (median: 10.5 vs 5.8 months). These results are consistent with the results of other reports.^{28,29} On the basis of these observations, it is comprehensible that studies with only six months of follow-up report a relatively low percentage of complete response rates.

Based on the available literature, the Dutch Working Party assigned the following definitions of response as a guide to the success of therapy (Level C):

A *complete response* includes no disease activity, i.e. proteinuria <0.5 g/24 hours, and/or a serum creatinine within 125% of the baseline value at 6 to 12 months after the start of induction therapy.

A *partial response* is defined as an improvement not sufficient for the definition of a complete response, i.e. a reduction of proteinuria of >50% (and at least <3 g/24 hours), and a serum creatinine within 125% of the baseline value at six to 12 months after the start of the induction therapy.

A *failure* of the initial induction therapy has been defined as a doubling of serum creatinine compared with the baseline value at three months after the start of induction therapy.

A *flare* is an increase in disease activity that requires intensification of the therapy and is defined as an increase of ≥25% in the lowest serum creatinine level measured during the period of induction therapy and/or the development of either a nephrotic syndrome (proteinuria >3.5 g/24 hours and serum albumin <30 g/l), while the lowest protein excretion so far has been ≤2.0 g/24 hours repeatedly, or proteinuria >1.5 g/24 hours in a previous non-proteinuric patient.

Refractory LN includes persistent or worsening renal disease activity as manifested by progressive deterioration of renal function and/or proteinuria despite optimal immunosuppressive therapy and supportive treatment, and involving at least one of the following conditions: I) failure of the initial induction treatment at three months, for which a switch to another induction therapy regime has already been carried out; II) intolerance for cyclophosphamide and mycophenolate mofetil (MMF); III) exceeding a cumulative dose of 15 gram of cyclophosphamide, IV) a second relapse within two years after start of the initial induction therapy, and V) a relative contraindication for high-dose oral or intravenous (iv) prednisone, such as avascular osteonecrosis, previous psychosis on corticosteroids, osteoporosis and/or severe obesity (BMI ≥35 kg/m²).

TREATMENT OF LN

Induction treatment

Cyclophosphamide-containing regimens have long been considered the gold standard in inducing renal remission and preventing renal flare in patients with proliferative LN.^{25,30,31} However, treatment-related toxicity raised a number of concerns.^{32,33} Furthermore, while cyclophosphamide induces renal remission in a significant proportion of patients with proliferative LN, the rate of relapse is considerable.³⁴ In order to reduce the toxicity but not the efficacy, alternative treatment regimens have been evaluated in recent years.

In the Euro-Lupus Nephritis Trial, 90 (mainly Caucasian) patients were randomised to high-dose iv cyclophosphamide (500-750 mg/m² six pulses monthly, followed by two pulses tri-monthly) or low-dose iv cyclophosphamide (500 mg fixed dose, six pulses every two weeks) in combination with methylprednisolone (three days, 750 mg) followed by oral prednisone (0.5 to 1.0 mg/kg).^{9,35} Following the cyclophosphamide pulses, oral azathioprine (2 mg/kg) was introduced in both treatment arms. After ten years of follow-up, no significant differences were found between the low-dose and high-dose arms with regard to survival, ESRD or doubling of serum creatinine. These data show that the 'Euro-Lupus regimen' achieves good clinical results in the long-term in an European (mainly Caucasian) population with moderately severe disease, and seems to be a good alternative for the high-dose NIH cyclophosphamide regimen, while a considerably lower cumulative dose of cyclophosphamide is given. However, it should be noticed that in the low-dose arm additional cyclophosphamide was necessary during follow-up, increasing the cumulative dose from 3.0 to 5.5 gram.

The first Dutch Lupus Nephritis Study was initiated to analyse the effect of induction therapy with either pulse iv cyclophosphamide or azathioprine combined with methylprednisolone in patients with proliferative LN.³⁶ In this study, cyclophosphamide was superior to azathioprine in terms of preventing renal relapse and progression of chronic lesions in repeat biopsies at 24 months. The long-term follow-up data of this study confirmed the superiority of cyclophosphamide in the prevention of renal relapses, but sustained doubling of serum creatinine, ESRD, mortality, and renal function did not differ between the two treatment groups after a median follow-up of 9.6 years.³⁷ These results indicate that azathioprine can not be considered to be the standard induction therapy in patients with proliferative LN and should be reserved for those patients with a strong wish to conceive and with a high risk of premature ovarian failure, who are willing to accept the higher risk of exacerbations.

The benefits of MMF for LN were first reported in uncontrolled studies of patients refractory to cyclophosphamide.^{38,39} Subsequently, relatively small randomised controlled trials have been performed.⁴⁰⁻⁴³ The Ginzler study, a non-inferiority RCT, demonstrated that MMF (initial dose 1 g/day, increased to 3 g/day) was significantly better in inducing complete remission (CR) at 24 weeks than the NIH-cyclophosphamide regimen (CR 22.5% vs 5.8% respectively).⁴⁴ In this study, 56% of the patients were Black.

In view of the small size of the MMF trials, several meta-analyses of RCTs comparing induction therapy with MMF or cyclophosphamide have been performed. The results of these analyses show that MMF appears to be superior to cyclophosphamide in terms of both response and safety (table 2).⁴⁵⁻⁴⁹ However, the results of these meta-analyses should be interpreted with caution, because of the inclusion of relatively small trials, the heterogeneity for race/ethnicity, class of LN, definitions of clinical response, duration of follow-up, and MMF and cyclophosphamide dosing regimens.

Recently, the results of the Aspreva Lupus Management Study (ALMS) were reported.⁵⁰ In this superiority RCT, 370 patients with either class III, IV or V LN were randomised

Table 2. Induction treatment: mycophenolate mofetil versus cyclophosphamide (RR or relative benefit; 95% CI)

	Mak et al.*	Nave-neethan et al.*	Walsh et al.*	Zhu et al.*	Kama-namool et al.**
PR	-	1.07 (0.72-1.60)	-	1.06 (0.71-1.59)	-
CR	-	1.36 (0.82-2.24)	-	1.81 (0.70-4.68)	1.60 (0.87-2.93)
PR/CR	1.05 (0.95-1.17)	1.15 (0.86-1.54)	-	1.20 (0.85-1.69)	1.20 (0.97-1.48)
Treatment failure	-	-	0.70 (0.54-0.90) [#]	-	-
ESRD	0.45 (0.18-1.12)	0.66 (0.25-1.70)	-	0.58 (0.20-1.65)	-
Death	0.71 (0.37-1.35)	0.35 (0.14-0.86) [#]	-	0.46 (0.17-1.30)	-
ESRD/Death	-	-	0.44 (0.23-0.87) [#]	-	-
Relapse	-	-	-	-	-

*RR <1 in favour of mycophenolate mofetil; **RR >1 in favour of mycophenolate mofetil; #p<0.05 in favour of mycophenolate mofetil; RR=relative risk; CI=confidence interval; PR=partial remission; CR=complete remission; ESRD=end-stage renal disease.

to MMF (target 3 g/day) or iv cyclophosphamide (target 0.5 to 1.0 g/m², six pulses monthly). Although most patients in both treatment groups experienced clinical improvement, MMF was not superior in inducing complete response at 24 weeks (MMF 56.2% and cyclophosphamide 53.0%). In addition, significant differences were not observed with regard to the rates of serious adverse events (MMF 28.0% and cyclophosphamide 23.0%) or infections (MMF 69.0% and cyclophosphamide 62.0%).

In this study, a heterogeneous population in terms of race and ethnicity was included. A subgroup analysis suggested a significantly worse response for cyclophosphamide in non-Asian, non-Caucasian mainly Black patients (MMF 60.4% vs cyclophosphamide 38.5%).³⁷ These findings seem consistent with the results of the Ginzler study where a greater proportion of Black patients were included than in the ALMS study (61.0% vs 25.9%).⁴⁴ So far, although MMF seems to be superior to cyclophosphamide in the high-risk Black patients, the efficacy of MMF in patients with other ethnicities seems to be comparable with cyclophosphamide.

Taking these studies together, although long-term data are not available, MMF seems to be a reasonable treatment alternative to high-dose iv cyclophosphamide in LN.

As only 60% of the patients with proliferative LN obtain a partial or complete response at 6 to 12 months in the studies discussed so far, new immunosuppressive therapies have been instituted. Given the substantial evidence for the role of B cells in the pathogenesis of SLE and the recent development of monoclonal antibodies to B-lymphocyte-specific targets, B-cell depletion seems to be an attractive approach in LN treatment. Several small, open-label uncontrolled studies suggested that rituximab may be effective in proliferative LN as initial induction therapy.³²⁻³⁴ However, in contrast to these studies, two randomised, controlled trials did not show any additional significant effect of anti-CD20 as add-on therapy in patients with LN treated with MMF and corticosteroids.⁵⁵⁻⁵⁶ Therefore, the use of rituximab as a first-line adjunctive agent in induction therapy is not justified (Level A).

Based on the results of the available literature, the Dutch Working Party proposes induction treatment in patients with proliferative LN with either the low-dose cyclophosphamide Euro-lupus regimen or MMF together with (methyl)prednisolone (Level A), as outlined in these protocols (*tables 3 and 4*).

In patients who do not meet the response criteria for partial/complete remission after 12 months of induction treatment or if induction treatment fails at three months, switch of the immunosuppressive agent from either cyclophosphamide to MMF, or from MMF to cyclophosphamide, accompanied by iv methylprednisolone (750 mg) for three days is recommended (Level C).

Table 3. Induction treatment: mycophenolate mofetil⁵⁰

<p>Mycophenolate mofetil Week 1: 1000 mg/day Week 2: 2000 mg/day Week 3: 3000 mg/day</p> <p>Corticosteroids Prednisone 1 mg/kg/day, maximum 60 mg/day After 4 weeks prednisone tapered every 4 weeks by 10 mg to 20 mg, followed by prednisone tapered every 4 weeks with 5 mg to 10 mg</p>
--

Table 4. Induction treatment: cyclophosphamide⁵⁵

<p>Cyclophosphamide A fixed dose of 500 mg iv, 6 times every two weeks</p> <p>Corticosteroids Methylprednisone pulse 750 mg iv at day 0, 1 and 2, followed by prednisone 0.5-1.0 mg/kg/day After 4 weeks prednisone tapered every 2 weeks with 2.5 mg to 5-7.5 mg at 30 months</p>

MAINTENANCE TREATMENT

Immunosuppressive treatment

MMF has been compared with azathioprine or tri-monthly iv cyclophosphamide as maintenance therapy in a small randomised controlled trial in non-Caucasian patients, following induction therapy with cyclophosphamide and corticosteroids. This trial showed that both MMF and azathioprine were significantly better in terms of patient survival, incidence of clinical events (death or chronic kidney failure) and prevention of relapses, if compared with cyclophosphamide.⁵⁷ However, differences between MMF and azathioprine could not be assessed due to the small number of patients included in these arms. Furthermore, it should be noted that the death rate in the cyclophosphamide arm was higher than that observed in other (NIH) studies.

Recently, two randomised, controlled trials with different study designs have been conducted to assess the optimal maintenance treatment in proliferative LN. In the MAINTAIN Nephritis Trial, MMF (2 g/day) was compared with azathioprine (2 mg/kg/day) as maintenance treatment after induction treatment with low-dose iv cyclophosphamide (Euro-Lupus regimen).⁵⁸ MMF and azathioprine were equally effective in preventing renal flares. In this study, patients were randomised at the start of the induction treatment.

Recently, data from the ALMS Maintenance Trial were published.⁵⁹ In contrast to the MAINTAIN Nephritis Trial, only patients achieving partial or complete remission during a six-month induction phase were re-randomised to corticosteroids plus MMF (2 g/day) or azathioprine (2 mg/kg/day) for up to 36 months. In this study, MMF was

superior to azathioprine in delaying the time to treatment failure, which was defined as either renal flare, necessity of rescue therapy, doubling of serum creatinine, ESRD or death (16.4% vs 32.4%). The completion rate at 36 months was higher in the MMF group compared with the azathioprine group (62.9% vs 48.6%). Superiority of MMF was consistent regardless of type of induction treatment, race or region. The discrepancy in the results between the MAINTAIN and the maintenance phase of the ALMS trial can have several explanations, such as the number of and the difference in ethnicity of the patients included in both studies, a different trial design and differences in study endpoints. Moreover, the randomisation procedure in the ALMS Maintenance Trial selected those patients with a good clinical response. As indicated before, a considerable proportion of patients do not show such a favourable response at six months.

Based on the above-mentioned studies, MMF is superior to azathioprine in maintaining a renal response and in preventing a renal flare in patients who had a response to induction therapy (Level A).

Duration of therapy

It is difficult to precisely define the criteria that allow the identification of patients in whom the dose of immunosuppression can be reduced safely. If the disease is clinically and serologically quiescent the immunosuppression could be tapered slowly. Based on the study by Grootsoorten *et al.* duration of therapy of at least five years seems warranted.⁶⁰ In this context, the ten-year follow-up data of the Euro-Lupus Nephritis Trial showed that 53% of the patients were still on maintenance immunosuppressive therapy.⁹ The Dutch Working Party proposes the following reduction schedule as a guidance in clinical practice (Level C): taper the dose of prednisone to 10 mg every other day at four years after the start of the induction therapy, followed by a 50% dose reduction of azathioprine/MMF six months later and continue this treatment regimen for at least two more years.³⁷ After this period (6.5 years), the decision to stop immunosuppressive treatment will be left to the discretion of the treating physician and the patient. This advice differs from the tapering schedule as proposed in the ALMS and MAINTAIN trial. In the ALMS trial the dose of corticosteroids was maximally 10 mg until 36 months with no data after 36 months. In the MAINTAIN trial prednisone was dosed at 7.5 mg at six months, 5 mg at 12 months, with further tapering after 24 months.^{38,39} There are no data available from controlled studies allowing clearer advice.

Supportive treatment

The importance of concomitant immune modulation with hydroxychloroquine has been highlighted by several recently published studies demonstrating lower rates

of renal flare, ESRD and mortality in those patients taking hydroxychloroquine.⁶¹⁻⁶⁴ Therefore, unless there are contraindications, the consensus opinion is that all patients should receive hydroxychloroquine (200 to 400 mg) from the start of the induction therapy onwards (Level B). To detect retinal toxicity a baseline examination within the first year of use and an annual screening after five years of use should be performed by an ophthalmologist. For patients with maculopathy or additional risk factors for retinal toxicity (cumulative dose of hydroxychloroquine >1000 g, elderly, kidney and/or liver dysfunction) annual screening should be performed from the initiation of the therapy.⁶⁵

In patients with LN, the indication for supportive treatment depends on the stage of chronic kidney disease and the presence of proteinuria. In general, the strategy aims at reduction of cardiovascular risk factors and should comprise lifestyle modifications (smoking cessation, weight reduction if BMI >25 kg/m², increased physical activity and dietary changes, especially salt restriction) together with adequate control of blood pressure (target of <130/80 mmHg, Level A for proteinuria >1 g/24 hours) with angiotensin inhibitors (ACEi) or angiotensin receptor blockers (ARBs) (Level A for proteinuria >1 g/24 hours), and treatment of hyperlipidaemia (Level C). As for stage 3 to 5 chronic kidney disease (creatinine clearance <60 ml/min), treatment options are summarised in table 5.⁶⁶

To reduce the risk of corticosteroid-induced osteoporosis each patient should receive calcium and vitamin D supplementation. In addition, a bisphosphonate should be started in each patient receiving >15 mg/day prednisone, or in postmenopausal women and males >70 years of age using prednisone in a dosage of 7.5 to 15 mg/day (see CBO Consensus Osteoporosis 2011).⁶⁷ However, in patients with renal failure (creatinine clearance <60 ml/min) and in patients with a pregnancy wish, bisphosphonates should not be given.⁶⁷ In addition to the supportive treatment options mentioned above,

Table 5. Supportive treatment in chronic kidney disease stage 3-5⁶⁶

Blood pressure
Dietary sodium reduction (5.0 g sodium chloride)
Achieve blood pressure <130/80 mmHg, using an ACEi or ARB as first-line treatment in the presence of >1 g/day of proteinuria
Proteinuria
Achieve proteinuria <1 g/day, using an ACEi or ARB as first-line treatment
Low protein diet (0.8 g/kg body weight per day)
Lipids
Achieve LDL cholesterol <2.6 mmol/l, using statins as first-line treatment
ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; LDL = low-density lipoprotein.

low-dose acetylsalicylic acid seems warranted in patients with positive anti-phospholipid antibodies for primary prevention of thrombosis and pregnancy loss (Level C).¹² Moreover, coumarines should be considered in patients with a nephrotic syndrome and a serum albumin <20 g/l (Level C).⁶⁸

Treatment of refractory LN

The evidence for any kind of immunosuppressive therapy in refractory LN is weak. Small observational studies provided evidence that rituximab seems to be an effective treatment for patients with active LN that is refractory to standard immunosuppressive therapy.^{52,53,69-73} However, the use of the different dosing schedules in these observational studies make an interpretation difficult.⁵⁴ Adjunctive treatment with tacrolimus resulted in a significant clinical response in patients resistant to MMF.⁷⁴⁻⁷⁶ However, although these newly introduced immunosuppressive regimens have proven their efficacy in some cases of refractory LN, the application of high-dose cyclophosphamide (NIH regimen) could still be a possibility. These (adjunctive) regimens are described in table 6 (Level C).

INDICATIONS FOR REPEAT BIOPSY IN PATIENTS TREATED FOR CLASS III/IV LN

The benefit of a repeat biopsy during the disease course of proliferative LN is questionable since there is no consensus in the literature. A recent retrospective study showed that in the presence of proliferative lesions in the original biopsy, a repeat biopsy during a clinical flare is not necessary as these patients rarely switch to a pure non-proliferative LN.⁷⁷ Moreover, histopathological variables in a protocolised biopsy at two years after induction therapy did not predict renal outcome at 77 months or at 115 months in patients with proliferative LN randomised to iv cyclophosphamide or azathioprine/methylprednisolone.^{37,78} In contrast to these findings, Hill *et al.* reported that certain histological findings in repeat

biopsies at six months had a better predictive power for subsequent doubling of serum creatinine than the same markers in the initial biopsy.⁷⁹

Given the conflicting results from the literature, the opinion of the Dutch Working Party is that a repeat biopsy is only justified in those patients where it is anticipated that the findings have therapeutic consequences (Level C). First, the persistence of proteinuria after reaching a partial response, despite optimal supportive treatment including salt restriction and treatment with ACEi or ARBs to differentiate between active disease, chronic lesions or transition to focal segmental glomerulosclerosis. Second, failure to respond (either complete or partial response) at 12 months after the start of the initial induction treatment to differentiate between active and chronic lesions.

CONCLUSION

In this report guidelines are proposed for the management of proliferative LN, with regard to the following topics: indications for a first renal biopsy, definitions of treatment response, selection of treatment options, and indications for repeat biopsy. This consensus approach provides agreed expert opinion for clinicians and will hopefully support the optimisation of treatment in patients with proliferative LN. Moreover, following this guideline throughout the Netherlands could be a basis for future central registration and follow-up on a national level.

ACKNOWLEDGEMENT

Conflicts of interest: none declared

REFERENCES

- Berden JHM, Licht R, Bruggen MCJ, et al. Role of nucleosomes for induction of glomerular binding of auto-antibodies in lupus nephritis. *Opin Nephrol Hypertens.* 1999;8:299-306.
- Berden JH. Lupus Nephritis. *Kidney Int.* 1997;52:538-58.
- Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. *Lupus.* 2006;15:308-18.
- Austin HA. Clinical evaluation and monitoring of lupus kidney disease. *Lupus.* 1998;7:618-21.
- Cameron JS. Lupus nephritis. *J Am Soc Nephrol.* 1999;10:413-24.
- Bastian HM, Roseman JM, McGwin G Jr. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. *Lupus.* 2002;11:152-60.
- Derksen RHW, Hené RJ, Kater L. The long-term clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single centre. *Lupus.* 1992;1:97-103.
- Donadio JV, Hart GM, Bergstrath EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinic-pathologic study. *Lupus.* 1995;4:109-15.

Table 6. Treatment of refractory lupus nephritis

<p>Rituximab* 1000 mg intravenous at day 1 and 15 as add-on therapy</p> <p>Tacrolimus*⁷⁵ 0.1 mg/kg/day, through level 4-10 µg/l as add-on therapy</p> <p>Cyclophosphamide*²⁵ 750 mg/m² intravenous, increased with 250 mg per dose to a maximum of 1500 mg 6 times monthly, then every 3 months for an additional 2 years</p> <p>*Prednisone 1 mg/kg/day, maximum 60 mg/day.</p>
--

9. Houssiau FA, Vasconcelos C, D'Cruz D. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. *Ann Rheum Dis.* 2010;69:61-4.
10. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. *Am J Med.* 1987;83:877-85.
11. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcome in severe lupus nephritis: contributions of clinical and histological data. *Kidney Int.* 1994;45:544-50.
12. Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. *Ann Rheum Dis.* 2008;67:195-205.
13. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. *Kidney Int.* 2004;65:521-30.
14. Mahajan SK, Ordonez NG, Feitelson PJ, Lim VS, Spargo BH, Katz AI. Lupus nephropathy without clinical renal involvement. *Medicine.* 1977;56:493-500.
15. Faurischou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. *J Rheum.* 2006;33:1563-9.
16. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. *Lupus.* 2005;14:890-5.
17. Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J. Kidney biopsy in SLE. I. A clinical-morphologic evaluation. *Q J Med.* 1989;73:1125-33.
18. Nossent JC, Henzen-Logmans SC, Vroom TM, Huysen V, Berden JH, Swaak AJ. Relation between serological data at the time of the biopsy and renal histology in lupus nephritis. *Rheum Int.* 1991;11:77-82.
19. Berden JHM, Assman KJM. Renal involvement in collagen vascular diseases and dysproteinemias. *Atlas of Diseases of the kidney.* Vol IV. 1999. Blackwell Science. Editor S. Klahr.
20. Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. *Arthritis Rheum.* 2004;50:2569-79.
21. Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. *Arthritis Rheum.* 2006;55:348-52.
22. Bertsias G, Gordon C, Boumpas DT. Clinical trial in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future — the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. *Lupus.* 2008;17:437-42.
23. Gordon C, Bertsias G, Ioannidis JPA, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. *Ann Rheum Dis.* 2009;68:470-6.
24. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. *Arthritis Rheum.* 1991;60:5-7.
25. Gourley MF, Austin III HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. *Ann Int Med.* 1996;125:549-57.
26. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. *Arthritis Rheum.* 2004;50:3934-40.
27. Chen YE, Korbet SM, Katz RS, et al. Value of complete or partial remission in severe lupus nephritis. *Clin J Am Soc Nephrol.* 2008;3:46-53.
28. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone. *Lupus.* 2005;14:265-72.
29. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. *Kidney Int.* 2000;57:258-64.
30. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. *N Eng J Med.* 1986;314:614-9.
31. Boumpas DT, Astin III AH, Vaughan EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. *Lancet.* 1992;340:741-5.
32. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. *Ann Int Med.* 1993;119:366-9.
33. Petri M. Prospective study of systemic lupus erythematosus pregnancies. *Lupus.* 2004;13:688-9.
34. Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. *Am J Kidney Dis.* 1997;29:193-9.
35. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. *Arthritis Rheum.* 2002;46:2121-31.
36. Grootsholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. *Kidney Int.* 2006;70:732-42.
37. Arends S, Grootsholten C, Derksen RHW, et al. Long-term follow-up of a randomized controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. *Ann Rheum Dis.* 2011, nov 29 (Epub ahead of print).
38. Gaubitz M, Schorat A, Schotte A, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. *Lupus.* 1999;8:731-6.
39. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. *J Am Soc Nephrol.* 1999;10:833-9.
40. Chan TM, Li FK, Tang CSO, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. *N Engl J Med.* 2000;343:1156-62.
41. Chan TM, Tse K-C, Tang CS-O, et al. Long-term study of mycophenolate mofetil versus continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. *J Am Soc Nephrol.* 2005;16:1076-84.
42. On LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. *Nephrol.* 2005;10:504-10.
43. Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil versus cyclophosphamide therapy for patients with proliferative lupus nephritis. *Chin Med J.* 2002;115:705-9.
44. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. *N Eng J Med.* 2005;353:2219-28.
45. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. *Clin J Am Soc Nephrol.* 2007;2:968-75.
46. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. *Nephrol Dial Transplant.* 2007;22:1933-42.
47. Navaneethan SD, Viswanathan G, Strippoli GF. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. *Drugs.* 2008;68:2095-2104.
48. Mak A, Cheak AAC, Tan JYS, Su HC, Ho RCM, Sing Lau C. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. *Rheumatology.* 2009;48:944-52.
49. Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstant A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis. *Systemic review and meta-analysis.* *Medicine.* 2010;89:227-35.
50. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol.* 2009;20:1103-12.